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ABSTRACT
Campylobacter jejuni is the leading bacterial cause of human gastroenteritis in
the United States. Increasing resistance of Campylobacter to clinical antibiotics raises an
urgent need for novel strategies to prevent and control infections in humans and animal
reservoirs, which necessitates a better understanding of Campylobacter pathogenesis.
We hypothesize that multidrug efflux pump CmeABC and ferric enterobactin (FeEnt) iron
acquisition systems, which play a critical role in Campylobacter pathogenesis, are novel
targets for developing effective measures against Campylobacter. To test this, the
molecular, antigenic, functional, and protective characteristics of two outer membrane
proteins, CmeC (an essential component of CmeABC drug efflux pump) and CfrA (a
FeEnt receptor), were examined. Both CmeC and CfrA are highly conserved and widely
produced in C. jejuni strains. Anti-CmeC and Anti-CfrA antibodies inhibited the function
of CmeABC efflux pump and CfrA, resulting enhanced susceptibility to bile salts and
reduced utilization of FeEnt of C. jejuni, respectively. Immunoblotting analysis also
indicated that CfrA is expressed and immunogenic in vivo. Amino acid substitution
mutagenesis demonstrated that a highly conserved basic amino acid R327 in CfrA plays
a critical role in FeEnt acquisition. The purified recombinant CmeC and a Salmonella live
vaccine expressing the protective epitope of CfrA were evaluated as subunit vaccines
against Campylobacter infection in the chicken model. CmeC vaccination elicited
immune response but failed to reduce C. jejuni colonization in the intestine. However,
Salmonella-vectored vaccine conferred significant protection against C. jejuni challenge.
To further elucidate the role of iron acquisition in the pathogenesis of Campylobacter,
whole genome sequence of a unique C. jejuni strain was determined using a 454 GS
FLX sequencer with Titanium series reagents. Comparative genomics analysis led to the
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identification of a novel Campylobacter Enterobactin Esterase (Cee) that is essential in
the CfrB-dependent FeEnt utilization pathway. Extensive genetic manipulation revealed
molecular pathways and mechanistic features of the two orchestrated FeEnt acquisition
systems in Campylobacter. This project provides critical information about the feasibility
of targeting CmeC and CfrA for immune protection against Campylobacter colonization
in the intestine, and increases our understanding of the critical role of FeEnt acquisition
in the pathophysiology of Campylobacter.

Key Words: Campylobacter, vaccine, pathogenesis, CmeABC efflux pump, CfrA, CfrB,
ferric enterobactin acquisition, Cee
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INTRODUCTION

Since the late 1970s, Campylobacter has emerged as the leading bacterial cause
of foodborne human diseases (Slutsker et al. 1998). This pathogenic organism causes
watery diarrhea and/or hemorrhagic colitis in humans and is associated with GuillainBarre syndrome, an acute flaccid paralysis that may lead to respiratory muscle
compromise and death (Nachamkin et al. 1998). There are more than 2 million
estimated cases of campylobacteriosis in the United States each year, and the annual
medical and productivity costs resulting from Campylobacter infection are estimated at
1.5 to 8.0 billion dollars (Buzby et al. 1997). Human Campylobacter illnesses are caused
primarily by C. jejuni (~90%) and secondarily by C. coli (~10%). Poultry are the major
reservoir of Campylobacter and thus the main source for human campylobacteriosis
(Young et al. 2007). In parallel to its increased prevalence, Campylobacter has become
increasingly resistant to antibiotics including fluoroquinolones and macrolides, the major
antibiotics of choice for treating human campylobacteriosis (Engberg et al. 2001).
Therefore, alternative intervention strategies, such as vaccination, are urgently needed
to prevent and control Campylobacter infections. However, vaccines against
Campylobacter infection are still not available to date, primarily due to the antigenic
complexity of this organism and a lack of understanding of the mechanisms of
pathogenesis.

Outer membrane proteins (OMPs) of Gram-negative bacteria are considered the
major mediators of host-pathogen interactions and are promising candidates for the
design of protective vaccines (Nikaido 2003). Recently, a unique OMP CmeC, an
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essential component of multidrug efflux pump CmeABC that contributes C. jejuni
resistance to a broad spectrum of antimicrobials and is also essential for C. jejuni
colonization in the animal intestine by mediating bile resistance, has been characterized
(Lin et al. 2002; Lin et al. 2003; Lin et al. 2005). As an immunogenic OMP in vivo, CmeC
is constitutively expressed in Campylobacter and is induced by bile salts present in the
intestine (Lin et al. 2002; Lin et al. 2003; Lin et al. 2005). It has been demonstrated that
inhibition of CmeABC by efflux pump inhibitors dramatically increased the susceptibility
of Campylobacter to various antimicrobials, and reduced in vivo colonization of C. jejuni
using a chicken model system (Lin and Martinez 2006; Martinez and Lin 2006). These
observations have laid a solid foundation for us to further determine the feasibility of
using CmeC as a subunit vaccine against C. jejuni.
Iron acquisition is essential for survival and colonization of pathogenic bacteria in
the host and thus has been targeted for iron-dependent pathogen control (Lin et al.
2002). For example, iron-regulated OMPs have been recognized as potential vaccine
candidates to control bacterial pathogens (Lin et al. 2002). In Campylobacter, the ferric
enterobactin (FeEnt) acquisition system is of particular interest because of the extremely
high affinity of Ent for iron, the production of Ent by a wide variety of gut commensal
bacteria, and the essential role of the FeEnt receptor CfrA in the colonization of C. jejuni
in the intestine. Particularly, inactivation of the OMP CfrA alone completely abolished
colonization of C. jejuni in chickens (Palyada et al. 2004). This observation provides a
strong rationale to further examine molecular, antigenic, and functional features of CfrA,
and determine the feasibility of developing CfrA-based subunit vaccines to control
Campylobacter infection. Recently, we also identified a new FeEnt receptor CfrB in
Campylobacter (Xu et al. 2010). This work reveals the complexity of FeEnt systems in
the two closely related Campylobacter species (C. jejuni and C. coli), and demonstrates
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the important role of the new FeEnt receptor CfrB in Campylobacter iron acquisition and
in vivo colonization. We hypothesize that both CfrA- and CfrB-dependent FeEnt
acquisition systems play a critical role in the pathophysiology of Campylobacter despite
considerable difference in their function, genetic components, and molecular interaction;
thus, FeEnt acquisition systems in Campylobacter are promising targets for vaccine and
antimicrobial development.
To achieve our long-term goal of developing effective intervention strategies
against Campylobacter infections in humans and animal reservoirs, the following
objectives were pursued in this research project:
1) Develop and evaluate subunit vaccine CmeC in the chicken model system.
2) Determine molecular, antigenic, functional, and protective characteristics of
FeEnt receptor CfrA in Campylobacter.
3) Sequence whole genome of a unique C. jejuni strain JL11 and perform
comparative genomics analysis.
4) Characterize the key components and examine molecular interaction of the
CfrA-

and

CfrB-dependent

ferric

Campylobacter.

3

enterobactin

acquisition

systems

in

CHAPTER I
REVIEW OF LITERATURE
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Campylobacter infections in humans and chickens
Campylobacter, a microaerophilic and Gram-negative bacterium, is the leading
bacterial cause of human enteritis in many industrialized countries and the major
causative agent of traveler’s disease. Campylobacter infection is also associated with
Guillain-Barre syndrome (Baqar et al. 1995), an acute flaccid paralysis that may lead to
respiratory muscle compromise and death in humans. Campylobacter belongs to the
epsilon class of proteobacteria and the order campylobacteriales which includes two
other genera, Helicobacter and Wolinella. Like the other two genera, Campylobacter has
small genomes (1.6–2.0 mega bases) and can establish specific associations with hosts
(Parkhill et al. 2000). At present, 17 Campylobacter species have been identified that
can be separated into more than 60 Penner serotypes (heat-stable antigens) and more
than 100 Lior serotypes (heat-labile antigens). Two thermophilic species, C. jejuni ssp.
jejuni and C. coli (further referred as C. jejuni and C. coli) are responsible for the vast
majority of human campylobacteriosis (90% and 10%, respectively). It is estimated that
the annual economic burden caused by Campylobacter infection is up to 8 billion dollars
in the US.
Campylobacter infection in humans commonly results in an acute gastroenteritis
characterized by an inflammatory response, abdominal pain, fever and diarrhea. The
infective dose can be as low as 500–800 bacteria (Robinson 1981; Black et al. 1988).
The incubation period preceding the development of acute diarrhea is 2–5 days and,
although the disease is typically cured in one week, symptoms can persist for up to 2
weeks. Epidemiological studies indicate that there are two disease manifestations for
Campylobacter infection, which are dependent on the socio-economic status. In the
developed world, campylobacteriosis manifests as bloody diarrhea with mucus, and is
usually self-limiting. In the developing world, watery diarrhea predominates, and infection
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is more frequent among children, which might provide them acquired immunity against
further Campylobacter infections (Blaser et al. 1983). Reasons for this disparity of
outcomes are not clear but could reflect different levels (and the T-helper (TH) -1 versus
TH-2 bias) of pre-existing immunity that arises from differing natural immune stimulants in
these environments.
Birds are the primary reservoir of Campylobacter in nature. However, the
infection of chickens by C. jejuni typically does not result in the same symptoms and
pathological responses as seen in humans. C. jejuni can colonize and persist in
chickens at extremely high levels, up to 1010 colony-forming units (CFU) per gram of
intestinal contents. The primary colonization site is the deep crypts of the cecum, where
C. jejuni was found in the mucus layer close to epithelial cells (Young et al. 2007). The
cecal environment is similar to that of the human colon (Young et al. 2007). It has been
observed that the presence of chicken intestinal mucus slightly inhibited human epithelial
cell invasion by C. jejuni, suggesting that the mucus might contribute to the
asymptomatic nature of chick infection (Nachamkin et al. 1993).
Campylobacter pathogenesis
Through oral ingestion, C. jejuni enters the host intestine via the stomach acid
barrier and colonizes the distal ileum and cecum. Once inside the intestine, C. jejuni is
faced with multiple levels of stresses, such as the action of antimicrobial bile salts and
peptides, starvation (e.g. iron limitation), competition with other residential flora,
antibiotic treatments, oxidative stress and attack by the host immune system.
Campylobacter must counteract these harsh conditions in order to survive and multiply
in the host. In the past decades, many efforts have been directed to understanding
virulence factors involved in Campylobacter adhesion, invasion and cytotoxicity. The
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best-characterized virulence factor of the organism is the polar flagellum (Fla), which is
responsible for the characteristic darting motility of C. jejuni and appears to be involved
in colonization and invasion (Guerry 1997). The functional flagellar apparatus also
serves as export apparatus for secreting virulence factors (Konkel et al. 2004). In
addition to Fla, other known examples of putative virulence elements include cytolethal

distending toxin (CDT) (Hassane et al. 2001), major antigenic protein 1 (PEB1) (Pei
and Blaser 1993), Campylobacter invasion antigen (Cia) (Konkel et al. 1999),
Campylobacter adhesion to Fibronectin protein (CadF) (Konkel et al. 1997), jejuni
lipoprotein A (JlpA) (Jin et al. 2001), the pVir plasmid (Bacon et al. 2000), and phase
variable lipooligosaccharide (LOS) (Guerry et al. 2002) and capsule (Bacon et al. 2001).
Despite these advances in understanding the pathobiology of C. jejuni, limited
information is available concerning mechanisms utilized by C. jejuni to survive and grow
in hostile host niches. Stress response and resistance to host innate immunity are
essential for Campylobacter pathogenesis. Campylobacter catalase (KatA) contributes
to the resistance of C. jejuni to oxidative stress and is essential for persistence and
growth of C. jejuni in macrophages (Day et al. 2000).

The multidrug efflux pump

CmeABC that is inducible by bile salts in the intestinal tract is essential for bile
resistance and in vivo colonization of C. jejuni (Lin et al. 2003; Lin et al. 2005; Lin et al.
2005). Using a whole genome microarray, Gaynor et al. (2005) demonstrated recently a
critical role for the C. jejuni stringent response in multiple aspects of C. jejuni biology
and pathogenesis. Upon entry into epithelial cells, C. jejuni can undergo significant
physiological changes within the intracellular environment and use specific adaptation
mechanisms to survive within epithelial cells by avoiding delivery to lysosomes (Watson
and Galan 2008). Gene products involved in respiration-dependent energy conservation
(Pajaniappan et al. 2008) and utilization of specific nutrients (Hofreuter et al. 2008) are
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also important for Campylobacter to colonize in different hosts and even different
tissues. Although Campylobacter has evolved complex mechanisms to survive in the
environment and different host niches, there are significantly fewer sigma factors and
other global regulators in Campylobacter than other enteric pathogens based on whole
genome analysis (Palyada et al. 2004). The two-component regulatory (TCR) system is
a key player for bacteria to sense in vivo stimuli and regulate virulence genes for
adaptation and survival in the host (Stock et al. 1989). There are 10 putative response
regulators and 7 histidine kinases revealed in C. jejuni NCTC 11168 and RM1221
(Palyada et al. 2004). Several regulators or TCR systems, including reduced ability to
colonize regulator/sensor (RacR/S) (Bras et al. 1999), diminished capacity to colonize
factor R/S (DccR/S) (MacKichan et al. 2004), flagellum R/S (FlgS/R) (Wosten et al.
2004), Phosphate R/S (PhosR/S) (Wosten et al. 2006), Campylobacter planktonic
growth regulation R/S (CprR/S) (Svensson et al. 2009), and Campylobacter bile
resistance regulator (CbrR) (Raphael et al. 2005) have been studied, and all were found
to be required for Campylobacter colonization in vivo. However, environmental cues
that these TCR systems respond to are still largely unknown. Recently, Fields and
Thompson (2008) demonstrated the presence of a CsrA post-transcriptional regulatory
system in C. jejuni, which provide novel insight into the complex regulation of
Campylobacter physiology and pathogenesis.
Host immunity against Campylobacter infection
Host immunity plays an important role in anti-Campylobacter infection in humans
and animals. After the second week of infection in humans, Campylobacter-specific
antibodies, such as those directed against flagellin, major outer membrane protein
(MOMP) and lipopolysaccharides (LPS) can be detected in patients’ sera (Blaser and
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Duncan 1984; Mills and Bradbury 1984; Nachamkin and Yang 1992). Serum IgG and
IgM titers peak at about 8 to 14 days post-infection and then gradually decrease in about
2 months (IgM) to 1 year (IgG). However, serum IgA levels also peak at 1–2 weeks postinfection (Blaser and Duncan 1984; Herbrink et al. 1988; Cawthraw et al. 2002) but
return to pre-infection levels more rapidly, normally in the following several weeks (Lane
et al. 1987). Among the different isotypes of antibodies, Campylobacter specific
intestinal or serum IgA is a major effector contributing to the resistance against
Campylobacter colonization in the intestine (Wallis 1994). Maternal IgA from human
breast milk showed protection against enteric Campylobacter spp. (Renom et al. 1992).
In a volunteer study, re-challenge of previously infected volunteers could not reproduce
the disease via ingestion of C. jejuni 81-176, suggesting that immunity can be induced to
protect Campylobacter infections in humans (Black et al. 1988).
Although it is widely accepted that Campylobacter colonize chickens without
cellular adhesion and invasion, several studies have shown a strong correlation between
increased Campylobacter-specific antibody level in chicken serum and reduced
Campylobacter shedding, suggesting the role of the immune response in controlling
Campylobacter colonization in poultry (Myszewski and Stern 1990; Cawthraw et al.
1994; Rice et al. 1997). Campylobacter-specific antibodies in chicken serum rise
gradually at 2-3 week after oral challenge with Campylobacter, while biliary and intestinal
IgA appear from 3-4 weeks. Laboratory challenge experiments indicated that maternal
antibodies to Campylobacter partly contribute to the lack of Campylobacter infection in
young broiler chickens in natural environments during the first two weeks of life (Sahin et
al. 2001). Together, these findings strongly support the feasibility of development of
immunization-based approaches to control Campylobacter infections.
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Campylobacter vaccine development
Currently there is no vaccine available to control Campylobacter infections. The
following three approaches have been explored to develop effective and safe
Campylobacter vaccines: 1) Live attenuated vaccines. Because infection with wild-type
C. jejuni strain induced protective immunity in volunteers, it is likely that a live attenuated
vaccine will have a protective effect. However, the paucity of information on the
pathogenesis of the organism complicates this strategy. On the other hand, some C.
jejuni strains that exhibit mimicry of gangliosides in their lipooligosaccharides are
associated with development of Guillain-Barre Syndrome (Rees et al. 1995), which
makes live vaccines potentially unsafe. C. jejuni strain 81-176 was proposed as a safe
candidate for vaccine design because of absence of persistent anti-ganglioside
antibodies after experimental infection with the strain (Prendergast et al. 2004). 2) Killed
whole-cell vaccines. This type of vaccine could induce high protective immunity without
serious toxicity to the host. Vaccination with killed C. jejuni whole cells enhanced the
mucosal immune responses in humans and chickens and partially reduced colonization
of C. jejuni (Baqar et al. 1995; Widders et al. 1996); and 3) Subunit vaccine. Subunit
vaccine would have significantly less risk of post-vaccination sequelae than a
Campylobacter-based live attenuated or killed vaccine. As mentioned above, Fla is an
immunodominant antigen and is protective against C. jejuni infection in animal models.
However, Fla is modified by glycosylation and undergoes both phase and antigenic
variation, which complicates the use of Fla for vaccination. Interestingly, a truncated
recombinant FlaA subunit vaccine showed protection in an animal model (Lee et al.
1999). Oral immunization of chickens with CjaA that was expressed in a Salmonella
carrier strain elicited a specific immune response associated with protection against
challenge with wild-type C. jejuni (Wyszynska et al. 2004). However, there are several
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weaknesses of this CjaA-based vaccine study. First, the function of CjaA is still unclear.
Second, there were only two treatment groups (untreated chicken vs. vaccine treatment)
used for evaluation. Thus, it is not clear whether protection is conferred by CjaA specific
antibodies or by enhanced innate immunity triggered by the Salmonella carrier strain (Lin
2009). Third, one study (Wyszynska et al. 2008) showed that CjaA is an N-glycosylated
lipoprotein localized in the inner membrane, which is not amenable to access by and
recognition of specific host CjaA antibodies. Recently, a capsule polysaccharide vaccine
conjugated with the carrier protein CRM197 was reported to fully protect the New World
monkey Aotus nancymaae, a primate model, from disease symptoms caused by
Campylobacter infection (Monteiro et al. 2009). However, the infective dose used for this
non-human primate model was extremely high (5 × 1011 CFU/monkey) and this vaccine
did not protect the monkey against Campylobacter colonization.
Antigenicity of Campylobacter components
Elucidation of immunogenic and protective antigens in C. jejuni is a primary step
towards the design of effective vaccines. However, very limited studies have been done
to characterize immunological properties of Campylobacter components, primarily due to
a lack of understanding of mechanisms of Campylobacter pathogenesis and by the
antigenic

complexity

of

these organisms.

Immunogenic

proteins

identified in

Campylobacter include flagellin (Guerry 1997), major outer membrane protein MOMP
(Guerry 1997), cell-binding factor PEB1 (Pei and Blaser 1993), and outer membrane
protein Cja (Konkel et al. 1999). Motility-mediating flagellum (Fla) is the bestcharacterized immunogenic protein shown to be required for Campylobacter colonization
in birds and mammals (Guerry 1997). However, as an immunodominant protein in C.
jejuni, Fla is modified by glycosylation and undergoes both phase and antigenic
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variation, which complicates the use of Fla for vaccination (Caldwell et al. 1985).
Feeding chickens with a fla mutant resulted in complete protection against the flagellated
parent strain, indicating that protective antigens can be flagellin-independent (Pavlovskis
et al. 1991). Regarding another immunodominant protein MOMP, the definitive role of
MOMP in microbe-host interaction is still not clear, and both conserved and variable
regions were observed in MOMP (Zhang et al. 2000). The antigenicity of MOMP is also
unique as reflected by predominant conformational epitopes in nature (Zhang et al.
2000). In summary, protective antigens of C. jejuni are still poorly understood and
remain to be determined.
Multidrug efflux pumps and corresponding OMP components
In pathogenic bacteria, there are many different types of multidrug resistance
efflux systems (often named MDR pumps), which vary in size, structure, and energy
source (proton gradient or ATP hydrolysis) (Putman et al. 2000). One major and
important family of MDR pumps in Gram-negative bacteria is the Resistance-Nodulationcell Division (RND) efflux system, which consists of an inner membrane transporter, a
periplasmic fusion protein, and an OMP (Zgurskaya and Nikaido 2000). These three
components function together and form a membrane pump to extrude antimicrobials out
of cells. Genetically, many of the RND-type MDR efflux systems are encoded by a threegene operon located on bacterial chromosomes. Overexpression of RND-type efflux
pumps usually results in multi-drug resistance in bacterial pathogens (Poole 2001). Even
without overexpression, constitutively expressed MDR pumps function synergistically
with other non-efflux resistance mechanisms (such as target mutations) to confer high
levels of antimicrobial resistance in bacteria (Lomovskaya et al. 1999). A key feature of
these MDR efflux systems is their ability to extrude a broad spectrum of substrates.
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Gram-negative RND-type efflux systems play an important role in bacterial resistance to
a variety of antimicrobial compounds including those naturally present in animal hosts
(e.g. bile salts) (Poole 2001). A major natural function of RND efflux system is proposed
to be involved in in vivo adaptation in various host niches (e.g. bile resistance in
intestine) during infections (Poole 2001).
OMP components are essential players in MDR efflux systems and form a
distinct family of proteins specific for Gram-negative bacteria (Paulsen et al. 1997).
Such OMPs function as porin-type channels that facilitate translocation of diverse
substrates across the outer membrane (Nikaido 2003). Crystal structure analysis
showed the OMP trimer forms a channel that is constitutively open wide to the
extracellular side (Koronakis et al. 2000). Crystal structure of the OMP also confirmed
that the portion spanning the outer membrane is a β-barrel structure that is typical for
OMPs, such as porins and high affinity siderophore receptors (Koronakis et al. 2000).

Multidrug efflux pumps in Campylobacter
Based on the genome sequence of C. jejuni NCTC 11168, Campylobacter
contains 13 putative multidrug efflux systems, most of which have not been functionally
characterized (Parkhill et al. 2000). CmeABC is the best defined MDR pump in
Campylobacter to date, which functions as an energy-dependent efflux pump
contributing to Campylobacter resistance to antimicrobial agents and adaptation in
animal hosts (Lin et al. 2002; Lin et al. 2003; Lin et al. 2005; Akiba et al. 2006).
CmeABC represents a RND-type MDR efflux pump and is encoded by a three-gene
operon consisting of cmeA, cmeB, and cmeC (Lin et al. 2002). CmeABC shares
significant sequence and structural homology with known RND-type tripartite efflux
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pumps in other Gram-negative bacteria, which include an outer membrane protein
(CmeC), periplasmic lipoprotein (CmeA), and an inner membrane transporter (CmeB).
CmeABC efflux pump contributes C. jejuni resistance to a broad spectrum of
antimicrobials and is also essential for C. jejuni colonization in animal intestine by
mediating bile resistance (Lin et al. 2002; Lin et al. 2003; Lin et al. 2005; Akiba et al.
2006). The OMP CmeC is an essential component for the function of CmeABC. As an
immunogenic OMP in vivo, CmeC is highly conserved and constitutively expressed
among different Campylobacter strains (Lin et al. 2002; Lin et al. 2003; Lin et al. 2005;
Akiba et al. 2006). Particularly, expression of CmeC is induced dramatically by the
presence of bile salts in the intestine, further highlighting the critical role of CmeC in
Campylobacter pathogenesis (Lin et al. 2005). This notion is also supported by a recent
study from another group (Stintzi et al. 2005), in which expression of cmeABC operon
was found to be highly up-regulated in vivo. Inhibition of CmeABC by efflux pump
inhibitors dramatically increased the susceptibility of Campylobacter to various
antimicrobials, prevented emergence of macrolide resistant C. jejuni, and reduced in
vivo colonization of C. jejuni using chicken model system (Lin and Martinez 2006;
Martinez and Lin 2006). These observations have laid a solid foundation to further
determine the potential of CmeC as a subunit vaccine against C. jejuni as will be
addressed in this research project.

Iron acquisition systems and corresponding OMP components
Iron is the most abundant transition metal in living organisms with a critical role in
many diverse biological systems (Stintzi et al. 2008). All Gram-negative bacteria have an
absolute requirement for iron to survive. However, because of the low solubility of ferric
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iron and the need to avoid its participation in generating toxic oxygen-derived free
radicals, higher organisms have evolved mechanisms for lowering the levels of free iron
to well below those required for growth of Gram-negative bacteria (Litwin and
Calderwood 1993). For example, in the intestine, there are two potential sources of iron:
the mucosa and food. However, iron from these sources (e.g. lactoferrin in mucosal
secretions and haem in food) is normally not available to invading Gram-negative
bacteria in the intestine (Stintzi et al. 2008). Iron binding proteins in the intestine
sequester free ferric iron as low as 10-24 M and make it unavailable to most bacteria
which demand at least 10-7 M for normal growth (Braun et al. 1998). Therefore, to obtain
sufficient iron for survival and multiplication, Gram-negative bacteria have evolved
sophisticated genetic systems for iron uptake. Two major strategies are used by Gramnegative bacteria to assimilate iron in iron-restricted niches: 1) utilization of TonBdependent OMPs (e.g. FeEnt receptor FepA in Escherichia coli), which bind to ironsiderophore complex and promote iron-siderophore across the membrane and into cells.
Siderophores (500 - 1,000 dalton) are high-affinity iron chelators secreted by bacteria
and can competitively capture iron from host iron-binding proteins or iron-binding
compounds. This high affinity iron uptake is the most common strategy evolved by
Gram-negative bacteria; and 2) expression of specific outer membrane receptors to
directly bind host transferrin, lactoferrin, or hemoprotein followed by removal of iron from
iron-binding protein and internalization of iron into cells.
Since bacteria require iron for their growth and the levels of free iron in vivo are
well below microbial requirements, possession of iron uptake systems and functional
iron-regulated outer membrane proteins (IROMPs) are essential for bacterial survival
and virulence. Surface-exposed IROMPs directly interact with the iron-restricted
environment encountered by pathogenic bacteria and function as a “gate keeper” for iron
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assimilation in bacteria. There is a considerable body of experimental studies
demonstrating that IROMPs are antigenic and induced under iron-restricted conditions in
vivo (Lin et al. 2002). Genetic knockout of IROMP genes in Gram-negative bacteria
resulted in attenuated virulence in animal models or experimental human infections (Lin
et al. 2002). Antibodies directed against IROMPs can block iron assimilation of bacteria,
consequently inhibiting bacterial growth under iron-restricted conditions (Murphy et al.
1990). Thus, IROMPs have been recognized widely as important virulence factors and
potential vaccine candidates (Lin et al. 2002).
Iron acquisition systems in Campylobacter
Since iron is known to be central to the host-pathogen relationship (Stintzi et al.
2008), examination of iron uptake in C. jejuni has been initiated since the 1980s (Field et
al. 1986) but iron uptake systems and the associated regulatory systems in C. jejuni are
just beginning to be elucidated (reviewed by Stintzi et al. 2008 and Miller et al. 2009)),
primarily due to the completion of the first genome sequence of C. jejuni NCTC 11168
(Parkhill et al. 2000).
Genomic data showed a large number of genes implicated in iron scavenging,
metabolism, storage and regulation in C. jejuni (Stintzi et al. 2008). Although
Campylobacter can utilize multiple exogenous siderophores (e.g.Ent) to take up iron via
high affinity iron acquisition systems, it is widely accepted that Campylobacter cannot
synthesize siderophores. This is also supported by evidence that no siderophore
biosynthesis genes were identified in all published Campylobacter genome sequences
(Parkhill et al. 2000; Hofreuter et al. 2006). In addition to siderophores, recent studies
demonstrated that C. jejuni has evolved other systems to directly utilize host iron
sources, such as ChuABCDZ for heme (Ridley et al. 2006) and Cj0173c-Cj0178 for
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lactoferrin/transferrin (Miller et al. 2008). The FeoB-mediated ferrous iron acquisition was
also identified in C. jejuni and demonstrated to contribute to colonization of C. jejuni in
the intestine (Naikare et al. 2006). Inspection of published C. jejuni genomes showed
that C. jejuni can have multiple sets of homologous genes involved in acquisition of iron
(e.g. three TonB-ExbBD energy transduction systems in C. jejuni NCTC11168) (Parkhill
et al. 2000; Stintzi et al. 2008). Thus, different tonB gene products may specifically
interact with different iron uptake systems in C. jejuni. Similar to many other bacteria,
iron acquisition systems in C. jejuni are generally regulated by proteins of the Fur family,
which directly repress a set of iron acquisition genes if intracellular iron concentration is
too high (van Vliet et al. 1998; Stintzi et al. 2008).
FeEnt utilization systems in Campylobacter
The FeEnt iron acquisition is of particular interest because Ent has the highest
affinity for ferric iron of any natural siderophore compounds tested (Stintzi et al. 2008).
Although Campylobacter is not able to synthesize Ent, Ent can be produced by a wide
variety of commensal bacteria in the intestine and this compound is likely to be produced
in significant amounts by resident microflora in the gut (Stintzi et al. 2008). Thus, FeEnt
may be a significant source of iron to Campylobacter during colonization in vivo (Stintzi
et al. 2008). One FeEnt acquisition system in Campylobacter was recently identified and
it requires the OMP receptor CfrA and other cognate components, such as TonB-ExbBExbD protein complex and ABC transporter system CeuBCDE (Stintzi et al. 2008; Miller
et al. 2009). Strikingly, inactivation of the cfrA gene alone not only impaired Entmediated iron assimilation but also completely abolished colonization of C. jejuni in
chickens; however, the wild-type parent strain colonized all chickens with colonization
levels at > 107 CFU/g cecal content (Palyada et al. 2004). This finding indicates that
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other iron-uptake systems in C. jejuni cannot effectively compensate the function of CfrA
and that CfrA plays an essential role in colonization of C. jejuni in chickens.
Recently, our laboratory identified and characterized a new FeEnt receptor
(designated CfrB) using both in vitro and in vivo systems (Xu et al. 2010). CfrB, a
homolog of C. jejuni NCTC 11168 Cj0444, shares approximately 34% of amino acid
identity with CfrA. Alignment of complete CfrB sequences showed that the CfrB is highly
conserved in Campylobacter. Immunoblotting analysis using CfrB-specific antiserum
demonstrated that CfrB was induced dramatically under iron-restricted conditions and
was produced in the majority of C. coli (41 out of 45) and in some C. jejuni (8 out of 32)
primary strains from various sources and from geographically diverse areas. All of the
CfrB-producing C. coli strains also produced CfrA, which was rarely observed in the
tested C. jejuni strains. Isogenic cfrB, cfrA, and cfrA/cfrB double mutants were
constructed in 43 diverse Campylobacter strains. Growth promotion assays using these
mutants demonstrated that CfrB has a major role in FeEnt iron acquisition in C. coli.
Chicken colonization experiments indicated that inactivation of the cfrB gene alone
greatly reduced and even abolished Campylobacter colonization of the intestine. A
growth assay using CfrB-specific antiserum strongly suggested that specific CfrB
antibodies could block the function of CfrB and diminish FeEnt-mediated growth
promotion under iron-restricted conditions. Together, this work reveals the complexity of
FeEnt systems in the two closely related Campylobacter species, and demonstrates the
important role of the new FeEnt receptor CfrB in Campylobacter iron acquisition and in
vivo colonization.
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Animal models of Campylobacter infection
Several animal models are available to study the interaction between
Campylobacter and the host. Ferrets colonized by pathogenic C. jejuni exhibit symptoms
of disease that are seen in humans, including diarrhea and inflammation (Fox et al.
1987).

However, the high cost and lack of host genetic manipulation greatly limits

application of this model. Various murine models also have been explored, but results
have been inconsistent; most do not replicate human diseases by producing clinical
symptoms, although inflammation and other pathological indicators have been observed
(Yrios and Balish 1985; Yrios and Balish 1986; Yrios and Balish 1986; Yrios and Balish
1986; Fox et al. 2004). Recently, a primate model which mimics symptoms of humans
upon infection of Campylobacter was developed for evaluation of a capsule
polysaccharide conjugate vaccine (Monteiro et al. 2009). However, in addition to the
high cost, this model requires high doses of the bacteria to cause infection, which may
not mimic real infections in humans and limit the effectiveness of some genetic
approaches such as signature-tagged mutagenesis for identification of virulence factors
essential for C. jejuni infection.
Chickens are a useful animal model of Campylobacter infection because of
following major reasons. First, chickens are a natural host for Campylobacter. The high
susceptibility of chickens to Campylobacter colonization, the ease of handling, and the
low cost of chickens have provided an ideal model system to study colonization of
Campylobacter in the host (Lin et al. 2002; Lin et al. 2003; Lin et al. 2005). Second,
newly hatched chickens are always Campylobacter-free, providing a clean and
economical

host

for

evaluating

Campylobacter

colonization.

Third,

although

Campylobacter does not cause clinical disease in chickens (an infection model, not a
disease model), chicken is a sufficient model to evaluate adaptation and survival of
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Campylobacter in response to harsh in vivo conditions, such as bile salt stress and iron
starvation addressed in this project. Fourth, poultry are considered a major source for
Campylobacter infection in humans. Reduction of Campylobacter in poultry by effective
intervention measures should reduce the risk of exposure by humans who consume
poultry products. Therefore, findings from chicken studies are directly relevant to food
safety and public health.
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CHAPTER II

DEVELOPMENT AND EVALUATION OF SUBUNIT VACCINE
CmeC IN A CHICKEN MODEL SYSTEM

21

ABSTRACT
Outer membrane protein (OMP) CmeC is a novel subunit vaccine candidate
against Campylobacter jejuni colonization in humans and animal reservoirs. To test this
hypothesis, both in vitro and in vivo studies were performed. Amino acid sequences of
CmeC from diverse C. jejuni strains were determined and alignment indicated a highlevel of sequence homology of CmeC (97.3% to 100% identity). Anti-CmeC peptide
antibodies inhibited the function of CmeABC efflux pump and enhanced susceptibility of
C. jejuni to bile salts. Two types of full-length recombinant CmeC (rCmeC) proteins were
produced in Escherichia coli and the N-terminal His-tagged rCmeC with high purity was
obtained by single step affinity purification. Purified rCmeC was used in two vaccination
trials for evaluating immunogenicity and protective efficacy in a chicken model. In both
trials, oral vaccination of chickens with rCmeC and a mucosal adjuvant mLT (E. coli
heat-labile enterotoxin) elicited serum IgG response. CmeC-specific intestinal secretory
IgA response was not significantly stimulated regardless of vaccination regimen.
Subcutaneous vaccination of chickens with rCmeC remarkably stimulated both serum
IgG and IgA responses. The rCmeC vaccination did not reduce C. jejuni colonization in
chickens in both trials. The CmeC vaccination regimen should be optimized to enhance
CmeC-specific mucosal immune response in the intestine for protection against C. jejuni.
To achieve this, preliminary conditions for CmeC crystallization were also determined to
gain a better understanding of the structure of CmeC.
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INTRODUCTION

Campylobacter jejuni is the leading bacterial cause of human enteritis in many
industrialized countries (Ketley 1997). This pathogenic organism is also associated with
Guillain-Barre syndrome, an acute flaccid paralysis that may lead to respiratory muscle
compromise and death (Rees et al. 1995; Nachamkin et al. 1998). At the same time that
prevalence of infection is increasing, Campylobacter has become increasingly resistant
to antibiotics, including fluoroquinolones and macrolides, the major drugs of choice for
treating human campylobacteriosis (Engberg et al. 2001). Despite the growing need for
new antibiotics due to increasing drug resistance in Campylobacter and other bacteria,
many pharmaceutical companies have been placing less emphasis on antibiotic
discovery (Projan 2003). Therefore, alternative intervention strategies, such as
vaccination, are needed to prevent and control Campylobacter infections. To dates,
vaccines against Campylobacter infection are still not available, primarily due to the
antigenic complexity of this organism and a lack of understanding of the mechanisms of
pathogenesis. Information concerning protective antigens as vaccine candidates in C.
jejuni is limited and vaccinations against C. jejuni using animal models including
chickens have had only partial success (Wyszynska et al. 2004; Lin 2009).

Recently, we characterized a unique outer membrane protein (OMP) CmeC, an
essential component of multidrug efflux pump CmeABC that contributes C. jejuni
resistance to a broad spectrum of antimicrobials and is also essential for C. jejuni
colonization in animal intestine by mediating bile resistance (Lin et al. 2002; Lin et al.
2003; Lin et al. 2005). As an immunogenic OMP in vivo, CmeC is distributed widely and
expressed constitutively among different Campylobacter strains (Lin et al. 2002; Lin et
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al. 2003; Lin et al. 2005). Particularly, expression of CmeC is induced by bile salts
present in the intestine, further highlighting the critical role of CmeC in Campylobacter
pathogenesis (Lin et al. 2005). This notion is supported also by a recent study by Stintzi
et al. (2005), in which expression of cmeABC operon was found to be highly upregulated in vivo. We also demonstrated that inhibition of CmeABC by efflux pump
inhibitors

increased

dramatically

susceptibility

of

Campylobacter

to

various

antimicrobials, prevented emergence of macrolide resistant C. jejuni, and reduced in
vivo colonization of C. jejuni using a chicken model system (Lin and Martinez 2006;
Martinez and Lin 2006). Based on these observations, we hypothesize that CmeC
antibodies could inhibit functions of CmeABC pump and that CmeC is a promising
subunit vaccine candidate to prevent and control C. jejuni colonization in the intestine.
To test this hypothesis, the following four objectives were pursued:
1) Examine sequence homology of CmeC in diverse Campylobacter strains and
determine in vitro protection of anti-CmeC peptide antibodies.
2) Create constructs expressing full-length rCmeC and optimize conditions for
purification of large quantities of rCmeC.
3) Evaluate immunogenicity and protective efficacy of subunit CmeC vaccine in a
chicken model of C. jejuni infection.
4) Determine conditions for crystallization of rCmeC.

MATERIALS AND METHODS
Bacterial strains, plasmids and culture conditions
The major bacterial strains and plasmids used in this study are listed in Table 1.
Fourteen C. jejuni isolates (JL7, 10, 12, 36, 78, 81, 83, 85, 90, 91, 93, 94, 95 and 118)
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from various sources (human, chicken, turkey, bovine, and environment) were used for
PCR amplification and sequence analysis of the complete cmeC gene. The C. jejuni
strains were routinely grown in Mueller Hinton (MH) broth (Difco, Detroit, MI) or on MH
agar at 42°C under microaerophilic conditions, which were generated using CampyGen
Plus (Oxoid, Bashingstoke, Hampshire, England) gas pack in an enclosed jar.
Escherichia coli was grown in Luria-Bertani (LB) broth (Fisher Scientific, Fairlawn, NJ)
with shaking (250 rpm) or on agar at 37ºC overnight. When needed, culture media were
supplemented with ampicilin (100μg/ml) (Sigma, St Louis, MO).

PCR amplification and sequence analysis of the CmeC gene
Genomic DNA was extracted from each isolate by using Wizard® Genomic DNA
Purification

Kit

(Promega,

Madison,

WI).

Primers

CmeCF

(5’-

CAGCAAAACTTCGTTTTCGTC-3’) and CmeCR (5’-TGCCTGCTATTTACAAGGCTTA3’) were used to amplify the entire cmeC gene. Amplified PCR products were purified by
QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and sequenced in Molecular
Biology Resource Facility at The University of Tennessee (Knoxville, TN). The cmeC
sequences were converted to amino acid sequences and subjected to alignment
together with other publicly available CmeC sequences (Accession #: ABC59229,
AAT38952, CAL34515, YP_001000076, ZP_01100537, ZP_01069571, ZP_01067179,
YP_178433, ZP_01071951) using DNAStar package (version 6.0). Homology Modeling
was

performed

using

an

automated

model

on

SWISS

Model

Workspace

(http://swissmodel.expasy.org/workspace/), using NodT (1wp1.pdb) as a template.

Effect of CmeC peptide antibodies on susceptibility of C. jejuni to bile salts
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Our laboratory prepared a recombinant strain of E. coli JM109 expressing a
portion of CmeC (aa 41 to 248 of total 492 aa in length) and high-titer of specific rabbit
polyclonal antiserum directed against this CmeC peptide was also generated (Lin et al.
2002). This CmeC peptide antiserum was used to examine the effect of anti-CmeC
peptide antibodies on susceptibility of C. jejuni 81-176 to cholic acid, a representative
bile salt. Briefly, a log-phase culture of C. jejuni 81-176 was diluted to approximately 2 ×
106 colony forming unit (CFU) per milliliter in MH broth containing sublethal
concentration of cholic acid (2 mg/ml). The anti-CmeC and control sera were added to
cells with 1:10 dilution and cells were incubated for 6 hr at 42oC under microaerophilic
conditions. Samples were diluted serially in MH and plated on MH agar plates to
determine bacterial viability. Both sera were inactivated at 56oC for 30 min prior to use to
abolish complement activity. Two independent experiments were performed with
duplicate assays in each experiment.

Production and purification of full-length rCmeC
To construct recombinant strain producing full-length N-terminal His-tagged
rCmeC, a 1,444-bp fragment encoding mature 473-aa CmeC (aa 20 to 492) with the
removal of the 19 aa signal peptide was PCR amplified from C. jejuni NCTC 11168 using
primers CCF (5’-AAAGGATCCTGCTCTTTAAGTCCAAATTTAAATATT-3’) and CCR (5’AAACCCGGGCTATTCTCTAAAAGACATATCTAAATT-3). The restriction sites (BamHI
and SmaI, underlined in the primer sequences) were attached to the 5’ end of each
primer to facilitate directional cloning of the amplified PCR product into the pQE30 vector
(Qiagen, Hilden, Germany). The amplified cmeC fragment was digested with BamHI and
SmaI, and was cloned into the vector pQE-30, which previously had been digested with
BamHI and SmaI. Cloning, expression, and purification of rCmeC were performed using
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the procedures described previously (Lin et al. 2003; Lin et al. 2005; Akiba et al. 2006).
To construct a recombinant strain producing the full-length C-terminal His-tagged
rCmeC, a 1,472-bp fragment encoding full length of 492-aa CmeC (aa 1 to 492) was
PCR amplified from C.

jejuni NCTC 11168

using

primers

CmeC_FLF (5'-

ACATGCATGCATAAAATAATTTCAATTAGTG-3', SphI site underlined) and CmeC_FLR
(5'-CCTAGATCTTTCTCTAAAAGACATATCTAAA-3', BglII site underlined). The PCR
amplified cmeC fragment was digested with Sph I and Bgl II and was cloned into the
pQE-70 (Qiagen, Hilden, Germany), which previously had been digested with the same
enzymes. The other procedures are the same as above for constructing the strain
expressing N-terminal His-tagged rCmeC. Plasmids pCmeC-NHIS and pCmeC-CHIS in
E. coli constructs producing N- and C- His6 rCmeC, respectively, were sequenced, with
no frameshift and mutations in the coding sequence of cmeC detected. To optimize
conditions of producing high-purity rCmeC for vaccination and structural analysis, 5 mM
of ATP-Mg2+ was added in lysis buffer to remove contamination of molecule chaperone
GroEL (Graslund et al. 2008) and 0.1% Empigen BB (Sigma, St Louis, MO) was used to
facilitate solubilization of rCmeC and preserve the antigenicity of rCmeC (Lin et al. 2003;
Lin et al. 2005; Akiba et al. 2006).

CmeC vaccination and C. jejuni challenge: Trial 1
The CmeC vaccination trial 1 is described in Table 2. Briefly, newly hatched
broiler chickens (n = 120) were allocated randomly into 6 groups (20 per group). Each
group of chickens were maintained in a sanitized wire-floored cage and provided with
unlimited access to water and commercial chicken starter feed without antibiotic
additives. At 1-week-old age, chickens were immunized orally with 200 μl of CmeC
vaccine in PBS via oral gavage. CmeC doses used were 50 and 200 μg, either alone or
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coadministered with 10 μg of mLT (general gift from Dr. John Clements in Tulane
University Medical Center). Chickens receiving PBS only or mLT only were used as
control groups. Booster doses were administered 2 wk after primary immunization.
Blood samples were collected from the wing vein of each chicken at 1, 3, 5, 7 wk of the
experiment to monitor circulating CmeC specific IgA and IgG antibodies; intestinal
lavage samples were collected and prepared at 3, and 5 wk from euthanized chickens (5
bird/group) as described previously (Wyszynska et al. 2004) to monitor mucosal IgA
antibody response. Prior to challenge, chickens were screened again with conventional
culture methods to ensure that they were Campylobacter-free. At week 5, 100 μl culture
of C. jejuni NCTC 11168 was inoculated orally into broilers (106 CFU/bird).

After

challenge, cloacal swabs were collected every 2 d for 10 d. Swabs were diluted serially,
and plated on MH agar containing selective supplement (SR117E; Oxoid, Bashingstoke,
Hampshire, England) for enumeration of Campylobacter cells. The randomly selected
colonies were tested by PCR (Lin et al. 2003) to ensure that output Campylobacter were
the same as the inoculum and there were no contamination of chickens by other
sources.

CmeC vaccination and C. jejuni challenge: Trial 2
The second vaccination trial (Table 3) had four major modifications compared to
Trial 1 (Table 2). First, white leghorn chickens, which grow slower than broilers, were
used in this trial. Second, to compare effects of vaccination route on immune response
and protective efficacy of rCmeC, subcutaneous administration was included in this trial.
Third, the dose of mucosal adjuvant mLT was increased from 10 to 70 µg/chicken in this
trial. Finally, the dose of C. jejuni NCTC 11168 used for challenge was reduced to 105
CFU/bird.
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Enzyme-linked immunoabsorbant assay (ELISA)
CmeC-specific antibodies in intestinal lavage samples and sera were measured
by indirect ELISA, which was performed using a previously published protocol (Sahin et
al. 2001) with the following modifications. Microtiter plates (Nunc-Immuno Plate, Thermo
Fisher scientific, Fairlawn, NJ) were coated with 100 μl of CmeC (30 ng/well) in coating
buffer (ammonium acetate plus ammonium carbonate [pH 8.2]) overnight at room
temperature. For vaccination Trial 1, to examine the levels of circulating CmeC specific
IgA and IgG antibodies and mucosal IgA antibodies, chicken serum and intestinal lavage
samples were routinely diluted 1:100 and 1:4, respectively. For vaccination Trial 2,
chicken intestinal lavage samples were routinely diluted 1:4 for ELISA test while each
serum sample was serially diluted up to 4,096-fold for ELISA analysis. Three serum
samples from individual chickens in Trial 1 (group 1 on d 21) were diluted 64-fold and
were used in each ELISA plate as background control. End point titer was defined as the
last dilution at which the optical density of sample wells exceeded the mean optical
density of three control wells plus 3 × standard deviation of OD405

nm.

Titer was

expressed as the reciprocal of the end point dilution log2.

Statistical analysis
Differences in serum and intestinal lavage OD405nm readings or antibody titers
among treatment groups were analyzed by least square analysis of covariance with the
data at day 0 postimmunization as the covariant; main effects were day of sample
collection and treatment. Comparison of lavage OD405nm readings or antibody titers within
treatment groups across time were tested by ANOVA. Two-way ANOVA followed by
Least significant difference (LSD) test were used to assess significance of difference
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among percentages and shedding levels of the groups at each sampling point. Levels of
significance for P value are 5% (0.05). All statistical analyses were performed using SAS
software (v9.03, SAS Institute Inc., Cary, NC).

Crystallization of rCmeC
The rCmeC was concentrated to 10 mg/mL and dialyzed against 20 mM Tris-HCl
(pH7.5) supplemented with 0.1% Empigen BB. Approximately 8 mg of highly purified
rCmeC was subjected to automatic high-throughput screening of 1536 general
crystallization conditions at room temperature in the High Throughput Screening lab
(HTS, Hauptman-Woodward Institute, Buffalo, NY) in 2008. Recently, the HTS lab and
other pioneers have observed membrane proteins can form crystals close to the phase
separation boundaries of the detergent used to form the protein detergent complex
(Koszelak-Rosenblum et al. 2009). The HTS lab has designed a new series of detergent
phase partitioning studies using combinations of different polyethylene glycols (PEG),
salts, and detergents to generate chemically diverse phase boundaries for screening
conditions for screening of membrane protein crystallization (Koszelak-Rosenblum et al.
2009). Therefore, in 2010, approximately 1.35 mg rCmeC was used for high-throughput
automatic screening with the updated crystallization conditions for membrane proteins at
4oC in HTS lab. In addition to these automatic screening efforts, a total 100 mg of highly
purified rCmeC was sent to our collaborator Dr. Xiaojian Hu (Fudan University,
Shanghai, China) who performed manual screening to determine preliminary
crystallization conditions.
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RESULTS
CmeC is highly conserved in C. jejuni
Amino acid sequences of CmeC from C. jejuni strains with diverse backgrounds
showed 97.3% to 100% identity, indicating that CmeC is highly conserved in C. jejuni
(Fig. 1A). Homologous modeling of CmeC using NodT (1wp1.pdb) as a template showed
that the monomer of CmeC has 4 transmembrane beta sheets with the majority of
residues exposed to the periplasmic space, (Fig. 1B). Three such CmeC monomers may
interact with each other and form a functional porin with 12-stranded transmembrane
beta barrel to export substrates, as what has been shown for TolC, the CmeC homolog
in E. coli (Andersen et al. 2002).

CmeC peptide antibodies enhanced susceptibility of C. jejuni to bile salt
Supplementation of anti-CmeC serum in MH broth containing a sublethal
concentration of cholic acid resulted in moderate but significant growth reduction (~ 0.6
log10 unit, P < 0.05, Fig. 2) when compared to growth in the presence of control serum
(pre-immune serum, negative for CmeC). This finding suggests that anti-CmeC
antibodies specifically inhibit the function of CmeABC efflux pump and increases the
susceptibility of C.jejuni to bile salt, which may consequently reduce C. jejuni
colonization in the intestine. However, anti-CmeC serum used here directed against a
portion of CmeC (aa 41 to 248) (Lin et al. 2002) may not contain critical protective
epitopes of CmeC. To better study immune protection of CmeC, two E. coli constructs
were constructed for producing full-length rCmeC proteins.

Production of high purity His-tagged rCmeC
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Both N-terminal and C-terminal His-tagged rCmeC proteins were successfully
produced in E. coli and purified by Ni-NTA agarose affinity column (Fig. 3A and 3B).
However, the yield of C-terminal His-tagged rCmeC was significantly lower than that of
N-terminal His-tagged rCmeC; Approximately 1.5 mg of N-terminal His-tagged rCmeC
was consistently purified from 100 ml of induced culture using 1 ml of Ni-NTA resin.
Thus, to produce large amount of rCmeC for vaccination and crystallization, we chose
the construct producing N-terminal His-tagged rCmeC that lacks the predicted 19-aa
signal peptide. However, as shown in Fig. 3A, a protein band with approximate MW of
60 kDa was consistently co-purified with rCmeC when following the standard protocol.
Based on the molecular weight of this co-purified protein, it is likely this contaminated
protein is E. coli molecule chaperone GroEL (Graslund et al. 2008). Since it has been
reported that including Mg2+-ATP in washing buffer could efficiently remove the GroEL
contamination (Harjes et al. 2004), the purification procedure was modified to improve
the purity of the extracted rCmeC. As shown in Figure 3C, addition of 5 mM Mg2+-ATP
in lysis buffer completely removed contaminated bands, resulting in eluents containing
rCmeC with high purity. Approximately 240 mg of high-purity rCmeC was purified for the
vaccination, ELISA, and crystallization studies described below.

Systemic and local immunological responses to rCmeC
In Trial 1, oral vaccination of chickens with or without mLT adjuvant did not
significantly (P < 0.05) enhance IgG and IgA levels in serum and in intestinal lavage at
different days postimmunization (Fig. 4). Despite individual variations observed among
individual chickens, chickens in group 6 (200 μg rCmeC + mLT) at 28 d
postimmunization showed consistently and slightly higher serum IgG level (P < 0.1) than
other groups. Interestingly, all groups displayed relatively higher IgG and IgA levels
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immediately prior to primary CmeC immunization (Fig. 4), likely due to the effect of
maternal antibodies (Sahin et al. 2001; Sahin et al. 2003). Consistent with the patterns of
these antibody responses, challenge of chickens with NCTC 11168 following CmeC
vaccination did not show a significant difference of colonization among groups (P >
0.05). Two days after challenge, all chickens in each group were colonized by NCTC
11168 with an average shedding level of ~107 CFU/g feces.
In Trial 2, oral immunization of chickens with a higher dose of CmeC (200 μg)
and mucosal adjuvant (70 µg) (group D) significantly (P < 0.05) elevated the IgG titer
than those in the control groups (A and B) and the group C with a low dose of CmeC (50
μg) at 28 and 42 d postimmunization (Fig. 5A). However, serum IgA titers were similar
among the groups (A-D) that received oral vaccination. Subcutaneous vaccination of
chickens with CmeC together with Freund’s incomplete adjuvant (Group F in Fig. 5)
dramatically elevated serum IgG and IgA titers (P < 0.05) at 14, 28, and 42 d
postimmunization compared with the control group vaccinated with Freund’s incomplete
adjuvant only. With respect to CmeC-specific intestinal secretory IgA response, there
was no significant difference (P > 0.05) among treatment groups, regardless of
vaccination route and dosage (Fig. 6). However, intestinal IgA levels of each group were
consistently higher at 28 d postimmunization than those at 14 d postimmunization.
Consistent with the lack of significantly induced local IgA response to CmeC, CmeC
vaccination in Trial 2 did not significantly reduce C. jejuni colonization in the intestine
(Fig. 7).

Preliminary conditions for rCmeC crystallization
In the first automatic screening of crystallization conditions, 1536 conditions for
general protein crystallization were screened at room temperature. No potential
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crystallization conditions were determined in this trial. The manual screening in Dr.
Xiaojian Hu’s laboratory led to the observation of micro-crystals following incubation the
crystallization plates at 4oC (Fig. 8A); the corresponding solution consists of 0.2 M
ammonium dihydrogen phosphate, 0.1M Tris (pH 8.5) and 50% v/v (+/-) 2-methyl-2,4pentanediol. However, due to the small size of micro-crystals and salt contamination,
these micro-crystals could not generate good scatter data (Fig. 8B). Further optimization
efforts are underway to get larger and purer crystals. The recent automatic crystallization
screening using improved approaches has identified several potential conditions under
which small crystals were formed (the representive one in Fig. 8C); the corresponding
solution (cocktail M2_1393) consists of 0.2 M calcium chloride dehydrate, 0.1 M Bis-Tris
(pH6.5) and 45% (v/v) (+/-)-2-Methyl-2,4-pentanediol.

DISCUSSION
Previous studies have reported that CmeC is prevalent in C. jejuni, is induced
and immunogenic in vivo, and is essential for C. jejuni colonization (Lin et al. 2002; Lin et
al. 2003; Lin et al. 2005). These findings suggest that CmeC is a promising subunit
vaccine candidate against C. jejuni colonization in the intestine. In vitro studies in this
chapter provided further compelling evidence that CmeC is an attractive candidate for C.
jejuni vaccine development. Alignment of complete CmeC sequences from diverse
strains demonstrated that CmeC is highly conserved in C. jejuni (Fig. 1). This finding is
consistent with a recent report in which a small portion of cmeC was PCR amplified from
different Campylobacter strains for sequencing (Fakhr and Logue 2007). It is likely that
CmeC displayed variation between different Campylobacter species, such as C. jejuni
and C. coli, because alignment of partial CmeC sequence showed only 83% aa identity
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(Fakhr and Logue 2007). However, sequence analysis of full length CmeC in this study
clearly indicated that the genetic variation within C. jejuni, the major cause of human
campylobacteriosis, is extremely limited. This evidence together with in vitro inhibitory
effect of CmeC peptide antiserum on the function of CmeABC efflux pump (Fig. 2)
provides a strong rationale to develop CmeC-based subunit vaccine.

To overcome the potential limitations of using partial CmeC peptide for
vaccination and structural studies, full-length rCmeC proteins were successfully
produced and purified. Expression and purification of recombinant membrane proteins in
E. coli system are always coupled with problems such as low yield, insolubility, unfolding
or misfolding, co-purification of contaminations, proteolytic degradation, and less
biological activity. In the past decade, extensive efforts have been placed on the
modification of promoter, design of fusion with tags, refolding after purification,
chaperone co-expression/knockout, and protease gene knockout (de Marco 2006; de
Marco 2007; de Marco et al. 2007). In this study, the N-terminal His-tagged rCmeC is
located in cytoplasm due to removal of the 19-aa signal peptide. Thus, cytoplasmic
rCmeC proteins which have transmembrane domains (hydrophobic patch) are likely to
attract/arrest the chaperones (de Marco et al. 2007). During our preparation for rCmeC,
we consistently observed the co-purification of a protein with molecular weight of ~ 60
kDa together with the target rCmeC band (Fig. 3A and 3C), suggesting that that GroEL
(60 kDa)-GroES (10 kDa) chaperone system in E. coli (de Marco 2007; Graslund et al.
2008) may bind newly synthesized rCmeC. Since the binding of ATP can trigger the
turnover of substrates in GroEL-GroES systems by reducing the affinity of GroEL-GroES
with substrates (Harjes et al. 2004), 5 mM of Mg2+-ATP was added into the lysate to
facilitate the disassociation of rCmeC from GroEL-GroES. This single and simple
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modification increased the purity of extracted rCmeC without affecting yield (Fig. 3C). It
is also important to mention that the detergent Empigen BB was used to facilitate
solubilization of rCmeC during purification in this study because Empigen BB is a mild
zwitterionic detergent and is known for its ability to preserve the antigenicity and
functional activity of isolated proteins (Zhang et al. 2000). Together, the rCmeC protein
with high purity has been obtained in this study for various research projects, such as
vaccination and crystallization.

The two vaccination trials performed in this study showed that oral vaccination of
chickens with rCmeC triggered little or weak immune response and thus failed to confer
protection of chickens against C. jejuni colonization. The modifications of vaccination
regimen made in Trial 2 provided useful information for future vaccination trials using the
chicken as a model. For example, white leghorn appears a better animal host than
broiler for vaccination evaluation, primarily due to its slow growth rate, which makes
animal handling easier and also allows us to initiate late primary vaccination (e.g. 3 wk of
age) when Campylobacter specific maternal antibodies decrease to a low level. In this
study, although dramatic systemic immune reponse to CmeC was induced using the
subcutaneous vaccination route, elevated antibody titers in serum did not result in
increased levels of intestinal antibodies. Thus, mucosal vaccines instead of an injectable
vaccine should be developed to induce a strong mucosal immune response in the
intestine to control Campylobacter colonization. It is not surprising that sufficient levels of
CmeC-specific antibodies, particularly intestinal IgA, were not reached in these two
vaccination studies. Development of an oral subunit vaccine faces a common difficulty:
weak immunogenicity due to antigen degradation in the GI tract. We speculate that orally
administered rCmeC may be absorbed to the upper gastrointestinal tract (e.g., crop) and
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significantly degraded in the intestine before it can prime the host immune system. To
solve this problem, encapsulation of rCmeC using the chitosan microsphere, an effective
adjuvant/carrier system, is a promising approach to deliever rCmeC to the target site and
trigger a strong local intestinal mucosal immune response (Sinha et al. 2004; Arca et al.
2009). In addition, identification of protective epitopes of CmeC followed by construction
of live Salmonella-vectored vaccine is also a promising approach (Kwon et al. 2007),
which is strongly supported by the finding from using live Salmonella vaccine expressing
protective epitope of CfrA described in Chapter III.

CmeC functions as porin-type channels that facilitate translocation of diverse
substrates across the outer membrane. Crystal structure of TolC, a CmeC-homolog in E.
coli, showed that the TolC trimer forms a channel that is constitutively open wide to the
extracellular side (Koronakis et al. 2000), suggesting CmeC specific antibodies may be
easily accessible to CmeC. However, secondary structure prediction of CmeC (Fig. 1B)
showed that surface-exposed regions of CmeC may be limited, which might reduce our
workload in determining protective epitopes. It’s anticipated to be observed in the crystal
structure of rCmeC. Efforts were undertaken to determine optimal conditions for CmeC
crystallization. In this project, complementary approaches (automatic and manual
screening) were used to determine the appropriate combination of factors (e.g. choice of
detergent, buffer, temperature) for CmeC crystallization. We speculate that elucidation of
the structure of CmeC will facilitate construction of a Salmonella live vaccine expressing
specific surface region(s) of CmeC using the same approach described in Chapter III.
This hypothesis will be tested in future studies.
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Table 1. Key bacterial strains and plasmids used in this project (Chapter II).
Plasmids or
strains
Plasmids
pGEMT-Easy
pQE-30
pQE-70
pCmeC-NHIS
pCmeC-CHIS

PCR cloning vector, Ampr
N-His6 fusion recombinant protein vector
C-His6 fusion recombinant protein vector
pQE-30 ligated with cmeC segment encoding mature CmeC
pQE-70 ligated with cmeC segment encoding mature CmeC

Promega
Qiagen

Strains
C. jejuni
JL7
JL10
JL12
JL36
JL78
JL81
JL83
JL85
JL90
JL91
JL94
JL95
JL118
JL241

H49024, human isolate
ATCC 33291, human isolate
15046764, bovine isolate
S3B, chicken isolate
W42606, human isolate
F34078, human isolate
M76297, human isolate
F59966, human isolate
M33323, human isolate
W11805, human isolate
E46972, human isolate
19094451, ovine isolate
CVM20088, chicken isolate
NCTC 11168, human isolate

(Zhang et al. 2000)
ATCC
(Zhang et al. 2000)
(Lin et al. 2003)
(Huang et al. 2005)
(Huang et al. 2005)
(Huang et al. 2005)
(Huang et al. 2005)
(Huang et al. 2005)
(Huang et al. 2005)
(Huang et al. 2005)
(Zhang et al. 2000)
Chickena
(Gundogdu et al.
2007)
(Black et al. 1988)

JL242
E. coli
DH5α
JM109
JL243
JL348

Description

81-176, human isolate
F- Φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17
(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λendA1 recA1 gyrA96 thi hsdR17 (rk-, mk+) relA1 supE44 Δ(lacproAB) [F’ traD36 lacIqZΔM15]
JM109 containing pCmeC-NHIS
JM109 containing pCmeC-CHIS
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Source or
Reference

This study

Invitrogen
Promega
This study
This study

Table 2. The first CmeC vaccination and C. jejuni challenge using broilers (Trial 1).
Group

No. of
Chickens

1
2
3
4
5
6

20
20
20
20
20
20

Day 7
Primary Immunization

Day 21
Booster
Immunization

PBS
mLT
CmeC (50 μg)
CmeC (50 μg) + mLT
CmeC (200 μg)
CmeC (200 μg) + mLT
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Sample
collections
Blood: day 7,
21, 35, 42
Intestinal
lavage: day
21, 35

C. jejuni
challenge on
day 35
Yes
Yes
Yes
Yes
Yes
Yes

Table 3. The second CmeC vaccination and C. jejuni challenge using white leghorns
(Trial 2).
Day 21
Primary
Immunization

Day 35
Booster
Immunization

Group

No. of
Chickens

Vaccination
Route

A

20

Oral

mLT (70 μg)

B

20

Oral

CmeC (200 μg)

C

20

Oral

CmeC (50 μg)+ mLT (70 μg)

D

20

Oral

CmeC (200 μg) + mLT (70 μg)

E

20

Subcutaneous

FIA

Subcutaneous

CmeC (200 μg) + FIA

F

20

a

a

b

mucosal adjuvant heat-labile enterotoxin (LT) - R192G
Freund’s incomplete adjuvant

b
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b

Sample
collections
Blood: day 21,
35, 49, 63;
Intestinal
lavage: day
35, 49;
Cloacal swab:
day 49, 51,
53, 56, 58.

C. jejuni
challenge on
day 49
Yes
Yes
Yes
Yes
Yes
Yes

(A)

(B)

OM

PS

Figure 1. Sequence analysis and structural prediction of CmeC.
(A) Phylogenetic tree of CmeC from different strains. Phylogenetic tree was constructed
in UPGMA method in MEGA 4.0. (B) Predicted structure of CmeC. Homology Modelling
was performed in automated model on SWISS Model Workspace, using NodT
(1wp1.pdb) as a template. OM, outer membrane; PS, periplasmic space.
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7

log10CFU/ml

6.5

6

5.5

5
Control serum

Anti-CmeC serum

Figure 2. Growth responses of C. jejuni 81-176 to anti-CmeC serum and control serum
(pre-immune serum).
Each bar represents the mean value obtained from duplicate assays.
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(A)

(B)

(C)

GroEL

rCmeC

Figure 3. Expression and purification of rCmeC by SDS-PAGE analysis.
(A) Expression and purification of N- terminal His-tagged rCmeC. M, standard molecular
mass markers (Bio-rad); 0h and 3h, noninduced and 3 h-induced whole-cell lysate,
respectively; E, eluted rCmeC fraction using Ni-NTA affinity chromatography (Qiagen).
The putative GroEL, an E. coli molecule chaperone, was consistently co-purified with
rCmeC using the standard protocol. (B) Expression and purification of C-terminal Histagged rCmeC. FL: flow through; Ag, Ni-NTA agarose after elution; W1-W5, washing
fractions; E1-E3, elution fractions. (C) Efficient removal of GroEL contaminant by ATPMg2+ treatment. Eluted fractions (E3 to E10) during Ni-NTA purification with (right panel)
or without (left panel) addition of 5 mM of ATP- Mg2+ were subjected to SDS-PAGE
analysis.
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14

28
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Figure 4. Immunological responses to rCmeC (vaccination trial 1).
(A) Serum IgG response elicited by CmeC subunit vaccination in broiler chickens. All
chicken serum samples were diluted 1:100 for indirect ELISA. (B) Serum IgA and
intestinal IgA (the embedded figure) levels in chickens vaccinated with rCmeC. The
number for each bar corresponds to the group number described in Table 2. Each bar is
the average of OD405 readings from 10-20 individual serum samples or 5 individual
intestinal lavage samples with standard error indicated by error bar.
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(A)

(B)

Figure 5. Serum IgG and IgA titers to rCmeC (vaccination trial 2).
(A) Serum IgG titer in response to CmeC subunit vaccination. The letter for each bar
corresponds to the group described in Table 3. The embedded figure shows the average
of OD405 readings of group A-F at 28 and 42 days postimmunization. (B) Serum IgA
titer in response to CmeC subunit vaccination. Each bar is the average of log2
transformed titers from10-20 individual serum samples with standard error indicated by
error bar.
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Figure 6. Intestinal mucosal IgA titers to CmeC (vaccination Trial 2).
The letter for each bar corresponds to the group described in Table 3. Each bar is the
average of OD405 readings from 5 individual intestinal lavage samples with standard
error indicated by error bar.
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Figure 7. Campylobacter colonization levels after challenging CmeC-vaccinated
chickens with C. jejuni NCTC 11168 (Trial 2).
The letter for each type of point corresponds to the group described in Table 3. Each
point represents mean log10 CFU/g feces ± the standard deviation in each group.
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(A)

(B)

(C)

Day 0

Day 28

Figure 8. Crystallization of rCmeC.
(A) Micro-crystals of rCmeC determined by manual screening. (B) The X-ray scatter data
of the micro-crystals of rCmeC. The right panel is the magnification of the selected area
in the left panel. Both A and B figures are provided by Dr. Xiaojian Hu (Fudan University,
Shanghai, China). (C) CmeC crystal formation during the second high-throughput
automatic screening. The left graph was taken at day 0. The right graph was taken for
the same well after 28 days of incubation at 4 oC under specific crystallization conditions.
The potential crystals were indicated by arrows.
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CHAPTER III

MOLECULAR, ANTIGENIC, FUNCTIONAL, AND PROTECTIVE
CHARACTERISTICS OF FERRIC ENTEROBACTIN RECEPTOR
CfrA IN CAMPYLOBACTER
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ABSTRACT
Ferric enterobactin receptor CfrA is not only responsible for high-affinity iron
acquisition in Campylobacter jejuni but also essential for C. jejuni colonization in the
animal intestine. In this study, we determined the feasibility of targeting surface-exposed
CfrA for immune protection against Campylobacter colonization. Alignment of complete
CfrA sequences from 15 Campylobacter isolates showed that the amino acid identity of
CfrA ranged from 89% to 98%. Immunoblotting analysis using CfrA-specific antibodies
demonstrated that CfrA was induced under the iron-restricted condition and was
produced in 32 Campylobacter primary strains from various origins and geographically
diverse areas. Immunoblotting survey was correlated highly with the enterobactin growth
promotion assay and PCR analysis using cfrA-specific primers. Inactivation of cfrA also
impaired norepinephrine-mediated growth promotion, suggesting that CfrA is required for
C. jejuni to sense intestinal stress hormones during colonization. Complementation of a
cfrA mutant with a wild-type cfrA allele in trans fully restored production and function of
CfrA. A growth assay using purified anti-CfrA IgG demonstrated that specific CfrA
antibodies blocked the function of CfrA, consequently diminishing ferric enterobactinmediated growth promotion under iron-restricted condition. The inhibitory effect of CfrA
antibodies was in a dose-dependent manner. Immunoblotting analysis also indicated
that CfrA was expressed and immunogenic in chickens experimentally infected with C.
jejuni. Amino acid substitution mutagenesis demonstrated that a basic amino acid R327
that was highly conserved in CfrA played a critical role in ferric enterobactin acquisition
in C. jejuni. A live Salmonella vaccine producing protective epitope of CfrA was
constructed. Oral vaccination of chickens with the live Salmonella-vectored vaccine
conferred protection of chickens against Campylobacter infection. Together, these

52

findings strongly suggest that CfrA is a promising vaccine candidate to prevent and
control Campylobacter infection in humans and animal reservoirs.

INTRODUCTION
Campylobacter species including C. jejuni and C. coli are the most common
bacterial causes of human enteritis in many industrialized countries (Ketley 1997).
Human Campylobacter illnesses are caused primarily by C. jejuni (~90%) and
secondarily by C. coli (~10%). This pathogenic organism is also associated with GuillainBarré syndrome, an acute flaccid paralysis that may lead to respiratory muscle
compromise and death (Nachamkin et al. 1998). In parallel to its increased prevalence,
Campylobacter

has

become increasingly

resistant to clinical

antibiotics

(e.g.

fluoroquinolones and macrolides), greatly compromising the effectiveness of antibiotic
treatment (Engberg et al. 2001). Despite the growing need for new antibiotics due to the
increasing drug resistance in Campylobacter and other bacteria, many pharmaceutical
companies have been de-emphasizing antibiotic discovery (Projan 2003; Walsh 2003).
Therefore, development of alternative intervention strategies, such as vaccination, to
prevent and control Campylobacter infections in humans and animal reservoirs is
urgently needed. However, no commercial vaccine against C. jejuni is available to date.
Information concerning protective antigens as vaccine candidates in C. jejuni is limited,
primarily due to a lack of understanding of pathogenesis mechanisms and by the
antigenic complexity of this important bacterial pathogen.
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Bacterial outer membrane proteins (OMPs) are considered major mediators of
host-pathogen interactions and are promising candidates for the design of protective
vaccines (Lin et al. 2002). Iron-regulated OMPs are important virulence factors in
bacteria and play a critical role in bacterial adaptation to host niches primarily by
mediating iron uptake (Andersen et al. 2002). All Gram-negative bacteria have an
absolute requirement for iron to survive. However, levels of free iron in vivo are well
below those required for growth of Gram-negative bacteria (Stintzi et al. 2008). For
example, in the intestine, the principal site of colonization by C. jejuni, there are two
potential sources of iron; the mucosa and food (Stintzi et al. 2008). However, iron from
these sources (e.g. lactoferrin in mucosal secretions and haem in food) is not normally
available to invading Gram-negative bacteria in the intestine (Stintzi et al. 2008). Iron
binding proteins in the intestine sequester free ferric iron as low as 10-24 M and make it
unavailable to most bacteria which demand at least 10-7 M for normal growth (Braun and
Hantke 2002). Therefore, to obtain sufficient iron for survival and multiplication, enteric
Gram-negative bacteria have evolved sophisticated genetic systems for iron uptake. The
most efficient strategy is to utilize high affinity iron uptake systems, in which ironregulated OMPs (e.g. ferric enterobactin receptor FepA in Escherichia coli) can bind to
the iron-siderophore complex and promote iron-siderophore transport across the
membrane into cells (Moeck and Coulton 1998). Thus, iron-regulated OMPs interact
directly with iron-restricted environments encountered by pathogenic bacteria and
function as a “gate keeper” for iron assimilation in bacteria. Enterobactin is a siderophore
of particular interest because enterobactin has the highest affinity for ferric iron of any
natural siderophore compounds tested and can effectively capture iron from other iron
complexes in neutral and alkaline conditions (Stintzi et al. 2008). On the other hand,
enterobactin is produced by a wide variety of commensal bacteria in the intestine and
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this compound is likely to be produced in significant amounts by resident microflora of
the intestine (Stintzi et al. 2008). Thus, ferric enterobactin may be a significant source of
iron to enteric pathogens including C. jejuni during intestinal colonization and the
surface-exposed ferric enterobactin receptor is a potential target for vaccine
development.

Despite the lack of an ability to synthesize enterobactin, C. jejuni can express
ferric enterobactin receptor CfrA and other essential components of ferric enterobactin
uptake system (e.g. TonB and ceu ABC transport system) for utilization of ferric
enterobactin as a sole iron source (Stintzi et al. 2008). C. jejuni CfrA sequence has a
high similarity with BfeA, a ferric enterobactin receptor produced by Bordetella
bronchiseptica that does not have genes involved in synthesis of enterobactin (Anderson
and Armstrong 2006; Stintzi et al. 2008). CfrA was induced under iron-restricted
conditions and responsible for high affinity enterobactin-mediated iron acquisition in
Campylobacter (Guerry et al. 1997; van Vliet et al. 1998; Palyada et al. 2004; Holmes et
al. 2005). Strikingly, inactivation of cfrA alone not only impaired enterobactin-mediated
iron assimilation in C. jejuni but also completely abolish colonization of C. jejuni in
chickens although the parent strain colonized all chickens with colonization level > 107
colony forming units (CFU) per gram cecal content (Palyada et al. 2004). This finding
indicates that other iron-uptake system(s) in C. jejuni cannot compensate for the function
of CfrA and CfrA plays an essential role in colonization of C. jejuni in chickens. It was
suggested that CfrA may also have other novel function(s) important for intestinal
colonization of chickens by C. jejuni (Palyada et al. 2004). Together, these previous
studies strongly suggest that CfrA is a potential vaccine candidate against C. jejuni.
However, little information exists concerning sequence homology, immunogenicity,
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prevalence and novel functions of CfrA in C. jejuni. In addition, it is also unknown if CfrA
is expressed and antigenic in vivo and if CfrA specific antibodies can block the function
of CfrA. Addressing these issues is crucial for our understanding of the role of CfrA in C.
jejuni pathogenesis and the feasibility of targeting CfrA for immune protection against
Campylobacter colonization. In this study, we examined sequence homology,
immunogenicity, prevalence and novel functions of CfrA in C. jejuni. The protective
efficacy of a salmonella vaccine expressing a functionally important CfrA epitope was
evaluated in a chicken model.

MATERIALS AND METHODS
Bacterial strains, plasmids and culture conditions.
Bacterial strains and plasmids used in this study and their sources are listed in
Table 4. Seven C. jejuni isolates (JL10, 12, 36, 78, 81, 83, and 118; Table 4) were used
for amplification and sequencing of the full-length cfrA gene. Among the 32 strains used
for CfrA prevalence assay, 30 isolates were C. jejuni while 2 isolates (JL96 and JL170)
were C. coli. These Campylobacter primary strains were isolated from humans (n=15),
bovine (n=5), chicken (n=5), turkey (n=1), pig (n=1), ovine (n=1), and farm environments
including lagoon (n=1), bird dropping (n=2) and mouse trap (n=1). These Campylobacter
strains were from geographically diverse areas including Ohio (14 isolates), Tennessee
(5 isolates), Georgia (3 isolates), Michigan (2 isolates), Alabama (1 isolate), Iowa (1
isolate), Maryland (1 isolate), Minnesota (1 isolate), Colorado (1 isolate) as well as
France (2 isolates) and the United Kingtom (1 isolate). The C. jejuni strains were
routinely grown in Mueller Hinton (MH) broth (Difco, Detroit, MI) or on agar at 42°C
under microaerophilic conditions, which were generated using CampyGen Plus (Oxoid,
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Bashingstoke, Hampshire, England) gas pack in an enclosed jar. The final concentration
of 40 μM ferric sulfate was used for bacterial growth under the iron-rich condition. The
final concentration of 20 μM of deferoxamine mesylate (DFO) was supplemented in
medium to achieve the iron-limited condition. E. coli was grown in Luria-Bertani (LB)
broth (Fisher Scientific, Fairlawn, NJ) with shaking (250 rpm) or on agar at 37 ºC
overnight. When needed, culture media were supplemented with kanamycin (30 μg/ml)
or chloramphenicol (4 or 20 μg/ml). All antibiotics were purchased from Sigma (St Louis,
MO).

PCR
PCR primers used in this study and expected sizes of products are listed in Table
5. PCR was performed in a volume of 50 µl containing 200 µM of each deoxynucleotide
triphosphate, 200 nM of primers, 2.5 mM of MgSO4, 50 ng of template DNA and 5 U of
Taq DNA polymerase (Promega, Madison, WI) or PfuUltra® High-Fidelity DNA
polymerase (Stratagene, La Jolla, CA). Cycling conditions varied according to the
estimated annealing temperatures of primers and expected sizes of products. PCR
products were purified by QIAquick PCR Purification Kit (Qiagen, Hilden, Germany)
when needed for cloning or sequencing analysis. Notably, to examine the prevalence of
cfrA among various Campylobacter isolates, primer pairs CfrAF and CfrAR (Table 5)
were designed based on highly conserved regions of cfrA.

Sequence analysis of CfrA
The complete open reading frame of cfrA from C. jejuni was PCR amplified using
primer pairs of CfrAF1 and CfrAR1 (Table 5). The purified PCR products were subjected
to sequencing and alignment. Multiple sequence alignment was performed by ClustalW
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program in MEGA 4.0 (Kumar et al. 2008). The CfrA-based dendrogram was done by
neighbor-joining methods in MEGA 4.0 (Kumar et al. 2008). To identify the conserved
amino acids in CfrA that may play a critical role in ferric enterobactin assimilation,
multiple sequence alignment among FepA sequences from Escherichia coli (Lundrigan
and Kadner 1986), Salmonella enterica (Baumler et al. 1998), Pseudomonas aeruginosa
(Dean and Poole 1993), Bordetella pertussis (Beall and Sanden 1995) and CfrA
sequences from different Campylobacter strains was also carried out by using ClustalW
in MEGA 4.0 (Kumar et al. 2008).

Production of recombinant CfrA and generation of polyclonal antisera
A full-length histidine-tagged recombinant CfrA (rCfrA) was produced in E. coli by
using pQE-30 vector of the QIAexpress Expression System (Qiagen, Hilden, Germany).
Briefly, primers PF1 and PR1 (Table 5) were used to amplify a 2,043-bp fragment
encoding mature 676-aa CfrA (aa 21 to 696) from C. jejuni NCTC 11168. Restriction
sites (BamHI and SmaI, underlined in primer sequences) were attached to the 5’ end of
each primer to facilitate directional cloning of the amplified PCR product into the pQE30
vector. The amplified PCR product was digested with BamHI and SmaI and was ligated
into the pQE30 vector, which previously had been digested with the same enzymes.
Cloning, expression, and purification of rCfrA were performed as described in our
previous publications (Zhang et al. 2000; Lin et al. 2002; Lin et al. 2002; Lin et al. 2005;
Akiba et al. 2006). The plasmid pCFRA-NHIS in the E. coli JM109 clone (JL275)
producing rCfrA was sequenced, with no frameshift or other mutations in the coding
sequence of cfrA detected.
Approximately 2 mg of highly purified rCfrA obtained from JL275 was used for
production of rabbit polyclonal antisera against CfrA. Rabbit CfrA polyclonal antisera
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were prepared by Pacific Immunology Corp (Ramona, CA). Pre- and post-immune
serum samples were analyzed by immunoblotting, using both rCfrA and membrane
proteins of NCTC 11168 grown under iron-restricted condition. Post-immune sera
reacted specifically with CfrA while pre-immune sera were negative for CfrA.

SDS-PAGE and immunoblotting
Various C. jejuni isolates were grown in iron-rich medium (MH + 40 μM ferric
sulfate) or iron-limited medium (MH + 20 μM DFO) to late log phase at 42oC under
microaerophilic conditions. To prepare whole-cell lysates, Campylobacter cells grown in
iron-rich or iron-limited conditions were harvested and solubilized by boiling for 5 min in
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer.
The SDS-PAGE and immunoblotting were performed as detailed in a previous
publication (Lin et al. 2003).

Insertional mutation of cfrA and complementation in trans
An isogenic cfrA mutant of C. jejuni NCTC 11168 was constructed by insertional
mutagenesis as described (Lin et al. 2003; Lin et al. 2005; Akiba et al. 2006). Primers
CfrAF2 and CfrAR2 (Table 5) were used to amplify the 1.6-kb cfrA gene fragment. The
PCR product with a unique NheI restriction site was cloned into pGEMT-Easy (Promega,
Madison, WI), resulting in the construct pCA. The chloramphenicol resistance (Cmr)
cassette was PCR amplified from plasmid pUOA18 (Wang and Taylor 1990) using
primers CHLF1 and CHLR1 (Table 5) that had a NheI restriction site at the 5’ end. The
0.8-kb PCR product containing Cmr cassette was digested by NheI and ligated to NheIdigested pCA to obtain the construct pmCA (Table 4). Sequence analysis of the
construct indicated that the Cmr cassette was inserted in cfrA with the same
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transcriptional direction. The plasmid pmCA, which served as a suicide vector, was
transferred into C. jejuni NCTC 11168 by natural transformation. One Cmr mutant (JL324)
was selected on MH agar containing 4 μg/ml of Cm. Inactivation of cfrA in JL324 was
confirmed by PCR (data not shown) and immunoblotting using CfrA-specific antibodies.
To complement cfrA mutation in JL324, a 2.5-kb fragment spanning from the
promoter region of cfrA to 36 bp downstream of cfrA stop codon was PCR amplified from
C. jejuni NCTC 11168 using primers CfrAF2 and CfrAR1 (Table 5). The PCR was
performed using pfu DNA polymerase (Stratagene, La Jolla, CA) and the blunt-ended
PCR product was purified and ligated to shuttle vector pRY107 (Yao et al. 1993), which
was digested with SmaI prior to ligation. The ligation mix was introduced into E. coli
DH5α (Invitrogen, Carlsbad, CA) by transformation. The transformant with plasmid
bearing the intact cfrA gene (named ‘pCfrA’) was identified (JL334). The pCfrA from
JL334 was then transferred to JL324, a cfrA isogenic mutant, by tri-parental conjugation
using DH5α/pRK2013 as a helper strain (Akiba et al. 2006). The complementation strain
was named JL335 and was confirmed by immunoblotting using CfrA-specific antibodies.

Construction of JL364
An open reading frame CJJ81176_0471 of C. jejuni 81-176 was also annotated
as a TonB-dependent receptor responsible for ferric enterobactin assimilation
(http://www.ncbi.nlm.nih.gov/protein/121612217). Genomic DNA extracted from an
isogenic CJJ81176_0471 mutant of C. jejuni 81-176 was kindly provided by Dr. Julian M.
Ketley and Dr. Richard Haigh (University of Leicester, United Kingdom). Genomic DNA
was used to transform JL242 (Table 4) by natural transformation as described by Wang
and Taylor (1990). This transformation procedure introduced the insertional mutation of
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CJJ81176_0471 into JL242, creating isogenic mutant JL364 (Table 4).

The

CJJ81176_0471 mutation in JL364 was confirmed by PCR (Data not shown).

Purification of enterobactin
An enterobactin transport mutant E. coli AN102 (JL122, Table 4) was kindly
provided by Dr. Sandra K. Armstrong (University of Minnesota, Minneapolis, MN) for
enterobactin purification. Enterobactin was purified from E. coli AN102 as described
previously (Anderson and Armstrong 2004). The concentration was calculated using a
millimolar extinction coefficient of enterobactin of 9.39 at 316 nm in ethyl acetate
(O'Brien et al. 1971; Brickman and McIntosh 1992). Purified enterobactin was dissolved
in a methanolic solution and stored at 4oC for future work.

Growth promotion assay
Briefly, C. jejuni log-phase cells grown in MH broth (~ 2 x 107 cells) were mixed
with melted MH agar containing chelator DFO at final concentration of 20 µM (for
enterobactin growth promotion test) or 5 µM (for NE growth promotion test). The mix
was poured immediately into Petri dishes for solidification. A sterile disk containing 10 µl
of enterobactin (5 mM), norepinephrine bitartrate (100 mM, Sigma, St Louis, MO), or
H2O was placed upon the surface of the agar. The growth zone around the disks were
observed and measured after 24 h of incubation at 42oC under microaerophilic
conditions.

Inhibition of enterobactin uptake by anti-CfrA IgG
The ability of specific anti-CfrA IgG to inhibit CfrA-mediated ferric enterobactin
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assimilation was assessed by a modified growth promotion assay (Murphy et al. 1990).
The IgG fraction of heat-inactivated rabbit serum samples (preimmune control serum
and postimmune anti-CfrA serum) was purified by ammonium sulphate precipitation (Lin
et al. 1998). Purified IgG was dialyzed against phosphate buffered saline (PBS),
sterilized by membrane filtration, aliquoted and stored at -20oC prior to use. The IgG
concentration was measured by BCA protein assay reagent (Pierce, Rockford, IL). To
evaluate the inhibitory effect of anti-CfrA IgG on CfrA function, one ml of a log phase
culture of C. jejuni strain JL241 grown in MH broth was centrifuged, washed once with
PBS and resuspended in 0.5 ml PBS. The bacterial suspension was mixed with 0.5 ml of
purified anti-CfrA IgG (16 mg/ml), purified preimmune IgG (16 mg/ml) or PBS, and then
added into 24 ml MH agar containing 20 μM DFO and poured into Petri dishes for
solidification. A sterile disk containing 10 µl of enterobactin (5 mM) or H2O was placed
upon the surface of the agar. The growth zone around disk was observed and measured
after 24 h of incubation at 42oC under microaerophilic conditions. For measuring dosedependent inhibition of CfrA by CfrA antibodies, anti-CfrA IgG was added in agar plates
at final concentrations of 0, 12.8, 32, 64, or 320 µg/ml. All assays were performed in
three independent experiments with triplicate measurements within each independent
experiment. The significance of differences in growth inhibition was determined using the
Student’s t-test.

Immunoblotting analysis of CfrA expression in vivo
The rCfrA was separated by SDS-PAGE and then transferred electrophoretically
to a nitrocellulose membrane as described (Lin et al. 2003). Blots were incubated with
different chicken serum samples (1:100 dilution in blocking buffer), which included two
negative control serum samples from 3-wk-old Campylobacter-free broiler chickens, one
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serum sample from a 2-d-old Campylobacter-free broiler chicken but displaying high titer
of maternally derived antibodies to C. jejuni (Sahin et al. 2001) and one serum sample
from a 6-wk-old broiler experimentally infected with C. jejuni S3B (Sahin et al. 2003).
Immunoblotting was detailed in our previous publication (Lin et al. 2003). All chicken
sera were kindly provided by Dr. Qijing Zhang (Iowa State University, Ames, IA).

Site-directed amino acid substitution mutagenesis
The predicted basic or aromatic amino acids in CfrA that may be important for
ferric enterobactin assimilation were substituted by alanine using partial overlapping
PCR (Zheng et al. 2004). Briefly, the partial overlapping primer pairs containing the
desired mutation (Table 5) were used for PCR amplification of pCfrA plasmid. The
PfuUltra® High-Fidelity DNA polymerase (Stratagene) was used in PCR and the cycling
condition was programmed at 95oC for 2 min, 18 cycles of 94oC for 1 min, 56oC for 1 min
and 68oC for 9.5 min, followed by 68oC for 30 min. The 9.3 kb PCR product was purified,
concentrated and treated with DpnI (New England Biolabs) for 2 h to digest the
methylated, nonmutated parental DNA template. The digested product was transformed
into E. coli DH5α by transformation. The plasmid with the specific amino acid substitution
in CfrA was selected and confirmed by sequencing using primer CfrAR3 (Table 5). Four
plasmids with different amino acid substitutions (Table 4) were generated and then
transferred to an isogenic cfrA mutant of C. jejuni NCTC 11168 (JL324), creating
constructs JL442, JL446, JL494 and JL495 (Table 4). These constructs and the control
strain JL335 were used for enterobactin growth promotion assay to determine the role of
specific amino acid in ferric enterobactin assimilation in C. jejuni.

Construction and evaluation of an attenuated Salmonella enteritidis strain
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expressing CfrA protective epitope
S. enteritidis 13A strain was originally isolated from a chicken and was resistant
to nalidixic acid (25 µg/ml). The attenuated S. enteritidis vaccine strain was constructed
by Dr. Young Min Kwon (University of Arkansas, Fayetteville, AR) via deleting aroA and
htrA genes and inserting a 48-aa CfrA protective epitope (aa 307 to aa 354) into loop 9
of OMP LamB seamlessly (Layton et al. 2009). Expression of the CfrA epitope in S.
enteritidis 13A was examined by western immunoblotting using CfrA-specific antibodies.
The experimental design for evaluating the protective efficacy of the Salmonella mutant
expressing CfrA epitope is detailed in Table 6. Briefly, the S. enteritidis strains were
cultured in LB to log phase and cells were washed 1X with PBS and suspended with
PBS to a final concentration of ~ 1X 108 CFU/ml. On day 7 post-hatch, chickens were
immunized orally with 200 μl of live vaccine in PBS via oral gavage. Chickens receiving
PBS only or parent S. enteritidis 13A (∆aroA ∆htrA) only served as controls. At 28 d of
age, each bird was inoculated with C. jejuni NCTC 11168 at a dose of 1.5 × 104
CFU/chicken via oral gavage. Cloacal swabs were collected immediately before C. jejuni
challenge on day 28 and after the challenge on d 30, 33, 36 and 40. Swabs were serially
diluted, and plated on MH agar containing selective supplement (SR117E; Oxoid,
Bashingstoke, Hampshire, England) for enumeration of Campylobacter cells.

Nucleotide sequence accession number
The CfrA full coding sequences of 7 C. jejuni strains have been deposited into
GenBank under the accession numbers of FJ771033 (JL10), FJ771034 (JL12),
FJ771035 (JL36), FJ771036 (JL78), FJ771037 (JL81), FJ771038 (JL83), and FJ771039
(JL118).
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RESULTS
Sequence homology of CfrA
The full length cfrA gene from 7 C. jejuni isolates were sequenced in this study.
These new sequences were translated into protein sequences and aligned with the CfrA
sequences from 8 Campylobacter strains (6 C. jejuni including NCTC 11168, 84-25,
CF93-6, RM1221, CG8486, and 260.94; and 2 C. coli including VC167 and RM2228)
that were deposited in National Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi). ClustalW analysis in MEGA 4.0
showed the amino acid identity of CfrA ranges from 89% to 98%. According to
secondary structure prediction, CfrA consisted of 22 β-strands with long loops on the
external side of the membrane and short turns facing the periplasmic space. Highly
conserved regions were predicted to form β-strands, while variable regions were located
in the putative loop structure (data not shown). Interestingly, CfrA sequences of two C.
coli strains (C. coli VC167 from a human infection case and RM2228 from a chicken
carcass) had a high level of amino acid identity (98%) to that of C. jejuni NCTC 11168.
Together, the CfrA sequence analysis showed that CfrA is highly conserved among
Campylobacter isolates which possess the cfrA gene.

CfrA is widely expressed and immunogenically conserved among various
Campylobacter strains
To determine the prevalence and antigenicity of CfrA, a full-length histidinetagged recombinant CfrA was produced in E. coli and purified for preparing CfrA specific
antiserum. The rCfrA showed a molecular mass of approximately 76 kDa on SDS-PAGE
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(Fig. 9A), consistent with the calculated molecular mass from the deduced amino acid
sequence of CfrA. Expression and prevalence of CfrA among 32 Campylobacter primary
strains were first examined by immunoblotting using CfrA specific antibodies. As shown
in Fig. 9B, CfrA was induced under iron-limited condition while iron repletion suppressed
expression of CfrA. Each strain produced a significant band reactive to specific anti-CfrA
antibodies, suggesting CfrA is highly conserved in Campylobacter. However, C. jejuni
81-176 (JL242) that does not contain the cfrA gene (Hofreuter et al. 2006) also displayed
a band that reacted with CfrA antibodies but migrated slightly faster than the typical CfrA
in NCTC 11168 (JL241) (Fig. 9B). This finding suggests that CfrA antibodies may cross
react with other iron-regulated OMP in Campylobacter, consequently confounding data
interpretation if solely using CfrA antibodies. Thus, we conducted further experiments to
overcome this limitation. First, we designed highly cfrA gene-specific PCR primers based
on sequence alignment described above. PCR analysis demonstrated that 26 of 32
Campylobacter strains evaluated contained the cfrA gene. Second, we determined
ability of these strains for ferric enterobactin assimilation. As shown in Fig. 9B, all 26
PCR-positive strains displayed significant enterobactin-mediated growth promotion while
5 of 6 PCR-negative strains (JL84, SO40, SO48, JL90, JL242) failed to utilize
enterobactin. These findings indicated that the existence and expression of cfrA gene
are highly correlated with the phenotype of enterobactin utilization in C. jejuni.
Interestingly, JL11 that lacks the typical cfrA gene could still effectively utilize
enterobactin (Fig. 9B) and even produced significantly larger growth zones than other
tested Campylobacter strains (data not shown). Finally, we determined the identity of the
iron-regulated OMP that was reactive to CfrA antibodies in C. jejuni 81-176 (JL242, Fig.
9B).

Blast searches revealed a gene cjj81176_0471 in the genome of 81-176 that

encodes a putative iron-regulated OMP sharing 34% amino acid identity and 54% amino
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acid similarity with CfrA. The homolog of gene cjj81176_0471 in 81-176 was annotated
as a pseudogene (cj0444) in NCTC 11168. We hypothesized that the iron-regulated
protein band detected in 81-176 JL242 (Fig. 9B) was CJJ81176_0471 that can cross
react with CfrA antibodies. To test this hypothesis, we constructed JL364, an isogenic
cjj81176_0471 mutant of C. jejuni 81-176, for immunoblotting using CfrA specific
antibodies. We observed that inactivation of the cjj81176_0471 in JL364 completely
abolished production of the specific band observed in wild-type strain JL242 (data not
shown). Complementation of JL364 with complete cjj81176_0471 ORF fully restored
production of a band that reacts with CfrA antibodies as observed in wild-type 81-176
(data not shown), further indicating CJJ81176_0471 is an iron-regulated OMP that cross
reacts with CfrA specific antibodies in C. jejuni 81-176.

CfrA is also responsible for NE-mediated growth promotion
To confirm the role of CfrA in ferric enterobactin assimilation observed in a
previous study (Palyada et al. 2004) and further examine novel functions of CfrA, a cfrA
isogenic mutant (JL324) was constructed in this study. Distinct from a previous study
(Palyada et al. 2004), we also constructed a complemented strain (JL335) to preclude
any potential polar effect due to inactivation of cfrA in JL324. As shown in Fig. 10A,
insertional inactivation of cfrA abolished production of CfrA in NCTC 11168 under ironrestricted condition. Complementation of the cfrA mutation in trans completely restored
production of normal CfrA in JL335 (Fig. 10A). As expected, standard growth promotion
assay showed that the cfrA mutant failed to utilize enterobactin for growth while
complementation of the cfrA mutation resulted in a significant growth zone with similar
size as that for wild-type NCTC 11168 (Fig. 10B, top panel), consistent with
immunoblotting analysis (Fig. 10A).
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Recently, growing evidence demonstrated that catecholamine hormones, such
as norepinephrine (NE), may fulfill a nutritional need and/or serve as a host
environmental cue to promote growth and enhance virulence of a panel of enteric
bacterial pathogens including C. jejuni (Lyte 2004; Cogan et al. 2007; Hughes and
Sperandio 2008). Since an early study indicated that the growth response of E. coli to
NE requires a functional enterobactin uptake system (Burton et al. 2002),

we

determined the role of CfrA in the growth response of C. jejuni to NE using a modified
growth promotion assay. Compared to the diameter of growth zone observed for the
wild-type strain (2.50 ± 0.08 cm), the cfrA mutant exhibited a much weaker response (P
< 0.05) to NE by displaying a significantly smaller growth zone (1.43 ± 0.10 cm) (Fig.
10B, bottom panel).

Complementation of the cfrA mutation restored NE-mediated

growth promotion (zone size of 2.65 ± 0.13 cm, Fig. 10B) to the level comparable to wildtype NCTC 11168.

CfrA specific IgG inhibited enterobactin-mediated growth promotion
To test whether CfrA antibodies can inhibit enterobactin-mediated growth
promotion, IgG was purified from heat-inactivated rabbit pre-immune serum (serve as
control IgG) or CfrA specific antiserum by ammonium sulphate precipitation. The purified
IgG was dialyzed against PBS, adjusted to a final concentration of 16 mg/ml, and
sterilized by membrane filtration for growth assays. As shown in Fig 11A, the diameter of
the growth halo in the presence of anti-CfrA IgG (1.13 ± 0.08 cm) was significantly
smaller (P<0.01) than that in the presence of the same concentration of control IgG (2.87
± 0.12 cm) or PBS alone (3.50 ± 0.18 cm), strongly suggesting that CfrA specific IgG
blocked the ligand binding site of CfrA and consequently inhibited ferric enterobactin
assimilation for growth promotion. Inhibition of CfrA by specific anti-CfrA IgG was also
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dose-dependent and as low as 32 µg/ml of anti-CfrA IgG exerted a significant inhibitory
effect (P<0.01) when compared to growth in the presence of a high concentration of
control IgG (320 µg/ml) (Fig. 11B).

In vivo expression and immunogenicity of CfrA
To determine if CfrA is expressed and immunogenic in vivo, multiple chicken
sera were tested for reactivity with rCfrA (Fig. 11C). One serum sample from C. jejuni
S3B (JL36) infected chicken showed a vivid antibody reaction to rCfrA (lane 2 Fig. 11C).
Serum from 2-d-old broiler that was Campylobacter-free but showed a high titer of
maternally derived antibodies (Sahin et al. 2001; Lin et al. 2003) to C. jejuni also strongly
reacted with rCfrA (lane 3 Fig. 11C). Two sera from 21-d-old Campylobacter-free
chickens were negative for rCfrA (lane 4 and 5 Fig. 11C). These results indicate that
CfrA is expressed during in vivo Campylobacter infection and elicited a specific antibody
response in chickens. In addition, anti-CfrA maternal antibodies could transfer from yolks
to hatchlings.

The region and amino acids in CfrA critical for ferric enterobactin assimilation
Identification of functionally important regions and/or amino acids is critical for
vaccine optimization. To predict which region and amino acids in CfrA are likely
important for ferric enterobactin binding, we performed across-species sequence
alignment among FepA sequences from four other bacteria and CfrA sequences from 15
Campylobacter strains. It has been reported that the FepA region between residues 255
and 336 (Fig. 12A) contributes to the high affinity binding of FepA to its substrate ferric
enterobactin in E. coli (Murphy et al. 1990). As shown in Fig. 12A, the CfrA region
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between residue 265 and 343, which covers the third and fourth extracellular loops, is
highly conserved in CfrA and thus may be actively involved in the interaction between
CfrA and ferric enterobactin. Since the two positively charged amino acids K297 and
R327 in CfrA were well aligned to the two critical amino acids R286 and R316 in E. coli
FepA (Newton et al. 1997), K297 and R327 may contribute significantly to the binding of
CfrA to its substrate ferric enterobactin. Previous mutagenesis studies in E. coli also
showed that two aromatic amino acids (Y260 and F329; Fig. 12A) in FepA also played a
critical role in ferric enterobactin utilization (Newton et al. 1997; Cao et al. 2000). The
sequence alignment program did not reveal similar aromatic amino acids at
corresponding positions in CfrA. However, glutamine (Q) at 271 in CfrA and the
corresponding aromatic amino acid Y260 in E. coli FepA both have uncharged polar side
chains (Fig. 12A), suggesting Q271 in CfrA may also be involved in binding to ferric
enterobactin. In addition, manual adjustment aligned the highly conserved F337 in CfrA
to the F329 in E. coli FepA (Fig. 12A).
To test the above prediction, we conducted site-directed amino acid substitution
mutagenesis in conjunction with enterobactin growth promotion assay. As shown in Fig.
12B, the plasmid bearing R327A mutation in CfrA failed to complement the cfrA mutation
and no growth zone was observed for construct JL446, indicating that R327 in CfrA is
essential for ferric enterobactin assimilation in C. jejuni. However, substitution of the
other three predicted amino acids with alanine appeared to have little effect on the
function of CfrA because plasmids pCfrA(Q271A), pCfrA(K297A) and pCfrA(F337A) all
successfully complemented the cfrA mutation and resulted in a significant growth zone
with similar size as that for the control plasmid pCfrA (Fig. 12B).
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Live Salmonella vaccine conferred partial protection against C. jejuni colonization
in chickens
The epitope ranging from amino acid 307 to aa 354 (48 aa in length) that
includes R327 and is critical for FeEnt binding in CfrA was successfully cloned and
expressed in S. enteritidis 13A (∆aroA ∆htrA), an attenuated Salmonella mutant ideal for
vaccine delivery and evaluation in a chicken model system (Kwon et al. 2007). The
precise insertion of epitope-encoding sequence in the mutant was confirmed by PCR
amplification and DNA sequencing. Furthermore, expression of the epitope was verified
by immunoblotting analysis using CfrA specific antibody (Fig 13A).

The anti-CfrA

antibody detected a band of approximately 56 kDa that is consistent with the calculated
molecular mass of LamB-CfrA recombinant protein and was present only in the mutant.
The band with a smaller molecular mass detected in both strains was due to the
nonspecific cross-reaction of polyclonal CfrA antiserum with Salmonella proteins.
As shown in Fig. 13B, oral administration of the vaccine strain expressing the
CfrA epitope (group III) significantly reduced shedding (1.2 log10 units) of Campylobacter
in chickens (P < 0.05) when compared with PBS control (group I) at 5 and 8 d postinfection (Fig. 13B). However, oral administration of the control Salmonella vector strain
(group II) provided slight protection of chickens against C. jejuni colonization when
compared to the control group I (P<0.1 but > 0.05) at 5 days post infection. At 2 d
following challenge, C. jejuni NCTC 1168 colonized approximately one-half of chickens
in each treatment group. By 5 d post infection, all chickens in each group were colonized
by the C. jejuni strain.
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DISCUSSION
In this study, we provide compelling evidence to demonstrate the feasibility of
targeting CfrA for immune protection against Campylobacter. Firstly, CfrA is conserved
in Campylobacter strains with amino acid identity ranging from 89% to 98%. The
positively charged amino acid R327 that is essential for ferric enterobactin acquisition in
C. jejuni is highly conserved in CfrA (Fig. 12A). Secondly, CfrA-associated ferric
enterobactin uptake system is widely distributed, expressed and conserved in C. jejuni
strains (Fig. 9B). Thirdly, CfrA plays an important role in the responsiveness of C. jejuni
to catecholamine hormone NE (Fig. 10B), suggesting multiple physiological functions of
CfrA during Campylobacter colonization in the intestine. Finally, specific CfrA antibodies
clearly interacted with C. jejuni and inhibited enterobactin-mediated growth promotion in
C. jejuni (Fig. 11A and 11B). These findings plus the fact that CfrA was expressed
during the course of Campylobacter colonization of the chicken host (Fig. 11C) strongly
indicate that CfrA is a promising candidate for Campylobacter vaccine development.

Guerry et al. (1997) first reported that CfrA was an iron-regulated OMP involved
in iron acquisition in Campylobacter. More recently, CfrA was demonstrated to be an
outer membrane receptor specific for ferric enterobactin assimilation (Palyada et al.
2004). However, the published whole genome sequence of C. jejuni 81-176 showed that
this strain does not have a typical CfrA although it has the cognate components of ferric
enterobactin uptake system, such as TonB and ceu ABC transport system (Hofreuter et
al. 2006; Stintzi et al. 2008). To fill a significant gap of our understanding on the
prevalence, sequence and antigenic homology of CfrA in Campylobacter, we conducted
a comprehensive survey in this study by taking advantage of our diverse Campylobacter
strain collection. The C. jejuni and C. coli strains evaluated in this study were obtained
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from 9 different animal hosts and environmental niches, and were from 11 U.S. states
and European countries. With respect to sequence homology, our analysis showed that
CfrA displayed a high level of homology. Particularly, the R327 that is critical for ferric
enterobactin acquisition is highly conserved in CfrA (Fig. 12A).

Regarding the

prevalence and expression of CfrA, immunoblotting in conjunction with PCR analysis
and enterobactin growth promotion assay indicated that 26 of 32 Campylobacter strains
contained and expressed functional CfrA under iron-restricted conditions (Fig. 9B). The
cfrA insertional mutation in JL324 was also successfully transferred to the majority of
tested strains by natural transformation, consequently abolishing the production of CfrA
and the ability to use enterobactin for growth under iron-restricted condition (data not
shown). This finding further confirmed the presence of functional CfrA in the majority of
tested Campylobacter isolates. Only a small subset of Campylobacter strains (5 of 32)
did not utilize ferric enterobactin as a sole iron source for growth in this study (Fig. 9B).
Together, the high prevalence of functional CfrA in Campylobacter suggests that
enterobactin, which is produced by a wide variety of bacteria from the family
Enterobacteriaceae present in the intestine, may be a remarkable iron source during
Campylobacter colonization in animal and human intestines.

Interestingly, all five C. jejuni strains that showed negative results for PCR and
enterobactin growth promotion assay also expressed an iron-regulated OMP that
reacted to CfrA specific antibodies (Fig. 9B). Since one of these strains is C. jejuni 81176 (JL242) that clearly lacks typical CfrA (Hofreuter et al. 2006), we speculated that C.
jejuni 81-176 and the other isolates may contain an iron-regulated OMP homologous to
CfrA. Comparative genome sequence analysis indicated that CJJ81176_0471 in 81-176
shared the highest homology to CfrA of C. jejuni NCTC 11168 CfrA with amino acid
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similarity and identity about 54% and 34%, respectively. Our site-directed mutagenesis
and complementation experiments demonstrated that CJJ81176_0471 is indeed the
iron-regulated OMP that cross reacted with CfrA specific antibodies in C. jejuni 81-176.
At this stage, the function of CJJ81176_0471 is still unknown. According to the
sequence

analysis

and

secondary

structure

prediction

(http://www.ncbi.nlm.nih.gov/protein/121612217), it is likely that CJJ81176_0471 is also
a ferric enterobactin receptor but C. jejuni 81-176 does not have appropriate cognate
components of ferric enterobactin assimilation system, consequently leading to the
inability of C. jejuni 81-176 to utilize ferric enterobactin as sole iron source (Fig. 9B).
This hypothesis as well as the physiological significance of CJJ81176_0471 remains to
be determined in future studies. Another intriguing finding from our survey is that C.
jejuni JL11, originally isolated from bovine feces, displayed exceptional ability to utilize
ferric enterobactin although this strain did not have the typical cfrA gene (Fig. 9B). Lack
of a typical cfrA gene in JL11 was also confirmed by PCR analysis using different sets of
cfrA specific primers (data not shown). Therefore, it is tempting to speculate that JL11
has a novel ferric enterobactin receptor/system for ferric enterobactin-mediated uptake.
This possibility remains to be examined in future studies.

Microbial

endocrinology,

representing

the intersection

of

the fields

of

microbiology and neurobiology, is an emerging field in microbial pathogenesis
(Sperandio et al. 2003; Hughes and Sperandio 2008).

Recently, growing evidence

showed that a family of stress-related neuroendorine hormones (e.g. NE) can influence
both growth and elaboration of virulence-associated properties in an increasing number
of bacterial pathogens (Sperandio et al. 2003; Freestone et al. 2007; Hughes and
Sperandio 2008; Rasko et al. 2008). Notably, although these stress hormones, such as
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NE, are usually at a nanomolar level in sera, the level of NE in the intestine is much
higher due to the existence of the enteric nervous system rich in adrenergic neurons
(Sperandio et al. 2003; Freestone et al. 2007; Hughes and Sperandio 2008; Rasko et al.
2008). The enteric nervous system, consisting of about 100 million neurons (Hansen
2003), can secrete NE, the principal autonomic neurotransmitter, into the gastrointestinal
lumen with concentrations up to mM level or even higher under pathologic situations
(Eldrup and Richter 2000). Thus, NE is being considered as an important in vivo cue to
promote growth and modulate virulence of enteric pathogens (Sperandio et al. 2003;
Freestone et al. 2007; Hughes and Sperandio 2008; Rasko et al. 2008). Recently,
Cogan et al. (2007) reported that NE also enhanced the growth rate of C. jejuni under
iron-restricted conditions and increased some virulence-associated properties of
Campylobacter, such as motility and invasive ability. Unlike the significant progress
made in other enteric pathogens (Sperandio et al. 2003; Freestone et al. 2007; Hughes
and Sperandio 2008; Rasko et al. 2008), how NE interacts with C. jejuni is still largely
unknown. In this study, we consistently observed that the growth response of the
isogenic CfrA mutant to NE under iron-limited conditions was impaired greatly compared
to that for the wild-type strain; complementation of the CfrA mutation completely restored
NE-mediated growth promotion. Therefore, CfrA was at least partially responsible for
NE-mediated growth promotion although mutation in CfrA did not completely abolish NEmediated growth promotion in CfrA mutant. The underlying mechanism of NE-mediated
growth promotion in C. jejuni is not clear.

The simplest and most straightforward

explanation is that NE might facilitate the release of ferric iron from chelators or ironbinding proteins to fulfill a nutritional need of Campylobacter (Freestone et al. 2000).
However, given the recent novel findings in E. coli (Sperandio et al. 2003; Freestone et
al. 2007; Hughes and Sperandio 2008; Rasko et al. 2008), we cannot rule out the
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possibility that NE also functions as an in vivo cue to modulate physiological and
pathogenic properties in C. jejuni. Transcriptome analysis of C. jejuni in response to NE
treatment may help address this issue and understand the molecular basis of interaction
between NE and Campylobacter.

Ferric enterobactin receptor possesses intensively surface-exposed loops and
relatively high aqueous solvent exposure for ligand binding (Buchanan et al. 1999;
Carswell et al. 2008). Given this unique structural feature and its inducible nature in vivo,
ferric enterobactin receptor has been considered a promising subunit vaccine candidate
(Andersen et al. 2002). In previous studies, it has been demonstrated that both
monoclonal and polyclonal antibodies directed against FepA effectively inhibited the
function of FepA and reduced growth of coliform bacteria under iron-restricted condition
(Dittmar et al. 1998; Alekshun and Levy 2007). Based on these findings, we speculated
that CfrA specific antibodies may also physically block binding of Fe-enterobactin to the
ligand binding site of CfrA, resulting in impaired Campylobacter growth with ferric
enterobactin as a sole iron source. Our results clearly showed the effectiveness of
purified anti-CfrA IgG on inhibiting enterobactin-mediated growth promotion of
Campylobacter under the iron-limited condition (Fig. 11A). The inhibitory effect of antiCfrA IgG was also dose-dependent (Fig. 11B), further confirming the intimate interaction
between CfrA antibodies and CfrA receptor. Notably, distinct from previous studies
(Dittmar et al. 1998; Alekshun and Levy 2007), cells used for the growth assay in this
study were grown in normal MH broth with no or low level CfrA expression instead of in
iron-depleted MH broth with high-level CfrA expression. We believe such modification by
not using ‘low iron pre-adapted’ cells should better mimic the CfrA expression pattern
during infection from initial oral ingestion (low-level CfrA expression due to exposure to

76

iron-rich environment) to colonization in intestine (high-level CfrA expression due to ironrestricted conditions in vivo), thus better evaluating the inhibitory effect of CfrA
antibodies.

To enhance production of specific antibodies directed against ligand binding site
of CfrA, it is important to determine the structure of CfrA and its functional epitopes. A
recent report (Carswell et al. 2008) indicated that CfrA contains many of the structural
motifs conserved in other siderophore transporters and demonstrated relatively high
aqueous solvent exposure and high thermal stability of CfrA. In this study, we were
particularly interested in which amino acids in CfrA may be involved in ferric enterobactin
uptake. The mutagenesis study demonstrated that the basic amino acid R327 in CfrA is
essential for ferric enterobactin uptake in C. jejuni. The R327 is located in the fourth
extracellular loop of CfrA that is highly conserved in Campylobacter. Thus, the
conserved 48-aa protective epitope covering the R327 of CfrA was cloned into S.
enteritidis 13A mutant. Oral vaccination of chickens with this live vaccine significantly
reduced shedding (1.2 log10 units) of Campylobacter in chickens (P < 0.05) compared
with PBS control at 5 and 8 d postinfection. To increase the protective efficacy of this live
vaccine, some modifications will be performed in the future to enhance immunogenicity
of the CfrA epitope. For example, since significant immune enhancement was observed
after co-expression of the CD154 oligopeptide along with the inserted protective epitope
(Cox et al 2007; Karlyshev et al 2005), a modified mutant with the format of Loop
9::(Ser)3-CfrA epitope-(Ser)3-CD154-(Ser)3 will be constructed for evaluation. To
increase translation efficiency, nucleotides for the epitope cassettes also will be
designed using a codon-optimized sequence; codon optimization is based on the
commonly used amino acid codons in S. typhimurium (Cox et al 2007). Future studies
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may lead to the development of effective, inexpensive and practical oral vaccines to
prevent Campylobacter infections in humans and animal reservoirs.
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Table 4. Key bacterial plasmids and strains used in this study (Chapter III)
Plasmids or
strains
Plasmids
pGEMT-Easy
pCA
pmCA
pRY107
pQE-30
pCFRA-NHIS
pCfrA
pCfrA (K297A)
pCfrA (R327A)
pCfrA (Q271A)
pCfrA (F337A)
Strains
C. jejuni
JL10
JL12
JL36
JL78
JL81
JL83
JL118
JL241
JL242
JL364
JL324
JL335
JL442
JL446
JL494
JL495
E. coli
DH5α
JM109
JL48
JL122
JL275
JL334
S. enteritidis
13A
13A(vector)
13A-CfrA

Description

Source or Reference

PCR cloning vector, Ampr
pGEMT-Easy containing 1.6-kb N-terminal cfrA fragment,
Ampr
pCA with chloramphenicol resistance cassette inserted in cfrA
gene, Ampr Cmr
E. coli-C. jejuni shuttle vector, Kanr
N-His6 fusion recombinant protein vector
pQE-30 ligated with cfrA segment encoding mature CfrA
pRY107 derivative containing a 2.5 kb cfrA open reading frame
plus its promoter region
pCfrA derivative with K297A mutation in CfrA
pCfrA derivative with R327A mutation in CfrA
pCfrA derivative with Q271A mutation in CfrA
pCfrA derivative with F337A mutation in CfrA

Promega

ATCC 33291, human isolate
15046764, bovine isolate
S3B, chicken isolate
W42606, human isolate
F34078, human isolate
M76297, human isolate
CVM20088, chicken isolate
NCTC 11168, human isolate
81-176, human isolate
81-176, CJJ81176_0471 isogenic mutant, Kanr
JL241 derivative, cfrA::cm
JL324 containing pCfrA
JL324 containing pCfrA (K297A)
JL324 containing pCfrA (R327A)
JL324 containing pCfrA (Q271A)
JL324 containing pCfrA (F337A)

ATCC
(Zhang et al. 2000)
(Lin et al. 2003)
(Huang et al. 2005)
(Huang et al. 2005)
(Huang et al. 2005)
Chickena
(Gundogdu et al. 2007)
(Black et al. 1988)
This study
This study
This study
This study
This study
This study
This study

F- Φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17
(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λendA1 recA1 gyrA96 thi hsdR17 (rk-, mk+) relA1 supE44 Δ(lacproAB) [F’ traD36 lacIqZΔM15]
Conjugation helper strain, DH5α containing plasmid RK2013
E. coli AN102, an enterobactin transport mutant for
enterobactin purification.
JM109 containing pCFRA-NHIS
DH5α containing pCfrA

Invitrogen

(Akiba et al. 2006)
(Anderson and Armstrong
2004)
This study
This study

Widetype
13A derivative, ΔaroA ΔhtrA
13A (vector) derivative expressing CfrA epitope

This study
This study
This study

a

This study
This study
(Yao et al. 1993)
Qiagen
This study
This study
This study
This study
This study
This study

Promega

Isolated from chicken breast. Kindly provided by Shaohua Zhao (Center for Veterinary
Medicine, Food and Drug Administration).
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Table 5. Primers used in this study (Chapter III)
Primer

DNA sequence (5’-3’)a

Product
size (bp)
2,043

Target gene or
function
cfrA (no signal
peptide region)

PF1
PR1

AAAGGATCCCAAAATGTAGAACTAGATAGC (BamH I)
AAACCCGGGAAAGTTACCATTGATAGAAAT (Sma I)

CHFL1
CHFR1

TTTGCTAGCTGCTCGGCGGTGTTCCTTT (Nhe I)
TTTGCTAGCGCGCCCTTTAGTTCCTAAAG (Nhe I)

802

cat

CfrAF
CfrAR

GAGATGTTGCAGAGGCTATCG
TGCCTTTGTAGGACTTTGAGC

527

cfrA

CfrAF1
CfrAR1

TCAATATTTAACAAAAGGAGAAAAATG
AAGCCTTTGAAAGCTCTTTGG

2,151

cfrA (complete
ORF)

CfrAF2
CfrAR2

TTTCATTGGGTTGTATGTGTAAAAA
TCTGCAAAAATTGCCAATAAA

1,631

Part of cfrA plus
445 bp upstream
region

CfrAR3

TCTGCAAAAATTGCCAATAAA

N/A

cfrA sequencing
primer

Q271A_F

9,300

Create Q271A
mutation in CfrA

Q271A_R

GATAATAAACAAGGTgcATTAGGAACCATCACAAGTCCAG
G
TAGAACACC
GGTTCCTAATgcACCTTGTTTATTATCATAATGATTTC

K297A_F
K297A_R

GAAGTTGATgcATTTGTGACTTATTTAAGTCATG
GTCACAAATgcATCAACTTCCATAATATCTGC

9,300

Create K297A
mutation in CfrA

R327A_F
R327A_R

GATGGCgcaGAAGTCGTAGGGCAATCTACACAGCCG
GACTTCtgcGCCATCATTGCTCACTCTATTATATTG

9,300

Create R327A
mutation in CfrA

F337A_F
F337A_R

CACAGCCGgcTTTGGGAGAAAATAGAGATATAGTC
CTCCCAAAgcCGGCTGTGTAGATTGCCCTACGACTTCGCGG
CC

9,300

Create F337A
mutation in CfrA

a

Restriction sites are underlined in the primer sequence and the names are identified in
parentheses. Nucleotides in lower case are designed for desired amino acid substitution
mutagenesis.
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Table 6. Oral vaccination of chickens with the live Salmonella vaccine expressing CfrA
protective epitope and C. jejuni challenge.
Group

No. of
chickens

Day 7
immunization

Sample collection

I
II

15
15

III

15

PBS
Control strain (S.
enteritidis 13A)
Live-CfrA

Cloacal swabs were collected on days
28 (prior to C. jejuni challenge), 30,
33, 36, and 40
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C. jejuni
challenge on
day 28
Yes
Yes
Yes

(A)

kDa

1

2

3

4

200
116
97

rCfrA
(76 kDa)

66

45

31

(B)

Figure 9. Prevalence and expression of CfrA in different Campylobacter strains.
(A) SDS-PAGE analysis of rCfrA production in E. coli. Lane 1, molecular weight marker
(Bio-Rad); lane 2, whole cell lysate of noninduced E. coli; lane 3, whole-cell lysate of E.
coli induced for 1 h with 1 mM isopropyl-β-D-thiogalactopyranoside; lane 4, rCfrA purified
by Ni-NTA affinity chromatography. (B) Immunoblotting, PCR, and functional survey of
ferric enterobactin uptake systems in 32 Campylobacter strains from various origins and
geographically diverse areas. For immunoblotting analysis, each strain was grown in
iron-replete (+) or iron-limited (-) MH broth and whole-cell lysates were loaded onto SDSPAGE gel for CfrA blotting analysis. Successful amplification of cfrA sequence with cfrAspecific primers from specific strain was indicated as ‘+’ symbol while ‘-’ indicates
absence of specific cfrA sequence. With respect to enterobactin growth promotion assay
(abbreviated as ‘Ent’), the strain showing significant growth promotion in response to
enterobactin treatment was indicated as ‘+’ symbol, otherwise with ‘-’ symbol.
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(A)

kDa

1

2

3

4

250
150
100

CfrA

75

50

37

(B)

NCTC 11168

cfrA-

cfrA-/pCfrA

Ent

NE

Figure 10. Functional analysis of CfrA.
(A) Immunoblotting analysis of CfrA production in wild-type C. jejuni NCTC 11168 (lane
2), isogenic cfrA mutant JL324 (lane 3), and the complemented strain JL335 (lane 4). All
C. jejuni strains were grown in iron-restricted medium and similar amounts of bacterial
cells were loaded in each lane for immunoblotting using specific antibodies against CfrA.
Prestained molecular mass markers (lane 1; Bio-Rad) were coelectrophoresed and
blotted to allow estimation of the protein size. (B) Role of CfrA in enterobactin (Ent) and
norepinephrine (NE) mediated growth promotion.
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(A)

(B)

CfrA IgG

Diameter of growth zone (cm)

4

PBS

Control IgG

3.5
3
2.5
2
1.5
1
0.5
0

PBS
control

(C)
kDa

1

2

3

4

IgG control

5

IgG 320

IgG 64

IgG 32

IgG 12.8

6

150
100

rCfrA

75

50

Figure 11. Functional and immunological characteristics of CfrA antibodies.
(A) Inhibitory effect of anti-CfrA IgG on enterobactin-mediated growth promotion in C.
jejuni. Purified CfrA IgG (320 µg/ml), control IgG (320 µg/ml, from pre-immune serum),
or PBS was mixed together with C. jejuni NCTC 11168 cells in modified growth
promotion assay detailed in Materials and Methods; (B) Dose-dependent inhibitory effect
of anti-CfrA IgG on enterobactin-mediated growth promotion in C. jejuni. Approximately
1 x 108 C. jejuni cells were inoculated in iron-restricted MH agar supplemented with PBS
(PBS control), 320 µg/ml of IgG from preimmune serum (IgG control), or anti-CfrA IgG at
various concentrations of 320 µg/ml (IgG 320), 64 µg/ml (IgG 64), 32 µg/ml (IgG 32), and
12.8 µg/ml (IgG 12.8). Bars represent means of growth zone diameter ± standard
deviations of four independent measurements; and (C) Immunoblot analysis of in vivo
antibody responses to CfrA. The rCfrA was blotted with individual chicken serum
samples (lanes 2-5) or with rabbit anti-CfrA antibody (lane 6, positive control). Lane 2,
serum sample from a 7-wk-old broiler chickens infected with C. jejuni S3B; Lane 3,
serum sample from a 2-d-old broiler with high level maternal antibodies against C. jejuni;
Lanes 4 and 5, serum samples from 3-wk-old broiler chickens which were free of
Campylobacter. Prestained molecule mass markers (lane 1; Bio-Rad) were
coelectrophoresed and blotted to allow estimation of the sizes of the proteins.
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(A)
Y260

R286

R316

F329

E. coli

Q271

K297

R327

F337

C. jejuni

(B)

JL494
(Q271A)

JL442
(K297A)

JL335
(wild-type)

JL446
(R327A)

JL495
(F337A)

Figure 12. Identification of amino acids in CfrA critical for FeEnt assimilation.
(A) Cross-species sequence alignment of ferric enterobactin receptor. FepA sequences
from Escherichia coli (Lundrigan and Kadner 1986), Salmonella enterica (Baumler et al.
1998), Pseudomonas aeruginosa (Dean and Poole 1993) and Bordetella pertussis (Beall
and Sanden 1995) and CfrA sequences from 13 C. jejuni and 2 C. coli were used for
alignment. Specific amino acids in E. coli FepA that have been demonstrated to
contribute to interact with ferric enterobactin were indicated by solid arrows above the
alignment. Corresponding conserved amino acids in Campylobacter CfrA were indicated
by solid arrows below the alignment. Conserved amino acids across species that might
contribute to ferric enterobactin assimilation were also highlighted with solid boxes. (B)
Effect of specific amino acid substitution on CfrA-dependent ferric enterobactin
assimilation. Enterobactin growth promotion test was performed using an isogenic cfrA
mutant of C. jejuni NCTC 11168 containing a plasmid bearing wild-type cfrA gene or cfrA
gene with a specific amino acid substitution mutagenesis. The feature of the cfrA gene in
the plasmid of each construct (wild-type or the specific aa substitution) is shown in
parentheses below the construct name.
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LamB-CfrA

56

43

(B)
CFU/g Fecal Sample (Log10)

7
6
5
4
3
I (PBS)
2

II (Vector)
III (live-CfrA)

1
0
0

2

4

6

8

10

12

14

Day Postinfection

Figure 13. Construction and evaluation of a live Salmonella vaccine expressing CfrA
protective epitope.
(A) Immunoblotting analysis of the parent S. enteritids 13A (Control) and its isogenic
mutant with desired CfrA epitope inserted into LamB locus (mutant). Whole cells were
used for immunoblotting analysis using CfrA specific antiserum. (B) Protective efficacy of
the live Salmonella vaccine against Campylobacter infection. Group I, PBS control;
Group II, Salmonella vector strain as the other control; Group III, the Salmonella strain
expressing the CfrA epitope. Each point represents mean log10CFU/g feces ± standard
deviation in each group.
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CHAPTER IV

WHOLE GENOME SEQUENCING AND COMPARATIVE GENOMIC
ANALYSIS OF A UNIQUE CAMPYLOBACTER JEJUNI STRAIN
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ABSTRACT

Recently, we identified a novel ferric enterobactin (FeEnt) receptor CfrB that is
involved in FeEnt-mediated iron acquisition and is critical for Campylobacter colonization
in the intestine. One unique C. jejuni strain (JL11) was identified, which can efficiently
utilize FeEnt by producing a functional CfrB only although it does not have cfrA gene.
Interestingly, C. jejuni 81-176 with published whole genome available was unable to
utilize FeEnt although it produces CfrB only. PCR analysis further indicated that these
two strains shared the identical major components required for FeEnt acquisition. Thus,
we hypothesize that JL11 contains an additional unidentified component that is missing
in C. jejuni 81-176, but essential for CfrB-dependent FeEnt acquisition. To test this,
whole genome sequencing and comparative genomic analysis of the JL11 strain were
performed. The genomic DNA from JL11 was sequenced with 454 GS FLX sequencer
with Titanium series reagents. The 454 assembly software Newbler yielded unordered
contigs, which consisted of 38 large contigs and 7 small contigs. All gaps were closed
between contigs, and the draft genome sequence was subjected to automatic
annotation. Comparative analysis of C. jejuni JL11, 81-176 and NCTC 11168 genomes
identified that 81-176 lacks 10 genes that are present in JL11 and 11168. Based on
published microarray data, of these genes only cj1376 is potentially induced under ironlimited conditions. Sequence analysis and structural prediction of Cj1376 strongly
suggested that Cj1376 is an enterobactin esterase homolog located in the periplasm.
Complementation of 81-176 with cj1376 successfully restored its ability to utilize FeEnt.
In conclusion, whole genome sequencing of C. jejuni JL11 and comparative genomic
analysis led to identification of a novel periplasmic enterobactin esterase that is essential
for CfrB-dependent FeEnt acquisition in Campylobacter.
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INTRODUCTION
Campylobacter jejuni is the leading bacterial cause of human enteritis in the
United States (Ketley 1997). However, molecular mechanisms of Campylobacter
pathogenesis are still largely unknown, which hampers the development of effective
intervention strategies against Campylobacter infection. Gram-negative bacterial iron
acquisition systems are unique and therefore attractive targets for vaccine and
antimicrobial development (Lin et al. 2002; Miethke and Marahiel 2007). Studies in
Chapter III provide compelling evidence that FeEnt receptor CfrA is a novel subunit
vaccine against C. jejuni. Recently, our laboratory identified a new FeEnt receptor CfrB
in Campylobacter (Xu et al. 2010). The CfrB is conserved in Campylobacter and widely
produced in Campylobacter coli. The CfrB plays a major role in FeEnt acquisition in C.
coli and is critical for in vivo colonization of both C. jejuni and C. coli in the intestine (Xu
et al. 2010).

Interestingly, the widely studied C. jejuni strain 81-176 was unable to utilize
FeEnt even though this strain could express and produce functional CfrB (Xu et al.
2010). However, a C. jejuni strain JL11, originally isolated from bovine, displayed an
exceptional ability to use FeEnt although this strain has the same FeEnt receptor pattern
as that observed for 81-176 (producing CfrB but lacking CfrA). Whole genome sequence
of 81-176 (Hofreuter et al. 2006) showed that 81-176 contains a functional energy
transduction system (TonB2/ExbB2/ExbD2) and an ABC transport system (CeuBCDE).
Given that FeEnt acquisition is a process which involves multiple components from outer
membrane to cytoplasm, we hypothesize that 81-176 may lack essential component(s)
in the pathway, consequently leading to its inability to utilize FeEnt. Since
complementation of the isogenic cfrA mutant of NCTC 11168 with wild-type cfrB gene
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completely rescued the defect of the mutant for FeEnt utilization (Xu et al. 2010), it is
probable that C. jejuni NCTC 11168 contains the same novel component for CfrBmediated FeEnt acquisition.

In this project, after further confirming the similarity between JL11 and 81-176
with respect to key components of FeEnt acquisition system using PCR analysis, whole
genome sequencing of JL11 was performed. Comparative genomic analysis of JL11, 81176 and NCTC 11168 in conjunction with the available transcriptome of C. jejuni NCTC
11168 in response to iron (Palyada et al. 2004; Holmes et al. 2005), led to the
identification of a novel enterobactin esterase Cj1376 that is essential in the CfrBdependent enterobactin utilization pathway. The Cj1376 was designated as Cee, which
stands for Campylobacter enterobactin esterase.

MATERIALS AND METHODS

Bacterial strains, plasmids and culture conditions
The major bacterial strains and plasmids used in this study are in Table 7. The C.
jejuni strains were grown routinely in MH broth (Difco) or on MH agar at 42°C under
microaerophilic conditions, which were generated using CampyGen Plus (Oxoid) gas
pack in an enclosed jar. Escherichia coli was grown in Luria-Bertani (LB) broth ((Fisher
Scientific, Fairlawn, NJ)) with shaking (250 rpm) or on agar at 37 ºC overnight. When
needed, culture media were supplemented with ampicilin (100 μg/ml) or kanamycin (30
μg/ml). All antibiotics were purchased from Sigma (St Louis, MO).

Genomic DNA extraction and PCR
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Genomic DNA was extracted from C. jejuni JL11, 81-176, and NCTC 11168 by
using Wizard® Genomic DNA Purification Kit (Promega, Madison, WI). Genomic DNA
was diluted 20-fold with distilled water and used as the template for PCR analysis. PCR
primers used in this study are in Table 8. The CeuEF and CeuER primer pairs were
derived from Gonzalez et al. (1997) with minor modification. All other primers were
designed based on published whole genome sequences of Campylobacter (Parkhill et al.
2000; Fouts et al. 2005; Hofreuter et al. 2006). PCR was performed in a volume of 50 µl
containing 200 µM of each deoxynucleotide triphosphate, 200 nM of primers, 2.5 mM of
MgSO4, 50 ng of template DNA and 5 U of Taq DNA polymerase (Promega, Madison,
WI) or PfuUltra® High-Fidelity DNA polymerase (Stratagene, Santa Clara, CA). Cycling
conditions varied according to estimated annealing temperatures of primers and
expected sizes of products. PCR products were purified by QIAquick PCR Purification
Kit (Qiagen, Valencia, CA) when needed for sequencing analysis.

Whole genome sequencing of C. jejuni JL11
To generate high quality draft sequence of JL11 with lower cost and higher
throughput than classical Sanger technology, a new ultra-high-throughput DNA
sequencing technology, 454 GS FLX (Voelkerding et al. 2009), was used to sequence
the JL11 genome at the 454 center at the University of Tennessee, Knoxville. Briefly,
JL11 genomic DNA was size fractioned into 400-500 bp fragments, which subsequently
were blunt end repaired, ligated to specific adaptors, immobilized and amplified on DNA
Capture Beads, followed by sequencing using the PicoTiter Plate in the 454-FLX
instrument, following the FLX Titanium protocol. A quarter of plate, which could provide
up to 100 Mbp of sequence, was used for JL11 genome sequencing. The generated
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reads were de novo assembled into contigs using the 454 Newbler Assembler software.
All contigs were subjected to a BLAST search to exclude contaminated sequences.

Gap closure
Contigs generated by the 454 Newbler Assembler were aligned against three
reference genomes; Campylobacter jejuni NCTC 11168, RM1221 and 81-176 (Parkhill
et al. 2000; Fouts et al. 2005; Hofreuter et al. 2006) by using Mauve (v 2.3.0) (Darling et
al. 2004; Rissman et al. 2009). C. jejuni RM1221 was chosen as template for contig
extension. Primers targeted to the ends of each contig were designed using Primer3Plus
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi).

Since

contig

ends

used for primer design often contain unreliable sequences, priming sites of primers were
designated at least 50 bp from each end of contigs. Gaps between the ordered contigs
were amplified by PCR and subsequently sequenced by Sanger sequencing at the
Molecular Biology Resource Facility at The University of Tennessee.

Automatic annotation of assembled scaffolds
The assembled JL11 genome sequence draft was analyzed by the RAST server
(Rapid Annotation using Subsystem Technology, http://rast.nmpdr.org/) for automatic
annotation (Aziz et al. 2008).

Comparative genomics analysis
Genes present in C. jejuni NCTC 11168 and JL11 but absent in C. jejuni 81-176
were identified by both Integrated Microbial Genomes-Human Microbiome Project
(IMG/HMP) system (http://www.hmpdacc-resources.org/cgi-bin/img_hmp/main.cgi) and
literature search followed by manual inspection. Iron-regulated transcriptome data
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(Palyada et al. 2004; Holmes et al. 2005) were used to improve the power of
identification of novel gene(s) involved in iron acquisition.

Sequence analysis and homolog modeling
Across-species alignment of protein sequence of ferric enterobactin esterase
from E. coli CFT073, Salmonella enterica serovar Typhi Ty2, Pseudomonas aeruginosa
and Bordetella pertussis Tohama I (all obtained from database xBASE) (Chaudhuri et al.
2008),

and

Cj1376

homologs

from

different

Campylobacter

strains

(http://watson.bham.ac.uk:8003/campydb/) was performed using ClusterW algorithm in
MEGA4. The phylogenetic tree was constructed using neighbor-joining method in
MEGA4. Homolog modeling of Cj1376 was done by using Moe 2008 against IroE
(2GZS.pdb) template (Larsen et al. 2006).

Complementation and Ent growth promotion
To complement C. jejuni 81-176 (JL242), a 2.5-kb fragment spanning from the
promoter region of cj1375-76 operon to 32 bp downstream of cj1376 stop codon was
PCR amplified from NCTC 11168 using primers contig55F and contig55R (Table 8).
PCR was performed using pfu DNA polymerase (Stratagene, Santa Clara, CA) and the
blunt-ended PCR product was purified and ligated to shuttle vector pRY107 (Yao et al.
1993) which was digested with SmaI prior to ligation. The ligation mix was introduced
into E. coli DH5α by transformation. The transformant with plasmid bearing the intact
cj1375-1376 operon (named ‘pCj1375-76’) was identified (JL532). In-frame deletion of
cj1375 from pCj1375-76 was done by inverse PCR with the primer Cj1376F1 and
Cj1376R1 (Table 8). The PCR product was purified and transformed into E. coli
competent cell Top10. The correct transformant was identified (JL533) by sequencing
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the plasmid (pCj1376). The pCj1375-76, pCj1376, and the original vector pRY107
(control) were then transferred to C. jejuni 81-176 (JL242) by tri-parental conjugation
using DH5α/pRK2013 (JL48) as a helper strain (Akiba et al. 2006), creating JL535 (81176/pCj1375-76), JL536 (81-176/pCj1376), and JL689 (81-176/pRY107), respectively
(Table 7). These 81-176-derived constructs were subjected to standard Ent growth
promotion assay as described in Chapter III.

RESULTS

C. jejuni JL11 and 81-176 share identical major components involved in FeEnt
acquisition
Highly specific primers (Table 8) were designed to examine the presence of
major genes required for FeEnt acquisition, including those encoding energy
transduction (TonB/ExbB/ExbD) and ABC transporter (CeuBCDE). As shown in Table 9,
tonB2 and its associated genes exbB2 and exbD2 existed in all three strains while tonB1
and tonB3 were not detected in 81-176 and JL11. The ceuE gene was detected in all
strains. To further confirm the presence of complete operon of the ABC transport system,
specific primers (CeuF and CeuR, Table 8) were designed to cover complete ceuBCDE
operon. PCR results showed that ceuBCDE genes were also present in all three strains
(Table 9). This PCR analysis showed that C. jejuni JL11 and 81-176 shared identical
major components which we already realized to be involved in FeEnt acquisition,
strongly suggesting that C. jejuni JL11 may contain an unknown component that is
missing in 81-176 for CfrB-dependent FeEnt acquisition.

Whole genome sequencing of C. jejuni JL11
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A single run using a quarter of plate produced a total 171,669 reads and
66,433,940 bases with an average read length of 387 bases, providing a 38.3 average
coverage depth of the JL11 genome (Table 10). The 454 assembly software Newbler
yielded unordered contigs. A total of 169,213 reads were assembled into contigs with a
cumulative length of 1,736,771 bases. The threshold between large and small contigs is
set to 500 bp, which separates the contig group to 39 large contigs (601 to 312,882 bp,
1,730,551 bases of cumulative base length) and 18 small contigs (101 to 489 bp, 6220
bases of cumulative base length). However, the BLAST search against non-redundant
database revealed that one big contig (509 bp) and 11 small contigs were from
contaminated species Lactobacillus salivarius, whose genomic DNA was sequenced
together with the JL11 in the same PicoTiter Plate. Thus, 38 large contigs and 8 small
contigs were used for further gap closure and contig extension.

Gap closure
Contigs were aligned and ordered against three completed C. jejuni reference
genome sequences; NCTC 11168, 81-176 and RM1221 using Mauve (Rissman et al.
2009), As shown in Figure 14 A, most contigs were ordered against the C. jejuni
RM1221 reference. Based on the C. jejuni RM1221 genome as well as contig
sequences, a total of 46 pairs of primers were designed for PCR amplification of the gap
region. Approximately 1,100 PCR reactions were performed and 150 purified PCR
products were subjected to sequencing. Three copies of ribosomal contigs were
assembled into the scaffold (Parkhill et al. 2000). Although all gaps between contigs
have been filled, two small supercontigs (12 and 15 kbp, respectively) were still not
linked to the big super contig (1.74 Mbp) with appropriate order (Fig. 14B). The two small
supercontigs fall into the C. jejuni integrated element 3 (CJIE3) region, which was
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proposed to be related to an integrated megaplasmid in C. jejuni RM1221 (Parker et al.
2006). Two small supercontigs are composed of short contigs with less < 2kb in length,
which were often identified as repeat sequences.

Automatic annotation of the draft genome of C. jejuni JL11
After successful completion of Quality Check, Quality Revision, Similarity
Computation, Bidirectional Best Hit Computation, Auto Assignment, Computation of
Pairs of Close Homologs, and Scenario Computation (metabolic reconstruction),
automatic annotation using the RAST server revealed 1,954 coding sequences and 48
RNAs in JL11 genome, which fall into 223 subsystems (Fig. 15).

A total 31 gene

products were assigned in the virulence subsystem of “Campylobacter iron metabolism”.

Comparative genomic analysis
The comparison of general features among four C. jejuni genomes are described
in Table 11. The GC content of JL11 genome (the big supercontig) was 30.4%, similar to
those of NCTC 11168 (30.6%), 81-176 (30.6%) and RM1221 (30.3%). The chromosome
size of JL11 is similar to RM1221 but greater than NCTC 11168 and 81-176. JL11 is
predicted to have highest number of coding sequences (1954) among these four strains
(detailed in Table 11). A total 1382 genes were shared among these four strains, while
the number of unique genes of these strains is 32 (NCTC 11168), 111 (81-176), 223
(RM1221), and 132 (JL11).

In addition to the genes involved in FeEnt utilization detected by PCR (Table 9),
other annotated iron acquisition components in C. jejuni 81-176 were also detected in
JL11, such as exbB3/exbD3. There is only one FeEnt receptor (CfrB), one set of intact
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energy transduction system (TonB2/ExbB2/ExbD2), and an ABC transport system
(CeuBCDE) for FeEnt acquisition in C. jejuni JL11 (Table 12). In summary, C. jejuni 81176 and JL11 share identical major known components which may be involved in FeEnt
utilization.

Thus because JL 11 is able to utilize FeEnt, unidentified component(s) should
exist in the JL11 genome. To identify genes present in C. jejuni NCTC 11168 but absent
in 81-176, comparative genomic analysis was performed, which resulted in identification
of 51 genes (data not shown). The nucleotide and protein sequences of these 51 genes
were BLAST against the JL11 draft genome. In the case of some genes without
homologs in JL11, flanking regions were analyzed to make sure they are real deletion
mutations instead of artifacts caused by unclosed CJIE3 loci. As shown in Table 13, 10
genes were identified to in C. jejuni NCTC 11168 and JL11, but absent in 81-176. Given
that genes involved in iron metabolism are usually differentially expressed in response to
iron availability (van Vliet et al. 1998; Palyada et al. 2004; Miller et al. 2009), we took
advantage of the accessible microarray data focused on iron regulation in
Campylobacter (Palyada et al. 2004; Holmes et al. 2005) to determine which genes from
the final 10-gene list (Table 13) are subjected to iron regulation. However, none were
identified as an iron-regulated gene based on published microarray data (Palyada et al.
2004; Holmes et al. 2005) and the category of “Campylobacter iron metabolism” (van
Vliet et al. 2002). When taking a deep look into the genetic context, cj1375 and cj1377c,
the genes adjacent to cj1376, are both induced under iron-limited conditions (Palyada et
al. 2004). Furthermore, predicted ORFs of cj1375 and cj1376 overlap by 4-bp
nucleotides, indicating they might be organized into an operon and both subjected to iron
regulation. Other genes in Table 13 are not co-transcribed with any iron-regulated genes
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based on the published microarray data. Therefore, cj1376 seems to be the only ironregulated gene which is present in C. jejuni NCTC 11168 and JL11 but absent in 81-176.

Sequence analysis and structural modeling of Cj1376
Sequence annotation showed that Cj1376 (269 aa) is a putative periplasmic
protein, due to predicted N-terminal signal peptide sequence (Gundogdu et al. 2007).
The BLAST search indicates Cj1376 belongs to the Esterase_Lipase superfamily and is
homologous to IroE in E. coli CFT073 (30% identity and 47% similarity from residue 5 to
168). IroE is the periplasmic esterase to hydrolyze Ent and its modified derivative
salmochelin. IroE is featured by a typical α/β-hydrolase fold with an atypical catalytic
dyad composed of Ser 189 and His 287 (Lin et al, 2005). Thus, we designated Cj1376
as Cee (Campylobacter Enterobactin Esterase). Phylogenetic analysis among different
types of Ent esterases (e.g., Fes, IroD, and IroE) from other bacteria and the
corresponding homolog Cee in Campylobacter revealed that different Cee form a cluster
and is more close to the IroE cluster (Fig. 16A), suggesting that Cee is involved in Ent
utilization by cleavage of the cyclic trimer Ent to the linear 2,3-dihydroxybenzoylserine
trimer (DHBS3, Fig. 16B). The predicted structure of Cee matches the crystal structure of
IroE (Larsen et al. 2006) (Fig. 16C), particularly with respect to the atypical dyad
composed of two highly conserved and essential residues (Ser 189 and His 287 in IroE
versus Ser 157 and His 251 in Cee) (Fig. 16 C and D). In addition, the other two
important and conserved residues of IroE, Asp 90 and Arg 130 (Larsen et al. 2006), also
aligned well with the same conserved residues in Cee (Fig. 16D). Together, these
findings strongly suggest that Cee is an IroE-like enterobactin esterase in
Campylobacter.
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Complementation of C. jejuni 81-176 with Cj1376
Since cj1375 and cj1376 appear to form an operon, we complemented C. jejuni
81-176 with this operon and successfully restored its ability to utilize FeEnt, while vector
pRY107 could not complement the FeEnt utilization of 81-176 (Fig. 17). Deleting cj1375
from plasmid pCj1375-76 but keeping its promoter region yielded plasmid pCj1376.
Complementation of pCj1376 clearly demonstrated that single cj1376 gene product
restored the ability of 81-176 to utilize FeEnt (Fig. 17).

DISCUSSION
This project successfully identified a novel periplasmic enterobactin esterase Cee
in Campylobacter by strategically integrating our previous findings (Chapter III and Xu et
al. 2010), and using ultra-high-throughput genome sequencing technology, comparative
genomics, and bioinformatic approaches. The complementation experiment (Fig. 17)
strongly indicates that Cee is essential player in the CfrB-dependent FeEnt utilization
pathway. Preliminary sequence analysis and structural modeling of Cee suggested that
Cee is a novel periplasmic FeEnt esterase involved in FeEnt uptake and utilization in
Campylobacter. Together, this project has led to a novel finding in iron acquisition of
Campylobacter, and will move the project to new territory to greatly improve scientific
understanding of iron acquisition in Campylobacter and other bacteria.

To generate high quality draft sequences with lower cost and higher throughput
than with classical Sanger technology, we used new ultra-high-throughput DNA
sequencing technology 454 GS FLX. At present, there are two major types of highthroughput sequencing technologies, sequencing-by-synthesis and sequencing-by-
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ligation (Mardis 2008). The former includes 454/Roche (Margulies et al. 2005),
Solexa/Illumina

(Johnson

et

(http://www.pacificbiosciences.com).

al.

2007)

and

These

methods

monitor

Pacific
incorporation

Bio
of

nucleotides during complementary strand synthesis by DNA polymerase in a real-time
manner. The later includes Solid (MacLean et al. 2009), in which complementary strands
of templates are extended with short and specifically-tagged primers by DNA ligase
(Shendure and Ji 2008) in a real-time manner. The 454 sequencing technology used in
this project is based on pyrosequencing technology (Ronaghi et al. 1996). Briefly,
amplicon-bearing beads which are preincubated with DNA polymerase and singlestranded binding protein are deposited into microfabricated array of wells in the PicoTiter
Plate (one bead per well). Smaller beads which carry immobilized ATP sulfurylase and
luciferase are added also. During each sequencing cycle, single species of the
unlabeled nucleotide is added. Incorporation of the correct nucleotide results in release
of pyrophosphate, which subsequently drives the production of a burst of light via ATP
sulfurylase and luciferase. Light can be detected by charge coupled device (CCD). Then
the synthesis is stopped temporarily by washing away nucleotides from the PicoTiter
Plate. Soon after that, another cycle starts with the addition of the next nucleotide
species. The detected pattern of nucleotide incorporation events reveals the sequence
of templates. The 454/Roche has several advantages when compared with other highthroughput sequencing technologies. First, the 454 technology can generate a longer
read length (~400 bp for 454 GS FLX with Titanium series reagents used in current
study). Compared with small read length of Solexa (36 bp) and SOLiD (35 bp) (MacLean
et al. 2009), the long read length by 454 technology facilitates assembling of
complicated genome region (such as repeat or large insertion/deletion regions). Second,
the running time for 454 GS FLX Titanium/Roche (0.35 day for a single run) is shorter
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than Solexa’s GAII/llumina(4 days for a single run) and APG’s SOLiD 3/Life (7 days for a
single run) (Metzker 2010). Finally, Although the relative cost (cost per nucleotide) of
454 is the highest among all the second generation sequencing technologies (Shendure
and Ji 2008), the relatively smaller throughput (500Mbp/run) makes the total cost for
each 454 run less than other technologies (Voelkerding et al. 2009). When dealing with
Campylobacter genome, the throughput is not the major concern because the genome
size of Campylobacter is small (1.6 - 2.0 Mbp); we can get 30 - 50 fold genome depth
using only a quarter of the PicoTiter Plate (Voelkerding et al. 2009), as demonstrated for
our JL11 genome sequencing in this study.

The 454 sequencing and subsequent PCR-based gap closure were completed
successfully completed and assembled approximately 98% of JL11 genome (Table 10
and Fig. 14B). However, two small supercontigs are still difficult to assembeled properly
in the genome; this is not surprising and is likely caused by potential pitfalls of de novo
sequencing using 454 technologies. Small repeat sequences always affect continuity
with GS FLX sequencing data (Voelkerding et al. 2009), which could create a significant
difficulty for assembling. In addition, potential long homopolymeric regions, which are
common in C. jejuni genome (Parkhill et al. 2000), are difficult to read through accurately
by 454 sequencing (Shendure and Ji 2008). There are mutilple approaches to solve
these repeat region problems. First, direct sequencing from JL11 genomic DNA (Lin et
al. 2009) using custom primer-walking on purified genomic DNA template is likely a
straightforward approach to address this issue. However, this approach relies on the
specificity of the sequencing primer and has significant uncertainty. Second, we can
design primers based on sequences flanking repeated regions to perform long distance
PCR using long and accurate DNA polymerase, such as Sigma AccuTaq LA DNA
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polymerase (Hughes et al. 2010). However, successful amplification of long distance
PCR is affected greatly by the specificity of primers and the secondary structure of
template DNA. The length of products amplified from a bacterial genome is often < 20 kb
(according to Sigma’s manual). The third feasible approach is based on plasmid rescue.
For example, an antibiotic resistant marker with appropriate restriction sites can be
inserted into the desired site adjacent to the unfinished region. Then the genome will be
fragmented, ligated into a cloning plasmid, selected by resistance marker, and
sequenced. This approach has been used successfully for cloning of up to a 24 kb
region flanking ceuE (Richardson and Park 1995). To obtain more continuity with the
available GS FLX sequencing data and to solve problems with repeat sequences, we
could also sequence a “paired” library using the Roch/454 protocol as described
previously (Aury et al, 2008). During the paired-end sequencing, a sequence read is
tagged with information known to come from a genomic region within a known number of
nucleotides apart from another read (MacLean et al. 2009), i.e., certain paired reads are
known to be associated with each other on a given fragment with a given distance. This
extra space information would tell how far apart the paired reads can be placed during
assemblies, which allows more accurate placement and construction of contigs.
However, given that the purpose of this project is to obtain high-quality draft sequence
instead of finished complete genome, the paired-end sequencing (~ $4,500 one reaction
for JL11 genomic DNA, UTK price) is not a cost-effective approach to address the above
potential problems of de novo sequencing using 454 technologies. Finally, Solexa
(Illumina Genomic Services, San Diego, CA) sequencing data, which has a different bias
in error type, can significantly complement and improve the GS FLX assembly (Aury et
al. 2008) by effectively correcting errors resulting from reading through homopolymeric
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tracts of sequence. However, this approach would need additional significant budget as
well as analytical expertise.

In E. coli, Fes is a widely studied Ent esterase and is expressed in the cytoplasm
(Langman et al. 1972). Cytoplasmic FeEnt hydrolysis by Fes is considered to be a major
mechanism of iron release from FeEnt, the last essential step for utilization of FeEnt
(Miethke et al., 2007). Some pathogenic strains also possess a periplasmic Ent esterase
such as IroE (Hantke et al. 2003). However, the role of IroE in iron metabolism is not
clear; conflicting models of IroE suggest that it either involves secretion of synthesized
siderophore (Lin et al. 2005; Larsen et al. 2006) or plays a role in uptake of Fesiderophore (Zhu et al., 2005). An IroE-like periplasmic Ent esterase Cee was identified
in this study. Notably, we did not find an Ent esterase homolog other than Cee in
published whole genome sequences of Campylobacter, strongly suggesting that
Campylobacter only has a single Ent esterase Cee for FeEnt acquisition. Given that
Campylobacter does not synthesize Ent, Cee could be involved in uptake of FeEnt in
Campylobacter.

Further

characterization

of

Cee

would

greatly

improve

our

understanding of the critical role of similar periplasmic esterases in FeEnt-mediated iron
acquisition. The enzymatic feature of Cee and its unique role in CfrA- and CfrBdependent FeEnt acquisition are examined in Chapter V.
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Table 7 Key bacterial strains and plasmids used in this project (Chapter IV).
Plasmids or
strains
Plasmids
pRY107
pCj1375-76
pCj1376

Strains
C. jejuni
JL11
JL241
JL242
JL535
JL536
JL689
E. coli
DH5α
Top10
JL48
JL52
JL532
JL533

Description

Source or Reference

E. coli-Campylobacter shuttle vector
pRY107 derivative containing cj1375-76 operon plus its
promoter region (~2.5 kb)
pRY107 derivative containing cj1376 plus the cj1375-76
operon promoter region (1.2 kb)

(Yao et al. 1993)
This study

Bovine isolate with exceptional ability to utilize FeEnt in a
CfrB-dependent manner
NCTC 11168, human isolate
81-176, human isolate
81-176/pCj1375-76
81-176/pCj1376
81-176/pRY107

(Xu et al, 2010)

F- Φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17
(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λF- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1
araD139 Δ(ara-leu) 7697 galU galK rpsL endA1 nupG
DH5α/pRK2013
DH5α/pRY107
DH5α/pCj1375-76
Top10/pCj1376
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This study

(Parkhill et al. 2000)
(Black et al. 1988)
This Study
This Study
This study

Invitrogen
Invitrogen
Chapter III
This study
This study
This study

Table 8. Major primers used in this study (Chapter IV)
Product
size (bp)
503

Target gene or
function
tonB1

CCCAAACTAATCCAACAAATGA
TTGCCTTGGATAAAATTGTGC

308

tonB2

ExbB2F
TonB2R

TTGGCGGGCAATATAGATGT
TTGGTATTGGGTGTGGAGGT

844

Part of exbB2exbD2-tonB2

TonB3F
TonB3R

TCCGATATGAAACCGACACA
CTCCCCACTCATACGCATTT

327

tonB3

CeuEF
CeuER

CTGCTACGGTGAAAGTTTT
GATCTTTTTGTTTTGTGCTGC

785

ceuE

CeuF
CeuR

TGGCTATGGAGAAAGCCTTA
CTCTCTGTCCGCCACTAAAACT

3,904

complete ceuBCDE
operon

Contig55F
Contig55R

GCATTAAAAACCGCTCTTGC
TTGCAAGGCAAAAGTGATGA

2,474

complete cj1375-76
operon

Cj1376F1

GGAAATTGATAATGAAAAAAATATTATTTTTATTCT
GTTCTTTTTTTCTAGC
GAATAAAAATAATATTTTTTTCATTATCAATTTCCT
ATTAAATTTGAAATTTAAATTAGG

7,930

For inverse PCR to
generate in-frame
deletion of cj1375
from pCj1375-76

a

Primer

DNA Sequence (5’-3’)

TonB1F
TonB1R

CAGAGTTTCCTATCGGGGAAT
TGGCAATGGAGAAGCTCTTT

TonB2F
TonB2R

Cj1376R1
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Table 9. Identification of specific tonB and ceuBCDE genes in three C. jejuni strains as
determined by PCR.
C. jejuni strains
Genes
NCTC 11168

81-176

JL11

tonB1

+

-

-

tonB2

+

+

+

exbB2-exbD2-tonB2

+

+

+

tonB3

+

-

-

ceuE

+

+

+

ceuBCDE

+

+

+

“+”, presence of the gene product; “–“, absence of the gene product.
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Table 10. Sequencing statistics of C. jejuni JL11
Parameter

Corresponding Value

Total number of reads

171,669

Total number of bases

66,433,940

Average read length

387.0

No. of total bases in all contigs

1,736,771

No. of total bases in large contigs

1,730,551

No. of all contigs

56

No. of large contigs

39

Size (bp) of large contigs

509 to 312,882

N50 of large contig size

192,284

Average of large contig size

44,373

Size (bp) of small contigs

101 to 489

Average coverage fold depth

38.3
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Table 11. Genome features of four C. jejuni genomes
C. jejuni
Feature
NCTC
11168

81-176

RM1221

JL11

1,641,481

1,616,554

1,777,824

~1.78M

1

1

1

3

30.55%

30.61%

30.31%

30.26%a

Number of coding
sequencesb

1677

1758c

1838

1954a

Number of RNAsb

57

58c

53

48a

Chromosome size (bp)
Chromosome contigs
GC%

Shared genesb

1382

Unique genesb

32
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223

132a

Iron metabolism
genesb

34

31

30

31a

CJIEs

0

0

CJIE1-4

CJIE3

a

Calculated from the major supercontig of C. jejuni JL11.
Data generated by RAST server except those from the IMG/HMP system.
c
Data generated by the IMG/HMP system.
b
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Table 12. Potential components of CfrA- and CfrB-dependent FeEnt acquisition systems
among three C. jejuni strains as determined by genome sequence analysis.
C. jejuni Strains

NCTC 11168

81-176

JL11

FeEnt utilization

Yes

No

Yes

CfrA

+

–

–

CfrB

pseudogene

+

+

TonB1
ExbB1/ExbD1

+
+

–
–

–
–

TonB2
ExbB2/ExbD2

+
+

+
+

+
+

TonB3
ExbB3/ExbD3

+
+

–
+

–
+

CeuBCDE

+

+

+
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Table 13. Genes present in C. jejuni NCTC 11168 and JL11, but absent in 81-176
NCTC 11168
Locus

Gene Annotation

Coding
Length in
JL11(aa)

IronRegulateda

Cj0030

hypothetical protein

465

-

Cj0422c

putative helix-turn-helix containing protein

69

-

Cj0501

pseudogene (putative ammonium transporter)

372

-

Cj0668

putative ATP /GTP-binding protein

135

-

Cj1301

hypothetical protein

138

-

b

putative periplasmic protein

269

-

Cj1521c

putative CRISPR-associated protein

143

-

Cj1522c

putative CRISPR-associated protein

296

-

Cj1523c

putative CRISPR-associated protein

984

-

Cj1585c

putative oxidoreductase

923

-

Cj1376

a

Based on available transcriptome profiling of C. jejuni NCTC 11168 in response to iron
(Palyada et al. 2004).
b

The gene immediately upstream of cj1376 (cj1375) and the gene immediately
downstream of cj1376 (cj1377c) are induced under iron-restricted conditions (Palyada et
al. 2004).
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(A)

(B)

Figure 14. Ordering of JL11 contigs and the gap closure.
(A) Ordering of the C. jejuni JL11 contigs against three finished genomes of C. jejuni
NCTC 11168, 81-176 and RM1221. The red vertical lines delineate boundaries of
contigs. The unordered contigs are put on the right side of each diagram. (B) The
assembled draft genome of JL11. Two small supercontigs corresponding to the CJIE3
region (yellow solid arrow pointed) in the genome of C. jejuni RM1221 (Fouts et al.
2005).

113

Figure 15. Subsystem statistics of C. jejuni JL11 genome.
The pie diagram of subsystems in JL11 genome was based on automatic annotation by
RAST. The subsystem of Campylobacter iron metabolism is collapsed within the
subsystem of Virulence.
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(A)

(C)

(B)

(D)

Figure 16. Sequence analysis of Cee (Cj1376).
(A) Phylogenetic relationship of Ent esterase Fes, IroD, IroE and Cee; (B) The potential
role of Cee in FeEnt hydrolysis. The cleavage of ester bond by Cee may transform cyclic
trimer Ent to linear trimer (DHBS3); (C) Similarity of 3D structure between Cee and E.
coli IroE (backbone of IroE in green and Cee in red). The catalytic site was indicated as
the sidechains within the yellow box area. (D) Cross-species sequence alignment of Cee
in Campylobacter species with IroE from different organisms. The specific amino acids in
E. coli CFT073 IroE that have been demonstrated to contribute to in vitro catalytic
activity (Larsen et al. 2006) are shown above the alignment. The corresponding
conserved amino acids in Campylobacter Cee are below the alignment. These
conserved amino acids were encompassed with black boxes. Asterisks (*) above the
alignment represent the conserved residues across all tested organisms.

115

Figure 17. Complementation of C. jejuni 81-176 with Cj1376 gene restored its ability to
utilize FeEnt as a sole iron source for growth.
The plasmids with or without cj1376 gene were conjugatively transferred into C. jejuni
81-176. The constructs were subjected to standard Ent growth promotion assay as
described in Materials and Methods.
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CHAPTER V
KEY COMPONENTS AND MOLECULAR INTERACTIONS OF CfrAAND CfrB-DEPENDENT FERRIC ENTEROBACTIN ACQUISITION
SYSTEMS IN CAMPYLOBACTER
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ABSTRACT
The FeEnt acquisition system is a major and well studied siderophore-mediated
high affinity iron uptake system in Gram-negative bacteria. However, significant
knowledge gaps still exist with respect to the coordination of different components and
pathways for FeEnt transport, and mechanisms of iron release. Campylobacter appears
an ideal model organism to examine FeEnt acquisition due to its small genome, inability
to synthesize Ent, and enormous population diversity. In this project, the function of the
periplasmic FeEnt esterase Cee was studied using biochemical and amino acid
substitution mutagenesis approaches. Recombinant Cee was purified for future
enzymatic assays. Using delicate genetic manipulations in three different C. jejuni
strains, molecular interactions of the two FeEnt acquisitions systems were investigated.
The Cee is not only essential for CfrB-dependent FeEnt acquisition but also involved in
the CfrA-dependent pathway. However, periplasmic binding protein CeuE was only
involved in the CfrA-dependent pathway. Genome analysis and complementation
studies strongly suggested that CfrA interacted with TonB3 while CfrB interacts with
TonB2 in C. jejuni strains. The inner membrane ferrous iron transporter FeoB and the
putative ferric iron transporter Cj0174c did not play a significant role in FeEnt acquisition
in Campylobacter. In addition, Cj1377c, a putative ferredoxin, was essential for CfrAdependent FeEnt utilization, suggesting its critical role in reductive iron release from
FeEnt. Based on these findings and other published information, a model of the CfrAand CfrB-dependent FeEnt acquisition pathways in Campylobacter is proposed.
Validation of this model would greatly improve our understanding of iron acquisition in
Campylobacter and other bacteria, and facilitate development of novel vaccines and
antimicrobials against Campylobacter.
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INTRODUCTION
All Gram-negative bacteria have an absolute requirement for iron to survive.
However, because of the low solubility of ferric iron and the need to avoid its
participation in generating toxic oxygen-derived free radicals, higher organisms have
evolved mechanisms for lowering the levels of free iron to well below those required for
the growth of Gram-negative bacteria (Litwin and Calderwood 1993). To survive in an
iron-restricted

condition,

Gram-negative

bacteria

have

evolved

sophisticated

mechanisms to acquire iron from the environment. One unique and efficient strategy
used by Gram-negative bacteria is to synthesize siderophores (low-molecular-mass,
high-affinity iron-binding compounds) to scavenge iron from the environment (Miethke
and Marahiel 2007). One of the best studied siderophores is enterobactin (Ent), which is
produced by a wide variety of gut commensal bacteria. More importantly, Ent has the
highest affinity for ferric iron of the natural siderophores that have been tested and can
effectively scavenge iron from other iron complexes in neutral and alkaline conditions
(Stintzi et al. 2008). FeEnt acquisition in Gram-negative bacteria is a process in which
multiple components are involved from outer membrane to cytoplasm (Crosa and Walsh
2002; Raymond et al. 2003; Miethke and Marahiel 2007). Commonly, FeEnt complex is
bound specifically to a surface-exposed outer membrane receptor, and transported into
the periplasm using an energy transduction system TonB-ExbB-ExbD (Miethke and
Marahiel 2007). Subsequent delivery of the FeEnt complex from the periplasm to the
cytoplasm depends on ABC-type uptake systems (e.g. FepBDGC in E. coli) that
generally possess periplasmic binding proteins to bind substrate FeEnt (Sprencel et al.
2000). ATP hydrolysis provides the energy for ABC transporters to deliver FeEnt into the
cytoplasm (Davidson and Maloney 2007). Cytoplasmic FeEnt hydrolysis by a specific
esterase (e.g., Fes in E. coli) is considered to be a major mechanism of iron release
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from FeEnt (Langman et al. 1972; Brickman and McIntosh 1992). However, intracellular
reductive iron release from Ent has not been clearly demonstrated although this type of
mechanism of iron release has been widely demonstrated for other siderophores with
lower affinity to ferric iron (Faraldo-Gomez and Sansom 2003). Given its important role
in bacterial iron assimilation and pathogenesis, FeEnt iron acquisition is a major and well
studied siderophore-mediated high affinity iron uptake system in Gram-negative bacteria
(Crosa and Walsh 2002; Stintzi et al. 2008). However, significant knowledge gaps still
exist with respect to the coordination of different components and pathways for FeEnt
transport, and the mechanisms of iron release.

Campylobacter appears an ideal model organism to examine FeEnt acquisition
due to its small genome, inability to synthesize Ent, and enormous population diversity.
Several important components involved in FeEnt utilization in Campylobacter have been
identified, including outer membrane receptor CfrA (Guerry et al. 1997; Palyada et al.
2004) and CfrB (Xu et al. 2010), energy transduction component TonB3 (Guerry et al.
1997), periplasmic FeEnt binding protein CeuE and its cognate inner membrane ABC
transporter system CeuBCD (Park and Richardson 1995; Richardson and Park 1995),
and a putative periplasmic Ent esterase Cee (Chapter IV). Inactivation of CfrA, CfrB or
CeuE alone in Campylobacter greatly reduced and even abolished Campylobacter
colonization in chickens (Palyada et al. 2004; Xu et al. 2010), indicating that FeEnt
utilization systems play a critical role in Campylobacter colonization in the intestine.
Notably, our studies on CfrA and CfrB have revealed novel and complex features of
Campylobacter FeEnt acquisition systems in diverse strain backgrounds (Chapters III
and IV, Xu et al., 2010). For example, Cee is an esterase similar to IroE that hydrolyzes
Ent and salmochelin to produce linearized trimers in periplasm (Lin et al. 2005; Zhu et al.
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2005). Conflicting models of IroE suggest that it either involves secretion of synthesized
siderophore (Lin et al. 2005) or plays a role in uptake of Fe-siderophore (Zhu et al.
2005). Campylobacter does not synthesize Ent and does not have any other Ent
esterase homologs in the genome, suggesting that Cee is involved in FeEnt uptake.
Further characterization of Cee would also greatly improve our understanding of the
critical role of similar periplasmic esterases in FeEnt-mediated iron acquisition in other
bacteria. In addition, the wild-type 81-176 strain failed to utilize FeEnt as a sole iron
source for growth although it has functional receptor CfrB, energy transduction system
TonB2-ExbB2-ExbD2, and ABC transport system CeuBCDE (Chapter IV), indicating
CeuBCDE could not interact with the FeEnt transported via CfrB and warranting further
examination of Cee in CfrA- and CfrB-dependent FeEnt acquisition in Campylobacter.
Since we did not find cytoplasmic Ent esterase homolog in published genome
sequences of Campylobacter, intracellular reductive iron release from Ent is likely an
essential final step for FeEnt acquisition in Campylobacter; the nature of small genome
of Campylobacter may enable us to test this hypothesis, which has not been clearly
demonstrated in other Gram-negative bacteria.

In this study, Cee was further characterized using biochemical and genetic
approaches, fully establishing its function in FeEnt hydrolysis and critical role in FeEnt
acquisition in Campylobacter. In addition, extensive molecular and genetic manipulation
of three C. jejuni strains, NCTC 11168, 81-176 and RM1221, led to novel findings
regarding molecular interaction of two unique FeEnt acquisition systems in
Campylobacter, which provides the framework for examining functional and mechanistic
features of key components involved in this important pathophysiological process.
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MATERIALS AND METHODS

Bacterial strains, plasmids and culture conditions.
The major bacterial strains and plasmids used in this study and their sources are
in Table 14. C. jejuni strains were grown routinely in MH broth (Difco, Detroit, MI) or on
agar at 42°C under microaerophilic conditions, which were generated using CampyGen
Plus (Oxoid, Bashingstoke, Hampshire, England) gas pack in an enclosed jar. Ferric
sulfate (40 µM) was supplemented when iron-rich condition is required. Deferoxamine
mesylate (DFO, 20 µM) was supplemented in medium when iron-limited condition is
needed. E. coli was grown in Luria-Bertani (LB) broth (Fisher Scientific, Fairlawn, NJ)
with shaking (250 rpm) or on agar at 37 ºC overnight. When needed, culture media were
supplemented with kanamycin (30 μg/ml), chloramphenicol (4 μg/ml), erythromycin (5
μg/ml) or tetracycline (5 μg/ml). All antibiotics were purchased from Sigma (St Louis,
MO).

PCR
Major PCR primers used in this study and expected sizes of products are in
Table 15. PCR was performed in a volume of 50 µl containing 200 µM of each
deoxynucleotide triphosphate, 200 nM of primers, 2.5 mM of MgSO4, 50 ng of template
DNA and 5 U of Taq DNA polymerase (Promega, Madison, WI) or PfuUltra® HighFidelity DNA polymerase (Stratagene, Santa Clara, CA). Cycling conditions varied
according to estimated annealing temperatures of primers and expected sizes of
products. PCR products were purified by QIAquick PCR Purification Kit (Qiagen,
Valencia, CA) when needed for cloning or sequencing analysis.
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Enzymatic assay of Cee using whole cell extract
Whole cell extracts from C. jejuni JL241 (wild-type, Cee positive), JL540
(isogenic cee mutant), and JL324 (isogenic cfrA mutant as a control) were used for
determining their activities to hydrolyze FeEnt as described in a previous publication
(O'Brien et al. 1971). Briefly, a Campylobacter culture (OD600nm = 0.1) was diluted 1:50
into 100 ml MH broth containing 20 µM of DFO. Following overnight incubation under
microaerophilic conditions at 42 oC, cells were pelleted, washed once with PBS (pH 7.4),
and re-suspended in 2 ml of 0.1 M Tris-HCl buffer (pH 8.0). The cell suspension was
sonicated on ice with 3 cycles of action (20 sec per cycle). Sonicated cells were
centrifuged at 13,000 rpm for 10 min at 4oC; the supernatant was used as the raw cell
extract for esterase activity analysis. The protein concentration of each extract was
measured by BCA kit (Pierce, Rockford, IL). Equal volumes of cell extract (0.15 ml
containing approximately 180 µg of protein) and FeEnt solution (0.15 ml containing
approximately 21 µmol FeEnt) were mixed and incubated at 37°C for 90 min. The
reaction was stopped by adding 0.1 ml H2SO4 (1M) and the solutions were extracted
with 1 ml ethyl acetate for 30 min, followed by centrifugation at 13,000 rpm for 5 min.
The organic phase was dried over anhydrous Na2SO4 and then split into two parts for
analyses. One part was subjected to OD measurement at 316 nm to determine the
concentration of total FeEnt (intact FeEnt plus its hydrolyzed products) based upon a
millimolar extinction coefficient of Ent of 9.39 at 316 nm (O'Brien et al. 1971; Brickman
and McIntosh 1992). Another part of the organic phase was counter-extracted with equal
volumes of PBS (pH7.4) so that the hydrolyzed FeEnt was extracted from the organic
phase to PBS; the concentration of FeEnt in organic phase was determined as
described above. The esterase activity was expressed as picomoles of FeEnt
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hydrolyzed/h/mg of cell extract. These experiments were performed twice independently
with duplicate samples within each experiment.

Production of recombinant Cee
A full-length histidine-tagged recombinant Cee (rCee) was produced in pQE-30
vector (Qiagen, Hilden, Germany). Briefly, primers rCj1376F and rCj1376F (Table 14)
were used to amplify cee from C. jejuni NCTC 11168 with the removal of signal peptide
(the

first

17

aa)

predicted

using

Signal

P

3.0

server

(http://www.cbs.dtu.dk/services/SignalP/). Cloning, expression, and purification of rCfrA
were performed following procedures described in Chapter II.

Site-directed amino acid substitution mutagenesis
Conserved amino acid residues critical for the catalysis function of IroE and Cee
were identified by across-species alignment (Chapter IV). In this study, the two residues
(S157 and H251) were substituted by alanine in vector pCj1376 with appropriate primers
(Table 15) following the method described in Chapter III. These mutated plasmids were
conjugatively transferred into C. jejuni 81-176; resulting in constructs JL648 and JL649,
respectively (Table 14) Mutants and the control strain JL535 (81-176/pCj1376) were
used for Ent growth promotion assay to determine the role of specific aa in FeEnt
assimilation in C. jejuni.

Construction of insertional mutants
The cj1377c, a putative ferredoxin gene, was inactivated in C. jejuni NCTC
11168 by insertional mutagenesis described in our previous publications (Lin et al. 2003;
Lin et al. 2005; Akiba et al. 2006). Briefly, primers Cj1377c_F1 and Cj1377c_R1 (Table
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15) were used to amplify 1934 bp cj1377c gene fragment. The PCR product with a
unique NheI restriction site was cloned into pGEMT-Easy (Promega, Madison, MI),
resulting in the construct pFd. Chloramphenicol resistance (Cmr) cassette was PCR
amplified from plasmid pUOA18 (Wang and Taylor 1990) using PfuUltra® High-Fidelity
DNA polymerase (Stratagene, Santa Clara, CA) and primers CHLF1 and CHLR1 (Table
15). The 0.8-kb PCR product was digested with NheI (Promega, Madison, MI) and
ligated to NheI-digested pFd to obtain the construct pmFd (Table 14). Sequence
analysis of the construct indicated that the Cmr cassette was inserted in the cj1377c
fragment with the same transcriptional direction. The plasmid pmFd, which served as a
suicide vector, was transferred into C. jejuni NCTC 11168 by natural transformation. One
Cmr mutant (JL578) was selected on MH agar containing 4 μg/ml of Cm. Inactivation of
the cj1377c gene in JL578 was confirmed by PCR (data not shown). The cee, feoB,
ceuE and cj0174c mutants of different C. jejuni strains were constructed by natural
transformation (Wang and Taylor 1990) using corresponding genomic DNA kindly
provided by our collaborators Dr. Qijing Zhang (Iowa State University, US; cee mutant
DNA), and Dr. Alain Stintzi (University of Ottawa, Canada; feoB, ceuE and cj0174c
mutants).

Complementation in trans
Complementation plasmids were constructed by ligating PFU-amplified gene
fragments (corresponding primers listed in Table 15) with SmaI digested shuttle vector
pRY107 (Yao et al. 1993) with the exception of pTonB3-CfrA. pTonB3-CfrA was
constructed by ligating the ~1.2 kb segement, which was digested from pTonB3 using
PstI and PacI, with the vector part of PstI and PacI double digested pCfrA. Those
recombinant plasmids were then transferred to recipient strains, by tri-parental
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conjugation using E. coli DH5α/pRK2013 as a helper strain (Akiba et al. 2006). In brief,
plasmids bearing exbB1-exbD1-tonB1 operon, tonB3, cfrA, or tonB3-cfrA were
transferred into C. jejuni 81-176; cfrB was transferred into a cfrA mutant of NCTC 11168;
cfrA, ptonB3-cfrA and ceuBCDE operon were transferred into RM1221 (Table 14).

SDS-PAGE and immunoblotting
C. jejuni strains were grown in iron-rich medium (MH + 40 μM ferric sulfate) or
iron-limited medium (MH + 20 μM DFO) to late log phase at 42oC under microaerophilic
condition. To prepare whole-cell lysates, Campylobacter cells grown in above iron-rich or
iron-limited conditions were harvested and solubilized by boiling for 5 min in sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. SDSPAGE and immunoblotting were performed as described (Lin et al. 2003).

Purification of enterobactin and growth promotion assay.
Detailed procedure for Ent purification and standard Ent-mediated growth
promotion assay were described in Chapter III.

RESULTS

Cee is a FeEnt esterase critical for the FeEnt acquisition in C. jejuni
As shown in Figure 18A, extracts from wild-type C. jejuni NCTC 11168 effectively
catalyzed hydrolysis of FeEnt, hydrolyzing 9480 ± 1169 pmol of FeEnt h-1 mg-1. As a
control, extracts from cfrA mutant of 11168 showed similar activity, hydrolyzing 7849 ±
1617 pmol of FeEnt h-1mg-1. However, extracts from cee mutant showed little hydrolysis
activity for FeEnt, indicating that Cee is a FeEnt hydrolase. The in vivo assay (Fig. 18B)
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further supported that Cee is an IroE-like esterase. As shown in Figure 18B, alanine
substitution of Ser 157 or His 251, which are highly conserved in Campylobacter Cee
and are predicted to be critical for Cee’s function based on the crystal structure of IroE
(Chapter IV), completely impaired the function of Cee; unlike wild-type Cee, both Cee
mutants failed to restore C. jejuni 81-176’s ability to utilize FeEnt (Fig. 18B).

Expression and purification of rCee
High yield of rCee was achieved by using the pQE30 (Qiagen, Hilden, Germany)
expression system and following the protocol developed in Chapter II. However, large
amount of rCee was trapped inside the affinity column, and the eluted rCee quickly
precipitated. We speculated that rCee tends to aggregate likely through the interaction of
surface hydrophobic patches which were exposed by ATP-Mg2+ mediated dissociation of
rCee with chaperones. This phenomenon is also observed during the purification of
recombinant E. coli IroE (Lin et al. 2005). To enhance the solubility of rCmeC, cell
culturing temperature was lowered (room temperature) to slow down the biosynthesis of
rCee and allow newly synthesized protein to fold correctly. As a result, His-tagged rCee
was purified with high yield using pQE30 expression system (Fig. 18C) and remained
soluble in the elution buffer which consisted of 50 mM sodium phosphate, 300 nM NaCl,
500 mM imidazole, 10% glycerol and 0.1% Empigen. However, this purified rCee was
aggregated after dialysis against PBS even though the detergent, such as Empigen,
Triton X-100, or Tween 20 was supplemented.

Cee is essential for the CfrB-dependent FeEnt acquisition pathway
As demonstrated in Chapter IV, complementation of C. jejuni 81-176 with cee
rescued its defect to utilize FeEnt, indicating Cee is essential for CfrB-dependent FeEnt
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utilization pathway in this strain. However, based on comparative genomic analysis
regarding FeEnt acquisition systems, 81-176 is a ‘simpler’ strain compared with other
strains such as C. jejuni NCTC 11168 (Table 12). We examined the role of Cee in FeEnt
acquisition in C. jejuni NCTC 11168, a strain with more complex components involved in
FeEnt acquisition (Table 12). As shown in Fig. 19, inactivation of Cee (strain JL540) did
not affect CfrA-dependent FeEnt utilization compared with its parent wild-type 11168
strain. Insertional mutation in cfrA (JL491, Table 14) completely abolished FeEnt
utilization ability, consistent with results in Chapter III using a different marker (Cm) for
cfrA mutagenesis (Fig. 10). Complementation of the cfrA mutant JL491 with wild-type
cfrB created new construct JL531, which displayed exceptional ability to utilize FeEnt.
However, introduction of isogenic cee mutation into JL531 completely abolished its
ability to use FeEnt (Fig. 19). This finding together with our previous complementation
work in 81-176 (Fig. 17, Chapter IV) firmly established that Cee is an essential
component of the CfrB-dependent pathway. In addition, the phenotype of JL673 (Fig. 19)
also indicated that the CfrB-transported FeEnt in periplasm cannot bind to CeuE and
transport through CeuBCD ABC transporter for utilization.

Cee could be involved in the CfrA-dependent FeEnt aquisition pathway
Significant diversity among three different C. jejuni strains regarding major
components that may be involved in FeEnt acquisition were observed (Table 12,
Chapter IV). This population diversity has facilitated identification of key components and
molecular interactions of FeEnt acquisition systems in the studies. C. jejuni RM1221,
whose genome sequence is also available (Fouts et al. 2005), appears to be another
good strain for studying FeEnt acquisition because genome sequence of this strain
revealed natural mutations in CfrB, TonB2, and CeuE (Table 14) and this strain is
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defective in utilizing FeEnt (Fig. 20B). RM1221 expressed CfrA but not CfrB under ironlimited conditions (Fig. 20B), consistent with its genome contents. Complementation of
RM1221 with functional pCfrA or pTonB3-CfrA did not rescue the defect of FeEnt
utilization (Fig. 20A), ruling out the possibility that inability of our RM1221 strain to utilize
FeEnt is due to naturally occuring mutations in TonB3 and CfrA. Since Cee is absent in
RM1221 (Table 14), RM1221 was complemented with pCj1375-76, a plasmid
expressing functional Cee; complementation of RM1221 with this plasmid restored its
ability to utilize FeEnt. Given the lack of a functional CfrB in RM1221 (Fig. 20A), this
complementation experiment strongly indicates that Cee can participate in CfrAdependent FeEnt acquisition pathway.

The cognate TonB of the specific FeEnt receptor in C. jejuni
Both C. jejuni JL 11 and 81-176 only have functional TonB2, strongly suggesting
that TonB2 interacts with CfrB in these strains of C. jejuni. Complementation of 81-176
with functional CfrA failed to restore its ability to use FeEnt (Fig. 21). However,
complementation of 81-176 with both TonB3 and CfrA genes rescued its defect in FeEnt
utilization (Fig. 21), indicating that CfrA interacts with TonB3.

The role of CeuE in CfrA- and CfrB-dependent FeEnt acquisition systems
It has been proposed that CeuBCDE ABC transport system is required for FeEnt
acquisition in C. jejuni (Miller et al. 2009). However, inactivation of CeuE, a periplamic
binding protein of the ABC transport system, did not abolish the ability of NCTC 11168 to
use FeEnt (Fig. 22A, Palyada et al. 2004); the CeuE isogenic mutant only displayed
impaired ability to utilize FeEnt compared to wild-type strain. Double mutations in ceuE
and cee completely abolished the ability of NCTC 11168 to utilize FeEnt (Fig. 22A),
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indicating that CfrA-transported FeEnt could use Cee-mediated pathway when CeuE is
not functional, although Cee has been demonstrated to be dispensable for NCTC 11168
(Fig. 19). Analysis of C. jejuni RM1221 showed that this strain does not have functional
CfrB-dependent pathway and its CeuE gene is a pseudogene. Introduction of a plasmid
bearing a functional CeuE gene restored the CfrA-dependent FeEnt utilization in
RM1221 (Fig. 22B). Inactivation of ceuE in strains using the CfrB-dependent pathway for
FeEnt utilization did not result in any phenotypic changes, indicating that CeuE is not
required for CfrB-dependent pathway (Fig. 22 C). This result is also consistent with the
finding that CfrB-transported FeEnt into the periplasm can not bind to CeuE and
transport through CeuBCD ABC transporter for utilization (JL673 in Fig. 19).

The role of FeoB and Cj0174c in the FeEnt acquisition in C. jejuni
FeoB is an inner membrane ferrous iron transporter (Naikare et al. 2006) while
Cj0174c is a putative ferric iron transporter based on its homology to FbpB from V.
cholerae (Naikare et al. 2006; Wyckoff et al. 2006). Mutants with single or double
mutations in feoB and cj0174c did not affect either the CfrA-dependent or the CfrBdependent FeEnt utilization in C. jejuni (Table 16).

Cj1377c is involved in the CfrA-dependent FeEnt acquisition pathway
cj1377c, a putative ferredoxin gene immediately downstream of cee (Fig. 23A)
but with different transcriptional orientation, was required for CfrA-dependent FeEnt
acquisition (Fig. 23B). However, cj1377c mutation has little effect on the CfrB-dependent
pathway (Fig. 23C).
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DISCUSSION

In this project, FeEnt acquisition systems in Campylobacter were examined
comprehensively with a focus on several potentially important components (e.g.
periplasmic Ent esterase Cee, periplasmic energy transduction component TonB,
periplasmic FeEnt binding protein CeuE, inner membrane transporters FeoB and
Cj0174c, and cytoplasmic ferredoxin Cj1377c) and the interplay of CfrA- and CfrBdependent FeEnt acquisition. Based on these extensive molecular, biochemical and
genetic studies, a FeEnt acquisition model in Campylobacter is proposed (Fig. 24).
Further validation of this model in diverse strain backgrounds will substantially improve
our understanding of molecular pathways of two unique FeEnt acquisition systems in
Campylobacter, and reveal mechanistic features of key components involved in this
important pathophysiological process. Campylobacter FeEnt receptors and cognate key
pathway components may offer a broad array of possible intervention strategies, such as
FeEnt receptor-based subunit vaccines and FeEnt acquisition pathway inhibitors.

Despite compelling evidence obtained from this study demonstrating the function
of Cee in the hydrolysis of FeEnt, enzymatic features of Cee are still largely unknown.
IroE, a periplasmic Ent esterase homologous to Cee, has been demonstrated to degrade
Ent as well as salmochelin, C-glucosylated Ent analogs isolated from Salmonella
enterica and E. coli strains (Zhu et al. 2005). The main products of IroE–mediated
hydrolysis are linear trimers of cyclic substrates (Zhu et al. 2005), therefore, it is likely
that hydrolysis of FeEnt by Cee also generates the linear trimer Fe3+-(DHBS)3. Thus, it is
remotely possible that the Cee-hydrolyzed linear trimer is subjected to further Cee
hydrolysis of Fe3+-(DHBS)3 into dimers or even monomers, which would lead to a
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dramatic loss of complex stability and the direct release of ferric iron in the periplasm for
utilization (dashed line pathway in Fig. 24). Validation of this pathway largely depends on
enzymatic characterization of Cee. Therefore, understanding the catalytic efficiency and
specificity of Cee would enhance our understanding of its biochemical features and is
critical in validating our model (Fig. 24). In addition, comparison of Cee’s activity with
that of other trilactone esterases, such as IroE and Fes, would provide insights into the
role of these enzymes, the only known bacterial enzymes involved in hydrolytic iron
release, in bacterial pathophysiology. To achieve this goal, high-quality rCee should be
obtained for in vitro enzymatic characterization. Although the rCee with high-purity and
high yield has been produced in this project, the rCee tends to precipitate in the buffer
used for the enzymatic assay. This finding is not surprising and has been observed for
purification of E. coli rIroE (Lin et al. 2005). To increase the solubility of rCee, further
modifications (such as adjustment of buffer pH and ionic strength) for purification should
be explored in the future. Furthermore, construction of new recombinant plasmids
expressing rCee with removal of additional N-terminal hydrophobic peptide (10 – 20 aa
in length) is a promising approach to obtain desired soluble rCee suitable for enzyme
analysis; this approach has been successfully used for purification of recombinant IroE
(Zhu et al. 2005; Larsen et al. 2006).

This study not only demonstrated that Cee is essential for CfrB-dependent
pathway but also showed that Cee could use CfrA-transported FeEnt when CeuBCDE
ABC transport system is not functional (Fig. 22A and 22B). However, if CfrA-dependent
pathway is functional, Cee appears to be dispensable for FeEnt acquisition (Fig. 19).
These findings strongly support the unique role of Cee in FeEnt acquisition in C. jejuni.
Since both CfrA- and CfrB-dependent systems are co-produced in C. coli and CfrB plays
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a dominant role in FeEnt acquisition in C. coli (Xu et al. 2010), it is important to examine
the role of Cee in FeEnt acquisition in diverse C. coli strain backgrounds and the role of
Cee in Campylobacter colonization in the intestine. These future studies will provide
critical information to determine whether Cee is a promising target for novel antimicrobial
development.

It is intriguing that periplasmic CfrB-transported FeEnt can not interact with
functional CeuBCDE for further utilization (Fig. 19 and 21). We speculate that CfrBtransported FeEnt does not have access to CeuE, likely due to CeuE’s unique location
within a coordinated complex comprising CfrA, TonB/ExbBD, and CeuBCDE. The
structure and stoichiometry of these components are still largely unknown. Therefore, it
is premature to test this hypothesis at this stage. Successful validation of the proposed
model (Fig. 24) will provide a framework and rationale to analyze physical interactions of
various components of the CfrA-dependent pathway using approaches such as crosslinking and immuno-coprecipitation.

It is unknown if Cee is also directly involved in the release of ferric iron from Ent
as has been observed for Fes, a cytoplasmic FeEnt esterase in E. coli (O'Brien et al.
1971; Miethke and Marahiel 2007). Cytoplasmic FeEnt hydrolysis by Fes is considered
to be a major mechanism of iron release from FeEnt in E. coli (O'Brien et al. 1971;
Miethke and Marahiel 2007).

Based on the predicted structure of Cee and its

periplasmic location, it is likely Cee only hydrolyzes cyclic FeEnt to a linear trimer, which
still has high affinity to ferric iron. Thus, the linear trimer in periplasm should be
subjected to further transport and reaction (such as reduction described below) so that
iron is finally released for utilization.

However, we can not completely rule out the
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possibility that Cee could further degrade FeEnt into dimers or even monomers, leading
to a dramatically reduced affinity to iron and consequently, direct release of ferric iron in
the periplasm for utilization. This possibility will be tested by enzymatic analysis of Cee
in the future. Absence of Ent esterase homolog other than Cee in published whole
genome sequences of Campylobacter strongly indicated that Campylobacter use
another mechanism to release ferric iron in cytoplasm. This mechanism, reduction of
ferric-siderophore complex by reductase, is used commonly by bacteria for siderophores
other than Ent; intracellular reductive iron release from Ent, the siderophore with highest
affinity to iron, has not been clearly demonstrated (Miethke and Marahiel 2007; Miller et
al. 2009). Findings from this study would enable us to first demonstrate the intracellular
reductive iron release from Ent using Campylobacter as a model organism. The
important role of Cj1377c, a putative ferredoxin, in CfrA-dependent FeEnt utilization (Fig.
23) strongly suggests that ferric reduction is required for Campylobacter to utilize FeEnt.
Annotation analysis revealed that Cj1377c has a conserved domain (TIGR03224, Evalue of 2e-07) represented by BoxA, an NADPH-dependent reductase. Since
ferredoxin-NADPH reductase could function as a ferric reductase (Yeom et al. 2009),
Cj1377c may be a ferric reductase for iron release from Ent in Campylobacter. However,
it is also likely that Cj1377c functions as an essential redox partner of a ferric/flavin
reductase to reduce siderophore-bound Fe3+ (Schroder et al. 2003; Ceccarelli et al.
2004; Miethke and Marahiel 2007). Importantly, the loci adjacent to cj1377c are
implicated in iron metabolism (Fig. 23A), in which most of genes (6 out of 10) are ironregulated (Palyada et al. 2004; Holmes et al. 2005). Notably, examination of this locus
revealed another interesting gene cj1382c. Annotation also showed that Cj1382c has a
typical FMN_red super family domain (E value of 3.46e-66) conserved in NADPHdependent FMN reductase, strongly suggesting that Cj1382c is an iron-regulated
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ferric/flavin reductase for iron release from ferric siderophores, including FeEnt. To test
these hypotheses, recombinant Cj1377c and Cj1382c will be produced and used for a
standard ferric/flavin reductase assay (St Maurice et al. 2007) in the future.

The phenotype of our ceuE mutant was slightly different from a previous report
(Palyada et al. 2004). In the previous study, the Ent-mediated growth zone of ceuE
mutant was confluent while the ceuE mutant in this study exhibited isolated colonies
around the central disk (Fig. 22A). This slight difference is likely due to the different
quantities of Campylobacter cells used for the growth promotion assay. In Palyada’s
studies (2004), Campylobacter cells used for mixing with soft agar in each plate were 1
ml of cuture with an optical density of 1 at 600 nm, which is 50-fold more than what we
used. Using a similar high Campylobacter inoculum, we replicated findings reported in
Palyada et al (2004). Based on our extensive experience in FeEnt growth promotion
assay, approximately 2 x 107 Campylobacter cells used in each plate would offer better
sensitivity of the assay and result in clearer background.

This project has generated critical information and revealed novel features of
Campylobacter FeEnt acquisition systems. Campylobacter may be an ideal model
organism to examine FeEnt acquisition in Gram-negative bacteria. To validate the
proposed model (Fig. 24), we also should address following questions in the future: Can
CfrA and CfrB subunit vaccines trigger significant immune response and confer
protection against Campylobacter infection? Do CfrA and CfrB have functions other than
FeEnt acquisition? How do CfrA, CfrB, and their interplay affect Campylobacter
colonization in the intestine? How do CfrA- and CfrB-dependent pathways coordinate
with each other to contribute to FeEnt acquisition in different Campylobacter species?
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These future studies would greatly improve understanding of iron acquisition in
Campylobacter, and open new avenues for the prevention and control of Campylobacter
infections in humans and animal reservoirs.
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APPENDIX
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Table 14. Key bacterial strains and plasmids used in this project (Chapter V).
Plasmids or
strains
Plasmids
pFd
pmFd
pCfrA
pCfrB
pCj1375-76
pCj1376
pTonB3
pTonB3-CfrA
pCeu

Strains
C. jejuni
JL241
JL491
JL531
JL540
JL673
JL593
JL583
JL584
JL582
JL578
JL242
JL648
JL649
JL367
JL679
JL680
JL678
JL535
JL595
JL594
JL538
JL681
JL674
JL547
E. coli
DH5α

a

Description

Source or Reference

pGEM-T easy vector (Promega) containing cj1377c
pFd with chloramphenicol resistance cassette inserted in
r
r
cj1377c gene, Amp Cm
pRY107 derivative containing cfrA plus its promoter region
pRY107 derivative containing cfrB plus its promoter region
pRY107 derivative containing cj1375-76 operon plus its
promoter region
pRY107 derivative containing cj1376 plus cj1375’s promoter
pRY107 derivative containing tonB3 plus its promoter region
pRY107 derivative containing tonB3-cfrA loci
pRY107 derivative containing ceuBCDE operon plus its
promoter region

This study
This study

NCTC 11168, human isolate
11168 derivative cfrA::erm
JL491/pCfrB
11168 derivative cee::tetO
JL531 derivative with cee::tetO
JL531 derivative with ceuE::cm
11168 (ceuE::cm)
11168 (feoB::kan)
11168 (cj0174c::cm)
11168 derivative cj1377c::cm
81-176, human isolate
81-176/pCj1376(S157A)
81-176/pCj1376(H251A)
81-176/pCfrA
81-176/pTonB3
81-176/pTonB3-CfrA
81-176/pTonB1
81-176/pCj1375-76
81-176 derivative ceuE::cm/pCj1375-76
81-176 derivative cj0174c::cm /pCj1375-76
RM1221, a chicken isolate without FeEnt utilization ability
+
+
+
(cfrA tonB3 tonB2 ceuBCD ceuE cfrB cee )
RM1221/pTonB3-CfrA
RM1221/pCj1375-76
RM1221/pCeu

(Parkhill et al. 2000)
a
Dr. Richard Haigh
This study
a
Dr. Qijing Zhang
This study
This study
(Palyada et al. 2004)
(Naikare et al. 2006)
(Naikare et al. 2006)
This study
(Black et al. 1988)
This study
This study
This study
This study
This study
This study
Chapter IV
This study
This study
(Wang et al. 2009)

Chapter III
(Xu et al. 2010)
Chapter IV
Chapter IV
This study
This study
This study

This study
This study
This study

F- Φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17
Invitrogen
(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λJL48
DH5α/pRK2013
Chapter III
JL640
DH5α/pCee(S157A)
This study
JL641
DH5α/pCee(H251A)
This study
JL675
DH5α/pTonB1
This study
JL676
DH5α/pTonB3
This study
JL677
DH5α/pTonB3-CfrA
This study
JL542
DH5α/pCeu
This study
Dr. Richard Haigh is at University of Leicester and Dr. Qijing Zhang is at Iowa State University.
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Table 15. Major primers used in this study (Chapter V).
Primer
rCj1376F
rCj1376R

a

DNA Sequence (5’-3’)

CGCGGATCCAAACCAAGTCTAGAGATACCCAAGCT
C (BamHI)
CGGGGTACCTTAATTAAGATCAAGAAGCTTTTTCAT
CC (KpnI)

Product
size
(bp)
777

Cj1377c

Cj1377c_F1
Cj1377c_R1

AAAACTGCAGATTGTTTGGGTTGTGGAGGA
TGGCTTGTGGCATTATTTTTC

CHFL1
CHFR1

TTTGCTAGCTGCTCGGCGGTGTTCCTTT (NheI)
TTTGCTAGCGCGCCCTTTAGTTCCTAAAG (NheI)

S157A-F

CTTTGGACATgCTTTTGGAGGACTTTTTGCCATTGA
TAC
CCTCCAAAAGcATGTCCAAAGAGAATTTGATGGCTA
AAATC

Create S157A
mutation in Cee

CTTTTTAAAAATGAAACTgcTGGAAGTGTCATATCTA
AAGCTATGC
GATATGACACTTCCAgcAGTTTCATTTTTAAAAAGTT
TAAAATGAG

Create H251A
mutation in Cee

S157A-R

H251A-F
H251A-R

1934

Target gene/
operon or
function
cee full length

802

cat

TonB3F
TonB3R

TGGCAACACTTTACATAG
CATTGATAGTAGCAGGAG

1,343

tonB3

Ceu_F
Ceu_R

TGGCTATGGAGAAAGCCTTA
CTCTCTGTCCGCCACTAAAACT

3904

ceuBCDE
operon

a

Restriction sites are underlined in the primer sequence and the names are identified in
parentheses. The nucleotides in lower case are designed for desired aa substitution
mutagenesis.
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Table 16. The role of inner membrane iron transporters in FeEnt utilization in C. jejuni.
FeEnt
Utilization

Strain Names

Genotype

NCTC 11168

feoB-

+

NCTC 11168

cj0174c-

+

NCTC 11168

feoB- cj0174-

+

NCTC 11168

cfrA- cj0174c- with plasmid pCfrB

+

JL594 (81-176)

cj0174c- with plasmid pCj1375-76

+
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(A)

(B)

(C)

rCee

Figure 18. Validation of Cee as an enterobactin esterase.
(A) Hydrolysis of FeEnt by whole extract from JL241 (wild-type), JL324 (cfrA mutant),
and JL540 (cee mutant). Each bar represents the mean ± SD from two independent
measurements. (B) Critical role of amino acids S157 and H251 in Cee’s function and in
the CfrB-dependent FeEnt utilization in C. jejuni. The Ent growth promotion test was
performed using C. jejuni 81-176 containing a plasmid bearing wild-type cfrB gene or the
cfrB gene with a specific aa substitution mutagenesis. The features of the cfrB gene in
constructs (wild-type or the specific aa substitution) are shown below the results of
growth promotion assay. (C) Expression and purification of N-His6-rCmeC. 0h and 3h,
noninduced and 3 h IPTG induced whole-cell lysate, respectively; E4, The fourth eluted
fraction using Ni-NTA affinity chromatography (Qiagen). All samples were subjected to
SDS-PAGE analysis.
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Figure 19. Cee is essential for CfrB-dependent FeEnt utilization pathway.
All constructs were derived from C. jejuni NCTC 11168. All strains were subjected to
standard Ent growth promotion assay.
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(A)

(B)

Figure 20. Cee could be involved in CfrA-dependent FeEnt utilization pathway.
(A) Production of FeEnt receptor in C. jejuni RM1221determined by immunoblotting
analysis. Each strain was grown in iron-replete (+) or iron-limited (-) MH broth and
whole-cell lysates were loaded onto SDS-PAGE gel for blotting analysis by using CfrA
and CfrB antibodies. MW, molecular weight; Primary Ab, primary antibody. (B) Ent
growth promotion assays of C. jejuni RM1221 and its derivatives.The plasmid used for
complementation is listed below corresponding picture of growth promotion assay.

143

Figure 21. TonB3 is involved in CfrA-dependent FeEnt acquisition in C. jejuni.
C. jejuni 81-176 was complemented with plasmid bearing different gene/operon and
resulting constructs were subjected to starndard FeEnt growth promotion assay.
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(A)

(B)

(C)

Figure 22. Role of CeuE in FeEnt utilization in C. jejuni.
(A) Coordination of CeuE and Cee in the CfrA-dependent FeEnt acquisition in C. jejuni
NCTC 11168. (B) Complementation of C. jejuni RM1221 with ceuBCDE operon restored
its ability to utilize FeEnt. (C) CeuE is not required for the CfrB-dependent FeEnt
acquisition in C. jejuni. 11168, C. jejuni NCTC 11168 derivatives; 81-176, C. jejuni 81176 derivatives.
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(A)

(B)

(C)

Figure 23. The role of Cj1377c in FeEnt utilization in C. jejuni.
(A) Genomic context of the locus nearby cee which is important for FeEnt hydrolysis and
iron release in the C. jejuni NCTC 11168 genome. All solid arrow loci are induced under
iron-restricted conditions (Palyada et al. 2004; Holmes et al. 2005). (B) The important
role of Cj1377c in the CfrA-dependent FeEnt utilization pathway. (C) Inactivation of
Cj1377c did not affect the CfrB-dependent FeEnt acquisition.
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Figure 24. The CfrA- and CfrB-dependent FeEnt acquisition pathways in
Campylobacter.
The dashed line pathway is considered less likely than the solid line pathway. E,
extracellular space; OM, outer membrane; PS, periplasmic space; IM, inner membrane;
C, cytoplasm.
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Campylobacter species including C. jejuni and C. coli are the most common
bacterial causes of human gastroenteritis in the United States (Slutsker et al. 1998).
Poultry are the major reservoir of Campylobacter and thus the main source for human
campylobacteriosis (Young et al. 2007). In parallel to its increased prevalence,
Campylobacter has become increasingly resistant to clinical antibiotics, greatly
compromising the effectiveness of antibiotic treatment (Engberg et al. 2001). Therefore,
development of new strategies, such as vaccination, to prevent and control
Campylobacter infections in humans and animal reservoirs is needed urgently, which
relies on a better understanding of Campylobacter pathogenesis. However, no
commercial vaccine against C. jejuni is available to date. In this dissertation research,
two OMPs, CmeC and CfrA, were examined for their potential as protective vaccines
against Campylobacter infections. In addition, the molecular and mechanistic features of
FeEnt acquisitions systems, which play a critical role in Campylobacter pathogenesis,
were studied comprehensively. Findings from this work strongly suggest that
Campylobacter FeEnt receptors and cognate key pathway components offer a broad
array of possible intervention strategies, such as FeEnt receptor-based subunit vaccines
and FeEnt acquisition pathway inhibitors.

Early studies (Lin et al. 2002; Lin et al. 2003; Lin et al. 2005; Lin and Martinez
2006) showed that CmeC is a unique subunit vaccine candidate against C. jejuni.
Findings revealed in Chapter II showed that CmeC is highly conserved in C. jejuni.
Antibodies directed against CmeC blocked function of CmeABC, consequently inhibiting
Campylobacter growth in the presence of bile salts. A large amount of highly purified
rCmeC was produced for two vaccination studies using chicken model system. However,
oral vaccination of chickens with rCmeC did not confer protection against C. jejuni

149

challenge, which is consistent with the weak immunogenicity of rCmeC. The CmeC
vaccination regimen should be optimized to enhance CmeC-specific mucosal immune
response in the intestine for the protection against C. jejuni. To achieve this goal by
better understanding the structure of CmeC, preliminary conditions for CmeC
crystallization were also determined in Chapter II.

CfrA is a FeEnt receptor not only responsible for high-affinity iron acquisition in
Campylobacter but also essential for C. jejuni colonization in animal intestine (Guerry et
al. 1997; Palyada et al. 2004). Comprehensive examination using phylogenetic analysis,
PCR, immunoblotting in conjunction with a standard FeEnt growth promotion assay
revealed that CfrA is prevalent and highly conserved in Campylobacter (Chapter III). The
findings from Chapter III also demonstrated that CfrA is immunogenic in vivo and
specific CfrA antibodies could block the function of CfrA in a dose dependent manner.
The identification of functionally critical aa (R327) in CfrA led to the development of a live
Salmonella-vectored vaccine expressing protective epitope of CfrA, which partially
conferred the protection of chicken against Campylobacter infection (Chapter III).

Whole genome sequencing and subsequent comparative genomic analysis
successfully identified a novel periplasmic enterobactin esterase Cee, which is essential
for CfrB-dependent FeEnt acquisition in Campylobacter (Chapter IV). The function of
Cee was further studied using biochemical and amino acid substitution mutagenesis
approaches in Chapter V. Using comprehensively molecular manipulation in three
representative C. jejuni strains, key components and molecular interactions of the two
FeEnt acquisition systems were determined (Chapter V), with emphasis on TonBExbBD, CeuBCDE ABC transporter, FeEnt esterase Cee, and cytoplasmic ferric
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reduction. Based on findings from this research, a model of the CfrA- and CfrBdependent FeEnt acquisition pathways in Campylobacter was proposed (Fig. 24).
Validation of this model would greatly improve the understanding of FeEnt acquisition in
Campylobacter, and facilitate development of novel vaccines and antimicrobials against
Campylobacter.
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